

CURRICULUM VITAE

NAME: XIE, Feng

BUSINESS ADDRESS: Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics)
McMaster University
CRL223-1280 Main Street West
Hamilton ON L8S 4K1, Canada
E-mail: fengxie@mcmaster.ca
Website: www.phenomresearch.ca

Google scholar citations=4,359, H-index=39, H10-Index=107
Peer-reviewed journal publications=195

CURRENT MCMASTER STATUS:

Professor, Department of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology and Biostatistics) McMaster University (Effective 2018-07-01)

Professor, Centre for Health Economics and Policy Analysis, McMaster University (Effective 2018-07-01)

Chair, Board of Comprehensive Examination, Department of Health Research Methods, Evidence and Impact (Effective 2019-07-01)

EDUCATIONAL BACKGROUND:

- 2007 Doctor of Philosophy in Pharmacoeconomics and Outcomes Research (Ph.D.), Department of Pharmacy, National University of Singapore, Republic of Singapore; (Dissertation Title: Osteoarthritis of Knee and Hip: Assessing Pharmacoeconomic and Functional Outcomes in Singapore)
- 2003 Master of Science in Pharmacy Administration (MSc.), School of Pharmacy, Fudan University, Shanghai, People's Republic of China; (Dissertation Title: New Drug Application: Comparison between China and the United States)
- 1999 Bachelor of Science in Pharmacy (BSc.), Shanghai Medical University, Shanghai, People's Republic of China.

PROFESSIONAL ORGANIZATIONS

- 2009- Society for Medical Decision Making (SMDM)
- 2008- Health Technology Assessment International (HTAi)
- 2008-2013 Association of Rheumatology Health Professionals (ARHP)
- 2004- International Society for Quality of Life Research (ISOQOL)
- 2004- International Society for Pharmacoeconomics & Outcomes Research (ISPOR)

2003-2006 Vice-president, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) National University of Singapore Student Chapter

EMPLOYMENT HISTORY

i) Academic:

2017-2021 Department Education Coordinator, Department of Health Research Methods, Evidence and Impact, McMaster University

2017-2021 Chair, Department Education Council, Department of Health Research Methods, Evidence and Impact, McMaster University

2015-2016 Acting Assistant Dean (Health Research Methodology Program), Faculty of Health Sciences, McMaster University

2012-2018 Associate Professor, Department of CE&B, McMaster University, Hamilton, ON, Canada

2007-2012 Assistant Professor, Department of CE&B, McMaster University, Hamilton, ON, Canada

2007-2013 Faculty member, Program for Assessment of Technology in Health (PATH), St. Joseph's Healthcare Hamilton

2006-2007 Research Fellow, Centre for Health Services Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

1999-2000 Pharmacist, Department of Pharmacy, Renji Hospital, Shanghai, China

ii) Professional/Consultation:

2019-2022 Member, EuroQol Executive Committee (elected)

2013- Associate Editor, Medical Decision Making

2010- Member, the EuroQol Group

2016-2019 Member, Pharmacoeconomics Open Editorial Board

2016-2017 Co-Chair, Society of Medical Decision Making Annual Meeting Scientific Committee

2015-2019 Member, pan-Canadian Oncology Drug Review Economic Guidance Panel

2014-2019 Deputy Editor, Health and Quality of Life Outcomes

2014-2019 Member, St Joseph's Hospital Health Enquiry Learning Panel (H.E.L.P)

2013-2015 Chair, the EQ-5D Value Set Working Group

2012-2013 Member, Medavie Blue Cross Medication Advisory Panel

2011-2016 Member, Ontario Health Study Health Economics Working Group

2010-2013 Member, Editorial Board of Medical Decision Making

2010 Member, China Pharmacoeconomics Guidelines Expert Panel

2009 -2013 Associate Editor, Health and Quality of Life Outcomes

- 2009 -2015 Pharmacoconomics Expert Consultant, Ontario Ministry of Health and Long Term Care (MOHLTC), Canada
- 2009-2012 Leadership member, International Society for Pharmacoconomics and Outcomes Research Health Technology Assessment Working Group
- 2008 -2015 Member, Editorial Board, Journal of Inflammation Research
- 2008 -2015 Member, Editorial Board, Journal of Pain Research
- 2007-2015 Member, Panel of Expert Reviewers, the National Coordinating Centre for Health Technology Assessment (NCCHTA), the United Kingdom
- 2007-2012 Member, the Canadian Interdisciplinary Network for Complementary and Alternative Medicine Research (IN-CAM), Canada
- 2006-2007 Consultant, Lundbeck SAS Singapore, Singapore

SCHOLARLY AND PROFESSIONAL ACTIVITIES

i) Grant Referee (the number in the bracket is the number of grant proposal reviewed in 2013):

- 2019 EuroQol Group Foundation Grant Reviewer (43)
- 2019 Health Research Council of New Zealand
- 2014 EuroQol Group Foundation Grant Reviewer (6)
- 2013 EuroQol Group Foundation Grant Reviewer (8)
- 2013 External Reviewer, the National Institute for Health Research Health Technology Assessment Programme Clinical Evaluations and Trials, the United Kingdom (1)
- 2012 Member, CIHR Doctoral Award Peer Review Committee
- 2012 Member, CIHR Aboriginal Health Peer Review Committee
- 2012 Member, HAHSO AFP Innovation Fund Grants Review Committee
- 2011 Member, Peer-Review Committee, Health Authority, Abu Dhabi
- 2011 Member, HAHSO AFP Innovation Fund Grants Review Committee
- 2010 External Reviewer, the National Institute for Health Research Health Technology Assessment Programme Clinical Evaluations and Trials, the United Kingdom
- 2009 External Reviewer, Research Fund for the Control of Infectious Diseases (RFCID)/Health and Health Services Research Fund (HHSRF), Hong Kong Special Administrative Region
- 2007 External Reviewer, Peer-Review Committee of Genome British Columbia, Canada

ii) Journal Referee:

- Arthritis Care and Research
- Arthritis Research and Therapy
- British Medical Journal
- Cost Effectiveness and Resource Allocation
- Digestive Diseases and Sciences

Expert Review of Medical Devices
Expert Review of Pharmacoeconomics and Outcome Research
European Journal of Health Economics
European Heart Journal
Health Economics
Health Technology Assessment
Health and Quality of Life Outcomes
Journal of Clinical Epidemiology
Journal of Medical Economics
Journal of Thoracic and Cardiovascular Surgery
JAMA Oncology
Medical Decision Making
Pharmacoeconomics
Quality of Life Research
Rheumatology
Social Science and Medicine
Value in Health
Trial

iii) Conference Abstracts/Presentations Referee:

- 2013 Oral Presentation Judge, Faculty of Health Sciences Research Plenary, McMaster University, Hamilton, Canada
- 2012 Abstract reviewer, 29th Annual Plenary Meeting of the EuroQol Group, Rotterdam, the Netherlands
- 2010 Abstract reviewer, Health Technology Assessment International 2010 Annual International Meeting, Dublin, Ireland
- 2009 Judge (poster), Faculty of Health Sciences Research Day, McMaster University, Hamilton, Ontario, Canada
- 2009 Abstract reviewer, International Society for Pharmacoeconomics & Outcomes Research 14 Annual International Meeting, Orlando, Florida, USA
- 2008 Judge (poster and podium presentations), International Society for Pharmacoeconomics & Outcomes Research 13 Annual International Meeting, Toronto, Ontario, Canada
- 2007 Abstract and workshop reviewer, International Society for Pharmacoeconomics & Outcomes Research 3rd Asia-Pacific Meeting, Seoul, Korea
- 2006 Abstract reviewer, International Society for Pharmacoeconomics & Outcomes Research 2nd Asia-Pacific Meeting, Shanghai, China
- 2005 Abstract reviewer, International Society for Quality of Life Research, San Francisco, California, USA

iv) Pharmacoeconomics Submissions Referee:

Ontario MOHLTC Ontario Public Drug Programs – Committee to Evaluate Drugs (OPDP-CED)

AREAS OF INTEREST

i) Research:

1. Health technology assessment
2. Trial-based and model-based economic evaluations
3. Pharmacoeconomics
4. Health-related quality of life and patient-reported outcome measures
5. Health utility measurement
6. Shared decision making
7. Eliciting preferences and values

ii) Teaching:

1. Health technology assessment
2. Trial-based & model-based economic evaluations
3. Pharmacoeconomics
4. Health-related quality of life
5. Health preferences measurement

iii) Consulting:

1. Clinical and economic evaluation
2. Decision analytic modelling for clinical and program appraisal
3. Pharmacoeconomics
4. Critical appraisal of economic evaluation & health technology assessment reports
5. Health-related quality of life and patient-reported outcome measures
6. Health utility measurement

HONOURS

- | | |
|---------|---|
| 2019 | Best Podium Presentation, ISPOR Europe Congress, Copenhagen, Nov 2-6, 2019 |
| 2014 | Scientific Excellence Award, the EuroQoL Group |
| 2013 | Best Poster Presentation Finalist, the International Society for Pharmacoeconomics and Outcomes Research 18 th Annual Meeting, New Orleans |
| 2012-17 | New Investigator Award, Canadian Institutes of Health Research |
| 2011 | Canadian Fertility and Andrology Society, Dr Biljan Memorial Award, |

“Planning for an altruistic sperm donor program in Canada” (co-author)

- 2010 Career Scientist Award, Ontario Ministry of Health and Long Term Care
- 2007 Best PhD Thesis, National University of Singapore (the Winner of Inaugural Wang Gungwu Medal and Prize)
- 2007 Chinese Government Award for Outstanding Self-Financed Students Abroad, China
- 2006 Best Graduate Research Award, National University of Singapore, Singapore
- 2005 Outstanding Graduate Research Award, First Pharmacy Honours Day, National University of Singapore, Singapore
- 2005 Best Podium presentation Award, Clinical Pharmacy and Pharmacy Practice, 17th Singapore Pharmacy Congress, Singapore
- 2004 New Investigator Award, International Society for Quality of Life Research (ISOQOL)
- 2004 Best Poster Presentation Finalist in ISPOR 9th International Annual Meeting, Arlington, VA, US

EDUCATIONAL CONTRIBUTIONS

i) Graduate:

- 2015- HRM-737 Economic Analysis for the Evaluation of Health Services
Course coordinator/Lecturer/Tutor
- 2009- HRM-740, Advanced Decision Analysis in HTA, Course
coordinator/Lecturer/Tutor
- 2009-2018 HRM-733, Statistical and Methodological Issues in Clinical Trials,
Lecturer
- 2015-2016 HRM-730, Introduction to RCT, Lecturer
- 2008-2017 HRM-721, Fundamentals of Health Research and Evaluation
Course coordinator (2014)/Lecturer/Tutor
- 2009-2011 HRM-741 Introduction to HTA, Lecturer
- 2008-2009 HRM-751, Observational Research Methods, Lecturer

ii) Workshops/short courses:

- 2020 Using HTA to Enable Value-based Purchasing: Canada’s Experience, Executive Training Course for Sustainable and Effective Health Care Financing in China (Virtual), Harvard University, November 23-27, 2020.
- 2020 Yea or Nay? Making Coverage Decisions for Disruptive Therapies. Health Technology Assessment International (HTAi), Virtual Conference, 2020
- 2019 Measuring and Valuing Patient-Reported Outcomes in Economic Evaluations of

- Health Care Workshop. October 26, Beijing, China
- 2019 Measuring Patient-Reported Outcomes, Gilead Sciences, August 22, Singapore
- 2019 Introduction to Biostatistics and RCT, Gilead Sciences, August 21, Singapore
- 2019 Introduction to Health Economic Evaluation Workshop. National Health Commission. July 1-3, Nanjing, China
- 2017 Incorporating quality of life into economic evaluation. PATH Workshop Health Technology Assessment: From Theory to Evidence to Policy Workshop. June 12-14, 2017, Hamilton, Canada.
- 2017 Measuring and valuing patient preferences in randomized clinical trials. CADTH Symposium Pre-Conference Workshop, April 23-25, 2017. Ottawa, Canada
- 2016 Developments in preference-based measures of health: scoring approaches and guidance (with Simon Pickard, Ernest Law). 2016 ISOQOL Pre-Conference Workshop. Oct 19, 2016
- 2016 Engaging patients and general public in health technology assessment: Measuring and valuing health preferences (with Jeff Johnson, Eleanor Pullenayegum, and Simon Pickard). 2016 HTAi Pre-Conference Full Day Workshop. May 10, 2016
- 2014 Introduction to Health Technology Assessment Workshop
October 28-30, 2014, Hamilton, Ontario.
Session Leader: Incorporating Quality of Life into Economic Evaluation
- 2014 Incorporating Patient-Reported Outcome Measures in Reimbursement Decision-Making: Measuring and Valuing Health Using the EQ-5D (with Paul Kind and Simon Pickard), April 6, Canadian Agency for Drugs and Technologies in Health (CADTH) Annual Symposium
- 2012 Short course in economic evaluation methods in health care
(with Karl Claxton, Elizabeth Fenwick), July 28, Hospital Authority, Hong Kong
Session Leader: Measuring health benefit for health economic evaluation
- 2012 Health Technology Assessment Workshop (with Ron Goeree, Gord Blackhouse, Natasha Burke, Daria O'Reilly), December 11-12, 2012, Janssen-Ortho, North York, Ontario.
Session Leader: Incorporating Quality of Life into Economic Evaluation
Session Leader: Approaches to Economic Evaluation Part 1: Trial-Based Analyses
Tutoring 4 sessions of exercises
- 2012 Introduction to Health Technology Assessment Workshop (with Ron Goeree, Daria O'Reilly, James Bowen, Kaitryn Campbell, Rob Hopkins, Nazila Assasi), November 21-22, 2012, Hamilton, Ontario
Session Leader: Example of an HTA Process in Practice
Session Leader: Approaches to Economic Evaluation Part 1: Trial-Based Analyses
Tutoring 4 sessions of exercises

- 2012 Modeling Methods for Health Economic Evaluation Workshop (with Mark Sculpher, Karl Claxton, Elizabeth Fenwick), July 25-27, Hong Kong
Session Leader: Introduction to Markov Model
Tutoring 6 sessions of exercises
- 2011 Health Technology Assessment: From Theory to Evidence to Policy workshop with Ron Goeree, Daria O'Reilly, and Jean-Eric Tarride),
Session leader: Incorporating Quality of Life in Economic Evaluation.
Session leader: Good Practices & Guidelines in Modeling & Economic Evaluation. April 27-29, 2011, Ottawa, Ontario
Lecturer and Tutor
- 2011 Health Technology Assessment: From Theory to Evidence to Policy workshop with Michael Drummond, Ron Goeree, Daria O'Reilly, and Jean-Eric Tarride),
Session leader: Incorporating Quality of Life in Economic Evaluation.
Session leader: Good Practices & Guidelines in Modeling & Economic Evaluation. October 18-21, 2011, Toronto, Ontario
Lecturer and Tutor
- 2010 Pharmacoeconomics Modeling Using Excel Software, December 10, 2010, Taipei, Taiwan
Leading Lecturer
- 2010 Incorporating Quality of Life into Economic Evaluations: Health Utility Measurements, Half Day Short Course (with Eleanor Pullenayegum), 32 Annual Meeting of the Society for Medical Decision Making, October 24-27, 2010, Toronto, Ontario
Faculty Director and Lecturer
- 2010 Health Technology Assessment: From Theory to Evidence to Policy workshop with Michael Drummond, Ron Goeree, Daria O'Reilly, and Jean-Eric Tarride),
Session leader: Incorporating Quality of Life in Economic Evaluation.
Session leader: Good Practices & Guidelines in Modeling & Economic Evaluation. October 19-22, 2010, Toronto, Ontario
Lecturer and Tutor
- 2010 Conducting economic evaluation using pre-developed software, Half Day Workshop, International Health Economics Conference 2010: Application of Economic Models in Drug Listing and Reimbursement Policy, September 10-11, 2010, Hong Kong.
Lecturer
- 2010 Value of Information: Vision of Ingenuity or Venture of Icarus? Half Day Workshop (with Ron Goeree, Gord Blackhouse, Matthias Bischof), 2010 CADTH Symposium, April 18-20, 2010, Halifax, Nova Scotia
Lecturer
- 2009 Advanced Modelling Methods for Health Economic Evaluation Workshop (with Andrew Briggs, Mark Sculpher, Karl Claxton, Ron Goeree, and Elisabeth Fenwick), Toronto, ON, June 9-11, 2009
Tutor

- 2009 Development of an International Workshop in Alternative Modeling Approaches
- 2009 Health Technology Assessment: From Theory to Evidence to Policy workshop (with Michael Drummond, Ron Goeree, Daria O'Reilly, and Jean-Eric Tarride), Toronto, ON, April 27-29, 2009.
Lecturer and Tutor
- 2008 Health Technology Assessment: From Theory to Evidence to Policy Workshop (with Michael Drummond, Ron Goeree, Daria O'Reilly, and Jean-Eric Tarride). Toronto, ON, April 29 – May 2, 2008
Session leader, Incorporating Quality of Life in Economic Evaluation
Session leader, Good Research Practices for Economic Evaluation
Tutoring of 5 sessions of exercises
- 2008 Advanced Modelling Methods for Health Economic Evaluation Workshop (with Andrew Briggs, Mark Sculpher, Karl Claxton, Ron Goeree, and Elisabeth Fenwick)
Vancouver, BC, July 23-25, 2008.
Tutoring of 5 sessions of exercises
- 2007 Development of new workshop in Health Technology Assessment (with Michael Drummond, Jean-Eric Tarride, Daria O'Reilly, Feng Xie, Gord Blackhouse, Jim Bowen and Kaitryn Campbell), Hamilton, ON

SUPERVISORSHIPS

i) Undergraduate Level:

Date: 2020-
Student & status Leon He
Role: Advisor
Degree: BSc
Program: Bachelor of Health Sciences
Department & University: McMaster University

Date: 2019-
Student & status Preston Tse
Role: Advisor
Degree: BSc
Program: Bachelor of Health Sciences
Department & University: McMaster University

Date: 2014-2015
Student & status Julia Goyal
Role: Advisor
Degree: BSc
Program: Bachelor of Sciences

Department & University: McMaster University

Date: 2013-2014
Student & status: Arnav Agarwal
Role: Advisor
Degree: BHSc
Program: Bachelor of Health Sciences
Department & University: McMaster University

ii) Masters Level:

Date: 2019-2020
Student & status: Majid Abdulrahman Almadi
Role: Co-Supervisor
Degree: MSc
Program: International Healthcare Management MBA Program
Department & University: Frankfurt School

Date: 2019-2020
Student & status: Michel Kiflen
Role: Thesis committee member
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2018-2020
Student & status: Vincent Lau
Role: Thesis committee member
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2017-2019
Student & status: Zhiyuan Chen
Role: Supervisor
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2017-2018
Student & status: Danielle Hylton
Role: Thesis committee member
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2016-2017
Student & status: Juan Pablo Diaz Martinez
Role: Thesis committee member
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2016-2018
Student & status: Adam Haynes
Role: Thesis committee member
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2016-2017
Student & status: Zhengrong Lian
Role: Thesis committee member
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2015-2017
Student & status: Michael Xu
Role: Thesis committee member
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2015-2016
Student & status: Sara Hussain
Role: Thesis committee member
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2015
Student & status: Kevin Quach
Role: Thesis examiner
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2014-2015
Student & status: Dominik Podbielski
Role: Advisor

Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2014
Student & status: Simran Mundi
Role: Scholarly paper reviewer
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2012-2014
Student & status: Shazia Syed
Role: Supervisor
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2012
Student & status: Clare Reade
Role: Scholarly paper reviewer
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2012
Student & status: Jing He
Role: Scholarly paper reviewer
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2011
Student & status: Jing He
Role: Internship supervisor
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2009-2011
Student & status: Brett Doble
Role: Supervisor
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2008-2012
Student & status: Kuhan Perampaladas
Role: Supervisor
Degree: MSc
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

iii) PhD Level:

Date: 2020-
Student & status: Susan Mirabi
Role: Supervisor
Degree: PhD (Part time)
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2020-
Student & status: Jiajun Yan
Role: Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2020
Student & status: Xuan Zhu
Role: Thesis External Examiner
Degree: PhD
Program: Pharmacoeconomics and policy
University: Tianjin University, China

Date: 2020
Student & status: Shitong Xie
Role: Thesis External Examiner
Degree: PhD
Program: Pharmacoeconomics and policy
University: Tianjin University, China

Date: 2020
Student & status: Rajan Sharma
Role: Thesis External Examiner
Degree: PhD
Program: Macquarie Business School
University: Macquarie University, Australia

Date: 2019

Student & status	Wudong Guo
Role:	Thesis External Examiner
Degree:	PhD
Program:	Faculty of Applied Health Sciences
University:	University of Waterloo
Date:	2019-
Student & status	Xue Li
Role:	Supervisor
Degree:	PhD
Program:	Health Research Methodology (HRM) Program
Department & University:	HEI, McMaster University
Date:	2019-2020
Student & status	Artri Bhasin
Role:	Independent Study Supervisor
Degree:	PhD
Program:	Health Research Methodology (HRM) Program
Department & University:	HEI, McMaster University
Date:	2018-
Student & status	Mengmeng Zhang
Role:	Supervisor
Degree:	PhD
Program:	Health Research Methodology (HRM) Program
Department & University:	HEI, McMaster University
Date:	2018
Student & status	Naazish Bashir
Role:	Thesis Committee External Appraiser
Degree:	PhD
Program:	PhD-Health Services Research Program
Department & University:	Institute of Health Policy, Management, and Evaluation University of Toronto
Date:	2018-2019
Student & status	Mihir Gandhi
Role:	Thesis Defense Opponent
Degree:	PhD
Program:	PhD Program
Department & University:	Faulty of Medicine and Life Sciences University of Tempere (Finland)
Date:	2018-2020
Student & status	Sara Hussain
Role:	Thesis committee member

Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2018
Student & status: Chang-Ho Lee
Role: Thesis Committee External Voting Member
Degree: PhD
Program: PhD-Health Services Research Program
Department & University: Institute of Health Policy, Management, and Evaluation
University of Toronto

Date: 2018
Student & status: Ayesha Siddiqua
Role: Independent Study Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2016-2018
Student & status: Ernest Law
Role: Thesis Committee Member
Degree: PhD
Program: UIC Pharmacy Graduate Program
Department & University: Department of Pharmacy Systems, Outcomes and Policy
College of Pharmacy, University of Illinois at Chicago

Date: 2017-
Student & status: Brittany Humphries
Role: Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2017-
Student & status: Kevin Kennedy
Role: Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: HEI, McMaster University

Date: 2017
Student & status: Teresa Tsui
Role: Thesis Committee External Voting Member
Degree: PhD
Program: PhD Graduate Program

Department & University: Leslie Dan Faculty of Pharmacy, University of Toronto

Date: 2016-
Student & status Michael Zoratti
Role: Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2016-2017 (withdraw)
Student & status Shiyuan (William) Zhang
Role: Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2016-2017
Student & status Charlene Rae-St Amand
Role: Independent Study Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2015-2020
Student & status Gian Paolo Morgano
Role: Thesis Committee Member/Independent Study Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2015-2020
Student & status John Riva
Role: Thesis Committee Member
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2015-2019
Student & status Naghmeh Foroutan
Role: Thesis Committee Member
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2015-2016
Student & status Sergei Muratov

Role: Independent study supervisor
 Degree: PhD
 Program: Health Research Methodology (HRM) Program
 Department & University: CE&B, McMaster University

Date: 2014-2015
 Student & status: Ismaila Nofisat
 Role: Thesis Committee Member
 Degree: PhD (withdrawn in 2015)
 Program: Health Research Methodology (HRM) Program
 Department & University: CE&B, McMaster University

Date: 2014-2015
 Student & status: Sohail Mulla
 Role: Independent Study Supervisor
 Degree: PhD
 Program: Health Research Methodology (HRM) Program
 Department & University: CE&B, McMaster University

Date: 2014-2015
 Student & status: Juan José Yepes-Nuñez
 Role: Independent Study Member-at-Large
 Degree: PhD
 Program: Health Research Methodology (HRM) Program
 Department & University: CE&B, McMaster University

Date: 2014-2020
 Student & status: Manraj Kaur
 Role: Co-Supervisor
 Degree: PhD
 Department: School of Rehabilitation
 University: McMaster University

Date: 2013
 Student & status: Huijun Zhou
 Role: Thesis external examiner
 Degree: PhD
 Department & University: School of Public Health, National University of Singapore

Date: 2013-2017
 Student & status: Bruno Kovic
 Role: Supervisor
 Degree: PhD
 Program: Health Research Methodology (HRM) Program
 Department & University: CE&B, McMaster University

Date: 2013-2017
Student & status: Xuejing Jin
Role: Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2013-2015
Student & status: Yuan Zhang
Role: Project advisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2011
Student & status: Nazila Assasi
Role: Independent Study Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2011
Student & status: Xiuyun Wu
Role: Thesis external examiner
Degree: PhD
Program: School of Public Health
Department & University: University of Alberta

Date: 2011-2017
Student & status: Pimwara Tanvejsilp
Role: Supervisor
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2012-2013
Student & status: Bernice Tsoi
Role: Independent Study Member-at-Large
Degree: PhD
Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

Date: 2012-2013
Student & status: Yuqing Zhang
Role: Independent Study Member-at-Large
Degree: PhD

Program: Health Research Methodology (HRM) Program
Department & University: CE&B, McMaster University

iv) Post-Doc Fellow

Date: 2021-2023
Student & status: Shitong Xie
Role: Supervisor
Department & University: HEI, McMaster University

Date: 2018
Student & status: Bernhard Michalowski
Role: Supervisor
Department & University: HEI, McMaster University

Date: 2016-2017
Student & status: Stephanie Thomas
Role: Supervisor
Department & University: CE&B, McMaster University

Date: 2016-2017
Student & status: Junwei Gao
Role: Supervisor
Department & University: CE&B, McMaster University

v) Visiting Scholar:

Date: November-December 2018
Scholar: Dong Wu
Title: Visiting Professor
Affiliation: Peking Union Medical College
Role: Supervisor

Date: 2018-2019
Scholar: Ting Zhou
Title: PhD student
Affiliation: China Pharmaceutical University
Role: Supervisor

Date: 2016-2017
Scholar: Zhiyuan Chen
Title: MSc student
Affiliation: China Pharmaceutical University

Role:	Supervisor
Date:	2015-2016
Scholar	Xiaoning He
Title	PhD student
Affiliation	Tianjing University
Role:	Supervisor
Date:	2014-2015
Scholar	Mengxiao Wang
Title	Master's student
Affiliation	China Pharmaceutical University
Role:	Supervisor
Date:	2013-2014
Scholar	Hongchao Li
Title	Assistant Professor
Affiliation	China Pharmaceutical University
Role:	Supervisor
Date:	2012-2013
Scholar	Jie You
Title	Associate Professor
Affiliation	Department of Oncology, Longhua Hospital
Role:	Supervisor

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

Year 2021

1. *Assessing and comparing psychometric properties of both 3L/5L of EQ-5D-Y and adult EQ-5D versions in adolescents with prevalent disease conditions in Ethiopia*
Abraham Gebregziabiher Welie (Principal Investigator), Murray Krahn, Janine Verstraete, Mike Herdman, Mihretab Gebresilasie, **Feng Xie** (Co-Investigators)
EuroQol Research Foundation
January 2021-September 2021 (€24,693)
2. *Post-Bleed Management of Antithrombotic Therapy after Gastrointestinal Bleeding (PANTHER-GI): A Mixed-Methods Study of Patient Values and Preferences*
Deborah Siegal (Principal Investigator), Marc Carrier, Kenneth Deal, Joanna Dionne, James Douketis, Nauzer Forbes, Anne Holbrook, Derek Little, Lesile Skeith, Dawn Stacey, Ted Xenodemetropoulos, **Feng Xie**, (Co-Investigators)
Canadian Institutes of Health Research Project Grant
July 2021-May 2023 (\$179,776)
3. *PEITHO-3. Reduced-dose thrombolytic treatment for patients with higher-intermediate risk acute pulmonary embolism*
Kerstin de Wit, Lana Castellucci, and Jeff Perry (co-Principal Investigators); Susan Kahn, Marc Rodger, Alejandro LazoLangner, Leslie Skeith, Jason Weatherald, Justin Yan James Douketis, Sam Schulman, Alison Fox-Robichaud, Andrew Hirsch, Sudeep Shivakumar, Stavros Konstantinides, **Feng Xie** (co-Investigators)
Canadian Institutes of Health Research Project Grant
July 2021-May 2027 (\$478,125)
4. *Online Peer-Delivered Group Cognitive Behavioural Therapy for Postpartum Depression*
Ryan John Van Lieshout (Principal Investigator); Steve Hanna, June Brown, Peter Bieling, Andrea Feller, Mark Ferro, David Streiner, **Feng Xie** (co-Investigators)
Canadian Institutes of Health Research Project Grant
July 2021-May 2024 (\$348,074)
5. *Online Public Health Nurse-Delivered 1-Day Cognitive Behavioural Therapy-Based Workshops for Postpartum Depression*
Ryan John Van Lieshout (Principal Investigator); Steve Hanna, June Brown, Peter Bieling, Andrea Feller, Mark Ferro, David Streiner, **Feng Xie** (co-Investigators)
Canadian Institutes of Health Research Project Grant
July 2021-May 2022 (\$100,000)

Year 2020

6. *The impact of recent health events and fluctuations in health status on the assessment of health today using the EQ-5D-5L: A mixed-methods study among people with dementia and their caregivers*
Bernhard Michalowsky (Principal Investigator), **Feng Xie**, Lidia Engel, Lidia, Thomas Kohlmann (Co-Investigators).
EuroQol Research Foundation

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

- December 2020-June 2022 (€49,060)
7. *Promoting and Supporting the Use of EQ-5D instruments in China*
Xuejing Jin (Principal Investigator), Feng Xie, Jeff Johnson, Arto Ohinmaa, Fatima Al Sayah, Jiabi Wen (Co-Investigators)
EuroQol Research Foundation
December 2020-November 2021 (€22,400)
 8. *Translating the 'Methods for analysing and reporting EQ-5D data' into Chinese*
Zhihao Yang and Xuejing Jin (Co-Principal Investigators), Ningyan Gu, Yan Fen, Yaling Yang, **Feng Xie**, Nan Luo (Co-Investigators)
EuroQol Research Foundation
December 2020-October 2021 (€26,530)
 9. *US Regional Variation in COVID QoL Impact*
Nadine Zawadzki (Principal Investigator), **Feng Xie**, Simon Pickard, Xiayu Jiao, Ning Yan Gu, Joel Hay (Co-Investigators).
EuroQol Research Foundation
May 2020-Feb 2021 (€30,740)
 10. *Head-to-head comparison of the EQ-5D-3L and the EQ-5D-5L: Psychometric properties in Dementia*
Bernhard Michalowsky (Principal Investigator), **Feng Xie** (Co-Investigator).
EuroQol Research Foundation
June 2020-December 2020 (€20,840)
 11. *A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)*
Donald Arnold, Philippe Bégin, Jeannie Callum (Principal Investigators), Renée Bazin; Michael Chasse, Richard Cook, Nick Daneman, Dana Devine, Dean Fergusson, Andrés Finzi, Michael Fralick, Marshall Glesby, Nancy Heddle, Allison McGeer, Nancy Robitaille, Damon Scales, Lisa Schwartz, Nadine Shehata, Alan Tinmouth, Alexis Turgeon, **Feng Xie**, Ryan Zarychanski, Michelle Zeller.
Canadian Institutes of Health Research Project Grant
May 2020-April 2021(\$2,972,273)
 12. *The impact of COVID-19 on population health in the US, Sweden, and Norway: A longitudinal survey using the EQ-5D-5L*
Ning Yan Gu (Principal Investigator), **Feng Xie**, Joel Hay, Simon Pickard (co-Principal Investigators), Samuel Crawford, Nadine Zawadzki, Xiayu Jiao (Co-Investigators).
EuroQol Research Foundation
April 2020-October 2020 (€67,546)
 13. *Vascular events In noncardiac Surgery patients cOhort evaluation study-2 (VISION-2). Horizon 2020 - Research and Innovation Framework Programme*
PIs: McGillion M, Devereaux PJ, Scott T, Peter E, Doyle T.

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

Co-Is: Alvarado K, Andrews G, Bessissow A, Bhavnani S, Biccard B, Buckley N, Busse J, Carroll S, Cheng, D, Choiniere, M, Conen, D, Cortes, OL, Cowan, D, Downey, B Duceppe, E, Dvirnik, N, Fergusson, Dean, Garg A, Gilron I, Graham M, Guyatt G, Johnson A, Karanicolas P, Kavsak P, Kessler Borges F, Lalu M, Lamy A, Lavis J, MacDermid J, Marcucci M, Martin J, Mazer D, McAlister F, McManus B, Metcalfe K, Mrkobrada M, Ouellette C, Pare G, Parlow J, Parry M, Patel A, Paul J, Petch J, Roshanov P, Samavi R, Schunemann H, Sessler D, Srinathan S, Tandon V, Tarride, JE, Vanstone M, Watt-Watson J, Whitlock R, **Xie F**, Yang S, Bianco, D (Lived Experience Representative).

Canadian Institutes of Health Research Project Grant

June 2020-May 2022 (\$960,000)

In-kind, Industry and Partners (\$2,172,500)

14. *Stepping Up: Partnering with the Community to Prevent Early Mobility Decline*

Julia Richardson (Principal Investigator), Ayse Kuspinar (Co-Principal Investigator), **Feng Xie**, Marla Beauchamp, Andrew Costa, Sinead Dufour, Evelyne Durocher, Joy MacDermid, Ada Tang, Lehana Thabane, Barbara Brock (Co-Investigators)

Canadian Institutes of Health Research Project Grant

June 2020-June 2024 (\$750,000)

15. *Meeting Asian Policy Makers in HTAi 2020*

Feng Xie (Principal Investigator), Nan Luo and Simon Pickard (co-Investigators).

EuroQol Research Foundation

June 2020 (€28,800)

16. *Virtual Clinics to Improve Quality of Care and Outcomes in Heart Failure: A Multi-Centre Randomized Controlled Trial*

Harriette Van Spall, (Principal Investigator), **Feng Xie**, Jillianne Code, Scot Lear, Shun-Fu Lee, Ted Scott, Sera Whitelaw (Co-Investigators)

Canadian Institutes of Health Research Project Grant

June 2020-June 2023 (\$405,000)

17. *An Economic Evaluation and Budget Impact Analysis of a Paramedic-led Model of Palliative Care in the Home*

Jean-Eric Tarride, (Principal Investigator), **Feng Xie**, Gord Blackhouse, Hsien Seow, Michel Grignon (Co-Investigators)

Canadian Partnership Against Cancer

March 2020-March 2021 (\$143,976)

Year 2019

18. *Investigating heterogeneous reporting behaviour in the EQ-5D*

Paula Lorgelly (Principal Investigator), Mark Harris, **Feng Xie**, Jan Abel Olsen, Stephanie Thomas, Nils Gutacker, Nigel Rice (Co-Investigators)

EuroQol Research Foundation

March 2020-December 2020 (€46,000)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

19. *Measuring and Valuing Patient-Reported Outcomes in Economic Evaluations of Health Care Workshop*
Simon Pickard and **Feng Xie** (co-Principal Investigators)
EuroQol Research Foundation
October 2019 (€7,400)
20. *Modelling dependence in EQ-VT DCE data: impact on value sets*
Eleanor Pullenayegum (Principal Investigator), **Feng Xie** and Simon Pickard (co-Investigators).
EuroQol Research Foundation
July 2019-December 2020 (€31,800)
21. *Phase 2 field-test study to validate new BREAST-Q scales*
Anne Klassen (Principal Investigator); **Feng Xie**, Toni Zhong Louise Bordeleau, Andrea Pusic (Co-Investigators)
Canadian Cancer Society
July 2019-June 2020 (\$140,254)

Year 2018

22. *Development of a preference-based disease-specific health-related quality of life instrument for glaucoma (Validation)*
Feng Xie (Principal Investigator), Ike Ahmed, Sergei Muratov, Dominik Podbielski (Co-Investigators)
Glaucoma Research Society of Canada
June 1, 2018-May 31, 2019 (\$19,924)
23. *Non-parametric approach to valuing the EQ-5D-5L.*
Feng Xie (Principal Investigator), Stephanie Thomas (co-Investigator)
The EuroQoL Research Foundation
December 2018-November 2019 (€28,600)
24. *Assessing the certainty of evidence about patients' values, preferences and utilities*
Holger Schunemann (Principal Investigator), Jan Brozek, Tammy Clifford, Tahira Devji, Gordon Guyatt, Nancy Santesso, **Feng Xie**, Juan Yepes-Nuñez, Yuan Zhang (co-Investigators)
Canadian Institutes of Health Research Project Grant
June 2018-June 2021 (\$156,825)
25. *Patient Preferences in China-Application of Best-Worst Scaling*
Xiaoning He (Principal Investigator); **Feng Xie** and Jin Wu (Co-investigators)
China National Natural Sciences Foundation New Investigator Project Scheme
June 2018-May 2021 (\$36,000)
26. *Early Rehabilitation in Critically ill Children – The PICU Liber8 Pilot Study*

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

Karen Choong (Principal Investigator); Cynthia Cupido, Michelle Kho, Carlos A. Garcia Cuello, Lehana Thabane, **Feng Xie**, Canci Filomena, Melissa Brouwers (Co-Investigators).
Hamilton Academic Health Sciences Organization (HAHSO) AFP Grant
January 2018- December 2019 (\$274,979)

Year 2017

27. *REVISE: Re-Evaluating the Inhibition of Stress Erosions in the ICU*

Gordon Guyatt (Principal Investigator); Waleed Alhazzani, Mohammed Alshahrani, Ian Ball, Jeffrey Barletta, Rodrigo Cartin-Ceba, Emmanuel Charbonney, Laurence Chau, Deborah Cook, Adam Deane, Peter Dodek, Erick Duan, Shane English, Simon Finfer, Andreas Freitag, Alberto Goffi, Eyal Golan, Richard Hall, Margaret Herridge, Daniel Johnson, Salmaan Kanji, Timothy Karachi, Francois Lamontagne, François Lauzier, Osama Loubani, John Marshall, Sangeeta Mehta, John Muscedere, John Myburgh, Richard Oeckler, Daniel Ovakim, Brenda Reeve, Steven Reynolds, Bram Rochweg, Marios Roussos, Orla Smith, Michael Surette, Lehana Thabane, Jennifer Tsang, David Williamson, Gordon Wood, **Feng Xie**, Ryan Zarychanski (Co-Investigators)
Canadian Institutes of Health Research Project Grant
April 2017-March 2021(\$1,935,832)

28. *Improving decision making in pregnant women facing a thromboprophylaxis decision*

Brittany Humphries (Award recipient), **Feng Xie** (Principal Investigator), Pablo Alonso, Shannon Bates, Gordon Guyatt, Mark Eckman, Ian Greer, Yuqing Zhang, Luciane Lopes, , Susan Jack, Sarah McDonald, Saskia Middeldorp, Marc Rodger, Ampro Santamaria (co-investigators)
CIHR Doctoral Award
September 2017-August 2020 (\$105,000)

29. *Developing effective, cost-effective, personalized treatments for Chinese patients with systemic lupus erythematosus*

Liangjing Lu (Principal Investigator);Wanling Yang, Di Yu, **Feng Xie** (Co-Investigators).
The National Key Research and Development Program of China
July 2017- December 2019 (¥ 19,570,000 =C\$3,914,000)

Year 2016

30. *A multi-center, randomized controlled trial comparing the clinical effectiveness and cost-effectiveness of collagenase injection (Xiaflex) and palmar fasciectomy in the management of Dupuytren's disease - Evaluation of Xiaflex: Trial of Effectiveness in Dupuytren's (EXTEND)*

Achilles Thoma (Principal Investigator); **Feng Xie**, Gary Foster, Lehana Thabane (Co-Investigators).
Physicians' Services Incorporated Foundation
October 2016-September 2018 (\$106,000)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

31. *PROSPECT: Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial*
Jennie Johnstone (Principal Investigator), Ian Ball, Rodrigo Cartin-Ceba, Emmanuel Charbonney, Laurence Chau, Deborah Cook, Joanna Dionne, Peter Dodek, Erick Duan, Gary Garber, Martin Girard, Eyal Golan, Richard Hall, William Henderson, Margaret Herridge, Daniel Johnson, Timothy Karachi, Kosar Khwaja, Arnold Kristof, Demitrios Kutsogiannis, Daphnée Lamarche, Francois Lamontagne, François Lauzier, John Marshall, Lauralyn Mcintyre, Mauree Meade, Sangeeta Mehta, Andrew Morris, John Muscedere, Richard Oeckler, Daniel Ovakim, Brenda Reeve, Bram Rochweg, Louise Rose, Orla Smith, Michael Surette, Robert Taylor, Lehana Thabane, David Williamson, Gordon Wood, **Feng Xie**, Ryan Zarychanski (co-Investigators)
Canadian Institutes of Health Research Project Grant
July 2016-June 2021 (\$1,272,893)
32. *Randomized controlled trial of balance training for fall reduction in individuals with COPD*
Dina Brooks, Marla Beauchamp, Roger Goldstein (Principal Investigators); Jennifer Alison, Patricia Camp, Gail Dechman, Samantha Harrison, Anne Holland, Annemarie Lee, Alda Marques, Rahim Moineddin, Jacqueline Sandoz, Elizabeth Skinner, Lissa Spencer, Michael Stickland, **Feng Xie** (co-Investigators)
Canadian Institutes of Health Research Project Grant
July 2016-June 2019 (\$902,111)
33. *Aldosterone antagonism and enhanced Clearance for Health Improvement Evaluation in End-stage renal disease (ACHIEVE) Trial*
Michael Walsh (Principal Investigator); Jacqueline Bosch, Giuseppe Bueti, Sacha De Serres, Philip Devereaux, Amit Garg, Carmel Hawley, Richard Haynes, William Herrington, Rachel Holden, Lai Hooi, Adeera Levin, Zuo Li, Madore, Jolanta Malyszko, Braden Manns, Jan Menne, François Nessim, Sanjay Pandeya, Neesh Pannu, Vlado Perkovic, Christian Rabbat, Andrew Smyth, Rita Suri, Karthik Tennankore, Vladimir Tesar, Lehana Thabane, Ron Wald, Matthew Weir, **Feng Xie**, Deborah Zimmerman (co-Investigators)
Canadian Institutes of Health Research Project Grant
July 2016-June 2022 (\$2,652,816)
34. *Preventing cognitive and functional decline among seniors at risk: A community-based randomized controlled trial*
Dawson, Deirdre (Principal Investigator), Nicole Anderson, Anna Ballon, Malcolm Binns, Emily Nalder, Julie Richardson, Elizabeth Skidmore, Angela Troyer, Gordon Winocur, **Feng Xie** (Co-Investigators), Sherri Bulmer, Sue Hesjedahl, Leonna Rodall, Jasmine Surkari (Collaborators)
Canadian Institutes of Health Research Project Grant
July 2016-June 2021 (\$1,191,091)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

35. *Development of a preference-based disease-specific health-related quality of life instrument for glaucoma*
Ike Ahmed, **Feng Xie** (Co-Principal Investigators), Sergei Muratov, Dominik Podbielski (Co-Investigators)
Glaucoma Research Society of Canada
June 1, 2016-May 31, 2017 (\$19,959)
36. *Using eHealth to enhance the participation of adults with subjective cognitive decline: a pilot feasibility study*
Emily Nalder (Principal Investigator); **Feng Xie**, Deirdre Dawson, Deirdre, Catherine Donnelly, Nicole Anderson, Kelly Murphy (Co-Investigators)
AGE-WELL National Centre of Excellence Catalyst Program
May 1, 2016 – April 30, 2017 (\$35,000)
37. *Including quality of life in breast cancer funding policy decisions: development of a preference-based measure from the BREAST-Q*
Anne Klassen (Principal Investigator); **Feng Xie**, Toni Zhong Louise Bordeleau, Eleanor Pullenayegum, Stefan Cano, Evan Matrose, Andrea Pusic (Co-Investigators)
Canadian Breast Cancer Foundation
May 2016-April 2018 (\$277,872)
38. *An ounce of prevention: intensive resistance training to optimize health in prefrail older adults*
Ada Tang (Project Lead), Christopher Gordon, **Feng Xie** (Principal Investigators). Julie Richardson, Norma MacIntyre, Rick Adachi (Co-Investigators).
Canadian Frailty Network
April 2016-April 2017 (\$73,991 cash and \$81,900 in-kind)
39. *Traversing the boundaries – Impact of an integrated multidisciplinary tertiary-community Pediatric Complex Care clinic: A pilot study*
Audrey Lim (Principal Investigator), Peter Rosenbaum, Lehana Thabane, Madan Roy, Frank O'Toole, Dix Joanne, Brennan Cynthia, Ramsay Macnay, Anne Klassen, **Feng Xie** (Co-Investigators)
Hamilton Health Sciences Foundation
February 2016-January 2017 (\$50,000)
40. Engaging patients and general public in health technology assessment: Measuring and valuing health preferences (for Health Technology Assessment International Pre-Conference Workshop)
Feng Xie (Principal Applicant), Simon Pickard, Eleanor Pullenayegum, and Jeffrey Johnson (Co-applicants)
The EuroQol Research Foundation
May 2016 (€23,220)

Year 2015

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

41. *Making LIFE simple: Exploration of a hybrid of best-worst scaling and visual analogue scale in valuing EQ-5D-5L*
Feng Xie (Principal Investigator); Eleanor Pullenayegum, Simon Pickard (Co-Investigators)
EuroQol Research Foundation
September 2015-June 2017 (€59,450)
42. *Integrating a neonatal healthcare package in Malawi*
Kondwani Kawaza, David Goldfarb and Queen Dube (Co-Principal Investigator);
Lehana Thabane, Jeffrey Pernica, Lawrence Mbuagbaw, **Feng Xie**, Maureen Dobbins (Co-Investigators)
International Development Research Center
March 2015-Feb 2019 (\$1,000,000)
43. *Evaluating consistency between DCE and TTO valuations using multivariate mixed models and multivariate latent class analysis*
Eleanor Pullenayegum (Principal Investigator); **Feng Xie**, Simon Pickard (Co-Investigators)
EuroQol Research Foundation
June 2015-June 2016 (€21,650)
44. *Maintaining independence in everyday life among seniors with subjective cognitive complaints*
Deirdre Dawson (Principal Investigator); Malcolm Binns, Julie Richardson, Nicole Anderson, Emily Nalder, Elizabeth Skidmore, Angela Troyer, Gordon Winocur, **Feng Xie** (Co-Investigators)
Canadian Institutes for Health Research (CIHR)
July 2015 to June 2016 (\$100,000)
45. *Clinical Outcomes, Health-related Quality of Life and Costs Following Bariatric Surgery: An Analysis of the Ontario Bariatric Registry Linked to Ontario Administrative Databases*
Jean-Eric Tarride, Mehran Anvari (Co-Principal Investigators); Daria O'Reilly, Michael Paterson, Eleanor Pullenayegum, Valerie Taylor, David Urbach, **Feng Xie** (Co-Investigators)
Canadian Institutes for Health Research (CIHR)
July 2015 to June 2017 (\$149,106)
46. *Protection of the heart with aldosterone antagonism in end-stage renal disease trials (PHASE-2)*
Michael Walsh, Ron Wald, and PJ Devereaux (Principal Investigators); Brendan Barrett, Jacqueline Bosch, Giuseppe Buetti, Sacha De Serres, Amit Garg, Carmel Hawley, Rachel Holden, Adeera Levin, Francois Madore, Braden Manns, David Mendelsohn, Sharon Nissem, Patrick Parfrey, Vlado Perkovic, Janice Pogue, Andrew Smyth, Manish Sood, Rita Suri, Karthik Tennankore, Marcello Tonelli, **Feng Xie** (Co-Investigators)
Canadian Institutes for Health Research (CIHR)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

July 2015 to June 2016 (\$100,000)

47. *Tele-Rehabilitation for Cognitive Disability Post-Stroke: Enhancing Function in the Face of Geographical Disparities*

Deirdre Dawson (Principal Investigator); Nicole Anderson, Beth Linkewich, Sara McEwen, Emily Nalder, Elizabeth Skidmore, **Feng Xie** (Co-Investigators)
Heart and Stroke Foundation Canadian Partnership for Stroke Recovery (CPSR)
July 2015 to December 31, 2016 (\$50,000)

48. *Valuation of the EQ-5D in countries with limited research resources: investigating the potential of shrinkage analysis*

Eleanor Pullenayegum (Principal Investigator); Kelvin Chan, **Feng Xie** (Co-Investigators)
The EuroQoL Research Foundation
July 2015-Dec 2016 ((€21,300)

Year 2014

49. *Patient-centered Care Transitions in Heart Failure (PACT-HF): a pragmatic cluster randomized trial*

Harriette Van Spall (Principal Investigator); Brian Haynes, Stuart Connolly, Lehana Thabane, **Feng Xie** (co-Investigators)
Ministry of Health and Long-term Care (MOHLTC) Health Systems Research Fund Capacity Award
April 2014- March 2017 (\$1,018,126)

50. *Fit for Function: A Community Wellness Program for Persons with Stroke*

Julie Richardson, Ada Tang (Principal Investigator); Lisa Fronzi, Leanne Hammond, Rebecca Fleck, Gordon Guyatt, Robert Hart, Genevieve Hladysh, Louise Macrae, Demetrios Sahlas, Lehana Thabane, **Feng Xie** (Co-Investigators)
Canadian Institutes for Health Research (CIHR)
April 2014- March 2016 (\$347,043)

51. *Protection of the heart with aldosterone antagonism in end-stage renal disease trials (PHASE-2)*

Michael Walsh, Ron Wald, and PJ Devereaux (Principal Investigators); Brendan Barrett, Jacqueline Bosch, Giuseppe Buetti, Sacha De Serres, Amit Garg, Carmel Hawley, Rachel Holden, Adeera Levin, Francois Madore, Braden Manns, David Mendelssohn, Sharon Nissem, Patrick Parfrey, Vlado Perkovic, Janice Pogue, Andrew Smyth, Manish Sood, Rita Suri, Karthik Tennankore, Marcello Tonelli, **Feng Xie** (Co-Investigators)
Canadian Institutes for Health Research (CIHR)
April 2014 to March 2015 (\$100,000)

Year 2013

52. *Understanding participant's responses to the EQ-VT tasks; A qualitative study*

Feng Xie (Principal Investigator), Jeff Johnson (Co-Investigator)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

The EuroQol Group Foundation
December 2013 – May 2014 (€24,940)

53. *Transforming latent utilities to health utilities: Can one function fit other countries?*

Feng Xie (Principal Investigator), Eleanor Pullenayegum, Simon Pickard (Co-Investigators)

The EuroQol Group Foundation
November 2013 – April 2014 (€9,950)

54. *Establishing a tool for endorsing EQ-5D valuation studies*

Feng Xie (Principal Investigator), Simon Pickard (Co-Investigator)

The EuroQol Group Foundation
September 2013 – August 2014 (€38,500)

55. *Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF)*

Jafna Cox (Principal Investigator), Lehana Thabane, **Feng Xie**, Raza Abidi, Samina Abidi, Ratika Parkash (Co-Investigators)

Capital District Health Authority
July 2013-June 2018 (\$5,298,994)

56. *Assessing test-retest reliability of the EuroQol Group Valuation Technology in valuing the EQ-5D-5L*

Feng Xie (Principal Investigator), Jeffrey Johnson and Eleanor Pullenayegum (Co-Investigators)

The EuroQol Group Foundation
July 2013-June 2014 (\$93,599)

57. *Diabetes Education Centres in Ontario: Field Evaluation (Phase II)*

Ron Goeree (Principal Investigator), **Feng Xie** (Co-Principal Investigator); Jim Bowen, Daria O'Reilly, Gord Blackhouse, Robert Hopkins (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)

April 2013 – March 2015 (\$211,944)

58. *Using the general public to estimate health-related quality-of-life in Alzheimer's disease: development and validation of clinical vignettes*

Feng Xie, Mark Oremus (Co-Principal Investigators), Eleanor Pullenayegum (Co-Investigator)

Canadian Institutes for Health Research (CIHR)
April 2013- March 2014 (\$100,000)

Year 2012

59. *Valuing health status of general population using the EQ-5D Valuation Technology (EQ-VT)*

Feng Xie (Principal Investigator); Jeffrey Johnson, Nick Bansback, Stirling Bryan, Arto Ohinmaa, Lise Poissant, Eleanor Pullenayegum (Co-investigators)

The EuroQol Group Foundation

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

October 2012 – March 2013 (\$26,088)

60. *Improving patient-reported outcome measures: Valuation and application of the EQ-5D in Canada*

Feng Xie (Principal investigator)

Canadian Institutes for Health Research (CIHR) New Investigator Award

September 1, 2012 – August 30, 2017 (\$300,000)

61. *Health system design and health services reforms for aboriginal and other vulnerable populations: A systematic review of the evidence*

Nazila Assasi (Principal Investigator); Gord Blackhouse, Kaitryn Campbell, **Feng Xie**, Ron Goeree (Co-investigators)

Canadian Agency for Drugs and Technologies in Health (CADTH)

September 2012 - February 2013 (\$36,857)

62. *Valuing health status of general population: Development of the protocol for the Canadian EQ-5D-5L valuation study*

Feng Xie (Principal Investigator); Jeffrey Johnson, Nick Bansback, Stirling Bryan, Arto Ohinmaa, Lise Poissant, Eleanor Pullenayegum (Co-investigators)

The EuroQol Group Foundation

August 2012 (\$15,308)

63. *Be healthy in pregnancy (BHIP) with nutrition & exercise*

Stephanie Atkinson, Keyna Bracken, Maureen Dobbins, Eileen Hutton, Michele Mottola, Stuart Phillips (Co-Principal Investigators)

S. Grafe, D. Shrott, V. Taylor, L. Thabane, J. Vickers-Manzin, O. Wahoush, **Feng Xie** (Co-Investigators)

Canadian Institutes for Health Research (CIHR)

June 1, 2012 - May 30, 2017 (\$970,364)

64. *High-sensitivity cardiac Troponin for the rapid diagnosis of acute coronary syndrome and acute myocardial infarction in the emergency department: A clinical and cost-effectiveness evaluation*

Ron Goeree (Principal Investigator); Nazila Assasi Gord Blackhouse, Kaitryn Campbell, **Feng Xie**, Ron Goeree (Co-investigators)

Canadian Agency for Drugs and Technologies in Health (CADTH)

March 2012-March 2013 (\$122,509)

65. *Development of a generic health-related quality of life (HRQL) preference-based measure for preschoolers: Mapping the Health Status Classification System Preschool (HSCS-PS) to the HUI2/3 scoring algorithm*

Ronald Barr (Principal investigator); **Feng Xie**, Eleanor Pullenayegum (Co-investigators)

Canadian Institutes for Health Research (CIHR)

April 1, 2012 – March 31, 2015 (\$199,506)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

66. *Codeine and Acetaminophen for Pain Relief: A Review of the Clinical Efficacy and Safety*
Nazila Assasi (Principal Investigator); Gord Blackhouse, Kaitryn Campbell, Robert Hopkins, **Feng Xie**, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
March 2012-April 2012 (\$9,434)
67. *Improving patient-reported outcome measures to support evidence based decision making: establishing measurement properties of the EQ-5D*
Feng Xie (Principal investigator), Eleanor Pullenayegum; Daria O'Reilly, Jean-Eric Tarride, Ron Goeree (co-investigators)
Canadian Institutes for Health Research (CIHR)
February 1, 2012 – January 31, 2014 (\$198,435)
68. *Newborn Screening for Krabbe Leukodystrophy: Clinical and Cost effectiveness and Guidelines*
Gord Blackhouse (Principal Investigator); Nazila Assasi, Kaitryn Campbell, **Feng Xie**, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
January 2012- February 2012 (\$7,032)

Year 2011

69. *Valuing health status of general population: Development of a Canadian specific preference-based scoring algorithm for EQ-5D*
Feng Xie, Jeffrey Johnson (Co-Principal Investigators); Nick Bansback, Stirling Bryan, Nan Luo, Arto Ohinmaa, Lise Poissant, Eleanor Pullenayegum (Co-investigators)
Canadian Institutes for Health Research (CIHR)
April 2011 – March 2013 (\$443,766)
70. *Costs, Health-Related Quality of Life and Cost-Effectiveness of Bariatric Surgeries in Canada: An Analysis of the Bariatric Registry*
Jean-Eric Tarride, Mehran Anvari (Co-Principal Investigators); Ron Goeree, Daria O'Reilly, Ayra Sharma, **Feng Xie** (Co-investigators)
Canadian Institutes for Health Research (CIHR)
April 2011 – May 2012 (\$98,200)
71. *Health technology assessment and field evaluation program*
Ron Goeree (Principal Investigator); Daria O'Reilly, James Bowen, Kiran Chandra, Jean-Eric Tarride, **Feng Xie**, Gord Blackhouse, Rob Hopkins, Kaitryn Campbell (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
April 2011 – March 2012 (\$1,218,304)
72. *Medical Isotopes (Optimizing Health System Use of Medical Isotopes and Other Imaging Modalities): Part 3 - Evaluation Reports for Clinical Uses*

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

Ron Goeree (Principal Investigator); Nazila Assasi, Gord Blackhouse, Kaitryn Campbell, **Feng Xie**, K.Gulenchyn, Simone Sutherland, Kathy Gaebel, Jim Bowen. Canadian Agency for Drugs and Technologies in Health (CADTH)
February 2011-June 2011 (\$230,889)

73. *A meeting to develop a Canadian Diabetes Economic Model*

Daria O'Reilly (Principal Investigator) Gord Blackhouse, Andrew Briggs, Philip Clarke, Ron Goeree, Leslie Levin, Jean-Eric Tarride, **Feng Xie** (Co-Investigators)
CIHR - Meetings, Planning and Dissemination Grant
February 2011 – February 2012 (\$15,626)

74. *Development of an Ontario provincial epilepsy care strategy*

James Bowen (Principal Investigator); Daria O'Reilly, **Feng Xie**, Kaitryn Campbell, Jean-Eric Tarride, Gord Blackhouse Ron Goeree (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
January 2011 – March 2012 (\$135,367)

Year 2010

75. *Health technology assessment of laparoscopic band surgery in Ontario*

Jean-Eric Tarride (Principal Investigator); Daria O'Reilly, **Feng Xie**, James Bowen, Gord Blackhouse, Robert Hopkins, Ron Goeree (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
November 2010 – March 2015 (\$859,473)

76. *Medical Isotopes (Optimizing Health System Use of Medical Isotopes and Other Imaging Modalities): Part 2 - Pilot Evidence assessments*

Ron Goeree (Principal Investigator); Nazila Assasi, Gord Blackhouse, Kaitryn Campbell, **Feng Xie**, K. Gulenchyn, Simone Sutherland, Kathy Gaebel, Jim Bowen
Canadian Agency for Drugs and Technologies in Health (CADTH)
November 2010 - January 2011 (\$135,737)

77. *An economic evaluation of low-intensity pulsed ultrasound in patients with tibial shaft fractures*

Ron Goeree (Principal Investigator); Jean-Eric Tarride, O'Reilly D, **Feng Xie**, James Bowen, Natasha Burke (Co-investigators)
Sub-contract from Jason Busse (Institute for Work & Health, Toronto, Ontario)
Base funding provided by Canadian Institute for Health Research (CIHR)
October 2010 – September 2011 (\$17,800)

78. *The development and validation of an Ontario Policy and Economic model in Rheumatoid Arthritis (OPERA)*

Jean-Eric Tarride (Principal Investigator); Jim Bowen, Daria O'Reilly, Rob Hopkins, Gord Blackhouse, Jonathon D. Adachi, **Feng Xie**, Ron Goeree (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
October 2010 – March 2013 (\$145,000)

79. *Left atrial appendage occlusion: Cost-effectiveness in a Canadian setting*

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

- Feng Xie** (Principal Investigator); Gord Blackhouse, Nazila Assasi, Kaitryn Campbell, Kathryn Gaebel, Simone Sutherland, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
September 2010 – October 2010 (\$7,412)
80. *Multi-Country study on the relationship between discrete choice and time trade-off derived EQ-5D-5L health state values*
Paul Krabbe (Principal Investigator); Nancy Devlin, Luciana Scalone **Feng Xie** (Co-Principal Investigators), Jeffrey Johnson, Stirling Bryan, John Brazier, Aki Tsuchiya, Andrew Lloyd, Elly Stolk, Arto Ohinmaa, Nick Bansback (Co-Investigators)
The EuroQol Group Foundation
September 2010 – March 2011(€217,000)
81. *Diabetes education centres in Ontario: Costs, performance, and outcomes*
Feng Xie (Principal-Investigator); Daria O'Reilly, Jim Bowen, Jean-Eric Tarride, Ron Goeree (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
August 2010- March 2013 (\$297,000)
82. *Ventilation during patient transport: A review of clinical effectiveness and guidelines*
Feng Xie (Principal Investigator); Nazila Assasi, Kaitryn Campbell, Kathryn Gaebel, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
August 2010 – September 2010 (\$16,621)
83. *Alpha1-Proteinase Inhibitor therapy for Alpha1-Antitrypsin deficiency: A review of the clinical evidence*
Feng Xie (Principal Investigator); Kathryn Gaebel, Nazila Assasi, Kaitryn Campbell, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
August 2010 – September 2010 (\$13,167)
84. *Medical Isotopes (Optimizing Health System Use of Medical Isotopes and Other Imaging Modalities): Part1 - Feasibility Assessment*
Ron Goeree (Principal Investigator); Nazila Assasi, Kaitryn Campbell, **Feng Xie**, K.Gulenchyn, Simone Sutherland, Kathy Gaebel, Jim Bowen (Co-Investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
July 2010 - September 2010 (\$48,818)
85. *The health, social and financial effects of care-giving among primary caregivers of elderly stroke patients in the first post-stroke year: A prospective cohort study*
Gerald Koh (Principal Investigator); **Feng Xie**, Hong Song-Lee, Kalyani Mehta, David Matchar, Nandita Banerjee, Luo Nan, Angelique Chan, Ramani NV, Chan Kin Ming, Tan Boon Yeow, Edward Menon, Ee Chye He, Sherry Young, Ng Yee Sien, Effie Chew, Sandra Mackey (Co-Investigators)
Ministry of Health Singapore Health Services Research Competitive Research Grant

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

July 2010-August 2012 (S\$922,590)

86. *Development of an Ontario policy and economic model in chronic obstructive pulmonary disease*
Ron Goeree, Gord Blackhouse (Principal Investigators); Daria O'Reilly, Jean-Eric Tarride, **Feng Xie**, Jim Bowen (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
July 2010 – June 2011 (\$429,737)
87. *Bluetooth®-enabled hearing technologies: A review of the clinical cost-effectiveness*
Feng Xie (Principal Investigator); Simone Sutherland, Kathryn Gaebel, Kaitryn Campbell, Gord Blackhouse, Nazila Assasi, Brett Doble, Ron Goeree (Co-investigators).
Canadian Agency for Drugs and Technologies in Health (CADTH)
May 2010 – June 2010 (\$10,579)
88. *Valuing health status of general population: Development of a Canadian specific preference-based scoring algorithm for EQ-5D (Pilot)*
Feng Xie, Jeffrey Johnson (Co-Principal Investigator); Nick Bansback, Bryan Stirling, Nan Luo, Arto Ohinmaa (Co-investigators)
Canadian Institutes for Health Research (CIHR)
April 2010 - March 2012 (\$100,000)
89. *Comparative Efficacy of Oral Disease Modifying Drugs for the Prevention of Relapses in Patients with Relapsing-Remitting Multiple Sclerosis*
Feng Xie (Principal Investigator); Brett Doble (Student)
Canadian Institutes for Health Research (CIHR)
April 2010-March 2011 (\$17,850)
90. *Use of discrete choice experiment in measuring utilities: Binary or triplet?*
Feng Xie (Principal Investigator); Kathryn Gaebel, Mark Oppe, Eleanor Pullenayegum, Paul Krabbe (Co-investigators)
The EuroQol Group Foundation
February 2010-December 2010 (\$28,484)
91. *The effectiveness and costs effectiveness of laparoscopic adjustable gastric banding compared to Laparoscopic Roux-en-Y gastric bypass in Ontario*
Jean-Eric Tarride (Principal Investigator); Daria O'Reilly, **Feng Xie**, James Bowen, Gord Blackhouse, Robert Hopkins, Ron Goeree (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
February 2010 – March 2015 (\$275,000)
92. *Cost utility analysis of Anastrozole and Tamoxifen for early stage breast cancer*
Alexandre Chan (Principal Investigator); **Feng Xie**, Nancy Ko, Vivianne Lee (Co-Investigators),
The National University of Singapore Star-up Fund
January 2010-September 2010 (S\$20,000)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

Year 2009

93. *Development of an Ontario policy and economic model in rheumatoid arthritis (OPERA)*
Jean-Eric Tarride (Principal Investigator); **Feng Xie**, Matthias Bischof, Kiran Chandra, Daria O'Reilly, Gord Blackhouse, Robert Hopkins, Ron Goeree (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
December 2009 – December 2012 (\$409,883)
94. *Health technology assessment of diabetes education centres in Ontario*
Feng Xie (Principal Investigator); Daria O'Reilly, Jim Bowen, Jean-Eric Tarride, Gord Blackhouse, Ron Goeree (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
December 2009 – March 2013 (\$409,883)
95. *Valuing health status of general population: A pilot study on development of a Canadian preference-based scoring system for the new 5-level EQ-5D*
Feng Xie, Jeffrey Johnson (Co-Principal Investigators); Nick Bansback, Bryan Stirling, Arto Ohinmaa (Co-investigators)
The EuroQol Group Foundation
December 2009-December 2011 (€30,000)
96. *Health technology assessment of insulin pumps for Type 1 diabetes in Ontario*
Daria O'Reilly (Principal Investigator); **Feng Xie**, Jean-Eric Tarride, James Bowen, Gord Blackhouse, Robert Hopkins, Ron Goeree (Co-investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
December 2009 – June 2011 (\$409,883)
97. *Pharmacoeconomic evaluation of treatments for chronic diseases*
Nancy Ko (Principal Investigator); **Feng Xie**, Alex Chan, Vivianne Shih (Co-investigators)
National University of Singapore (Start-up Grant)
September 2009 – August 2012 (\$180,000)
98. *Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses*
Feng Xie (Principal Investigator); Nazila Assasi, Gord Blackhouse, Diana Robertson, Kathy Gaebel, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
July 2009-June 2010 (\$153,888)
99. *Feasibility of an Altruistic Sperm Donation Program in Canada*
Ed Hughes (Principal Investigator); **Feng Xie**, Daria O'Reilly, James Bowen, Kuhan Perampaladas (Co-Investigators)
Assisted Human Reproduction Canada (AHRC)
July 2009-December 2009 (\$25,000)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

100. *Triple therapy for Chronic Obstructive Pulmonary Disease*
Feng Xie (Principal Investigator); Kathy Gaebel, Gord Blackhouse, Diana Robertson, Nazila Assasi, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
April 2009-December 2009 (\$155,414)
101. *Modelling approaches for health technology assessment: A practical hands-on workshop*
Ron Goeree, Uwe Siebert (Co-Principal Investigators); Beate Jahn, **Feng Xie**, Daria O'Reilly, Ilia Ferrusi, Mirjam Kretzschmar, Jean-Eric Tarride, Gord Blackhouse Gaby Sroczynski (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
March 2009 - December 2009 (\$52,500)

Year 2008

102. *Portable ultrasound in small emergency departments: A review of the guidelines and clinical effectiveness*
Feng Xie (Principal Investigator); Kathy Gaebel, Kellee Kaulback, Diana Robertson, Gord Blackhouse, Nazila Assasi, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
Dec 2008 – Jan 2009 (\$13,163)
103. *Intravenous immunoglobulin (IVIG) for the treatment of chronic inflammatory demyelinating polyneuropathy: Clinical and cost-effectiveness analyses*
Feng Xie (Principal Investigator); Kathy Gaebel, Gord Blackhouse, Nazila Assasi, Kaitryn Campbell, Rob Hopkins, Colin Chalk, Mitchell Levine, Mita Giacomini, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
May 2008 – Dec 2008 (\$83,704)
104. *Development and implementation of a Type 2 Diploma program for university graduate level students to increase Canadian capacity for assessing and monitoring the use of new and existing health technologies (Letter of Intent)*
Ron Goeree, Murray Krahn, Larry Lynd (Co-Principal Investigators); Jean-Eric Tarride, Louise Lemieux-Charles, Carlo Marra, **Feng Xie**, Daria O'Reilly (Co-investigators)
Canadian Institutes for Health Research (CIHR)
April 2008 – March 2009 (\$5,000) (Preparation of full proposal)
105. *Health technology assessment of various programs considered by the Ontario Diabetes Evidentiary Working Group (DEWG)*
Ron Goeree (Principal Investigator); Kiran Chandra, Gord Blackhouse, Daria O'Reilly, Jim Bowen, Jean-Eric Tarride, **Feng Xie** (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
April 2008 – March 2009 (\$535,559)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

106. *Health technology assessment of magnetoencephalography (MEG) utilization in the diagnosis of drug refractory epilepsy in children*
Jim Bowen (Principal Investigator); Daria O'Reilly, Rob Hopkins, Jean-Eric Tarride, **Feng Xie**, Lisa Patterson, Ron Goeree (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
April 2008 – March 2011 (\$535,559)
107. *A retrospective, single-centre, descriptive chart review to characterize the health system delays associated with the neurological evaluation for surgery of children and adolescents with drug refractory epilepsy and to characterize the role of magnetoencephalography (MEG) in this diagnostic evaluation*
Ron Goeree (Principal Investigator); Daria O'Reilly, Jean-Eric Tarride, **Feng Xie**, Jim Bowen, Rob Hopkins (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
April 2008 – March 2011 (\$179,592)
108. *Anti-TNF- α drugs in refractory inflammatory bowel disease: Clinical and cost-effectiveness analyses*
Feng Xie (Principal Investigator); Gord Blackhouse, Nazila Assasi, Kaitryn Campbell, John Marshall, Jan Irvine, Mita Giacomini, Rob Hopkins, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
April 2008 – November 2008 (\$156,049)
109. *Health technology assessment of diabetes education programs (DEPs) in Ontario*
Daria O'Reilly (Principal Investigator); Jim Bowen, Jean-Eric Tarride, **Feng Xie**, Ron Goeree (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
March 2008 – December 2008 (\$252,109)
110. *Health technology assessment of computer assisted technology in chronic disease diabetes management*
Daria O'Reilly (Principal Investigator); Jim Bowen, Lisa Patterson, Gord Blackhouse, **Feng Xie**, Jean-Eric Tarride, Ron Goeree (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
March 2008 – March 2011 (\$252,109)
111. *Effectiveness and long-term cost-utility analysis of an interactive computer-assisted technology in chronic disease management: An application to a multi-faceted primary care diabetes management program*
Daria O'Reilly (Principal Investigator); Jim Bowen, Lisa Patterson, Gord Blackhouse, **Feng Xie**, Jean-Eric Tarride, Ron Goeree (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
March 2008 – March 2011 (\$220,000)

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

112. *Health technology assessment of health care interventions for community-based elderly based on the Falls/Fractures Economic Model in Ontario (FEMOR)*
Ron Goeree (Principal Investigator); Kiran Chandra, Gord Blackhouse, Daria O'Reilly, Jim Bowen, **Feng Xie**, Jean-Eric Tarride (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
January 2008 – March 2009 (\$252,109)

Year 2007

113. *Intravenous immunoglobulin (IVIG) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and immune thrombocytopenic purpura (ITP)*
Feng Xie (Principal Investigator); Gord Blackhouse, Nazila Assasi, Kaitryn Campbell, Rob Hopkins, Mitchell Levine, Jim Bowen, Mita Giacomini, Ron Goeree (Co-investigators)
Canadian Agency for Drugs and Technologies in Health (CADTH)
December 2007 – August 2008 (\$97,939)
114. *Development and application of a health outcome and costing prediction model for community-based elderly in Ontario*
Ron Goeree (Principal Investigator); Kiran Chandra, Gord Blackhouse, Rob Hopkins, Daria O'Reilly, Jean-Eric Tarride, **Feng Xie**, Jim Bowen, Tara Gomes, Michelle Bornstein, Tanya Khan, Gaylene Pron (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
November 2007 – March 2009 (\$252,109)
115. *Health Technology Assessment in context*
Ron Goeree (Principal Investigator); Jean-Eric Tarride, Daria O'Reilly, **Feng Xie** (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
November 2007 – March 2008 (\$15,000)
116. *Health-related quality of life and pharmacoeconomic evaluations in OA patients in Singapore, China, and Korea*
Shu-Chuen Li (Principal Investigator); **Feng Xie**, Hua Ye, SC Bae (Co-Investigators)
National University of Singapore Academic Research Grant
June 2007- August 2008 (S\$58,000)
117. *Negative pressure wound therapy (NPWT) for the treatment of chronic wounds. A 12-week, prospective, open-label, randomized, controlled clinical trial comparing negative pressure wound therapy (NPWT) to standard wound care for the treatment of chronic pressure wounds of the pelvic region*
Ron Goeree (Principal Investigator); Daria O'Reilly, Jean-Eric Tarride, **Feng Xie**, Jim Bowen, Lisa Patterson, Jim Mahoney (Co-Investigators)
Ontario Ministry of Health and Long Term Care (MOHLTC)
April 2007 – March 2011 (\$240,408)
118. *Cost-effectiveness analysis of total knee replacement and unicompartmental knee arthroplasty in patients with severe knee osteoarthritis*

RESEARCH FUNDING

i) Peer-reviewed agencies, and provincial and federal government bodies:

Feng Xie (Principal Investigator); Ngai-Nung Lo, Nan Luo, Hin-Peng Lee (Co-Investigators)

National University of Singapore Academic Research Grant
January 2007- December 2007 (S\$25,000)

119. *Cost-effectiveness analysis of population-based Helicobacter Pylori screening in prevention of gastric cancer in Chinese*

Feng Xie (Principal Investigator); Nan Luo, Hin-Peng Lee (Co-Investigators)

National University of Singapore Academic Research Grant
January 2007- August 2007 (S\$20,000)

120. *A prospective, double-blind, randomized, controlled clinical trial comparing standard wound care with adjunctive Hyperbaric Oxygen Therapy (HBOT) to standard wound care only for the treatment of chronic, non-healing ulcers of the lower limb in patients with diabetes mellitus*

Daria O'Reilly (Principal Investigator); Jim Bowen, Lisa Patterson, **Feng Xie**, Jean-Eric Tarride, Gord Blackhouse, Ron Goeree (Co-Investigators)

Ontario Ministry of Health and Long Term Care (MOHLTC)
January 2007 – August 2009 (\$270,000)

Year 2006

121. *Validation of International Classification of Functioning, Disability, and Health (ICF) Core Sets in Singapore*

Feng Xie (Principal Investigator); Shu-Chuen Li, Alarcos Cieza, Gerold Stucki, Ngai-Nung Lo, Hin-Peng Lee (Co-Investigators)

National University of Singapore Academic Research Grant
November 2006 – June 2007 (S\$28,000)

122. *Health Technology Assessment of the clinical and cost-effectiveness of Negative Pressure Wound Therapy (NPWT) for the treatment of chronic wounds in Ontario*

Jim Bowen (Principal Investigator); Ron Goeree, Daria O'Reilly, Jean-Eric Tarride, **Feng Xie**, Lisa Patterson, Gord Blackhouse (Co-Investigators)

Ontario Ministry of Health and Long Term Care (MOHLTC)
October 2006 – December 2009 (\$252,109)

123. *Health Technology Assessment of the clinical and cost-effectiveness of Hyperbaric Oxygen Therapy (HBOT) compared to standard wound care for the treatment of chronic, non-healing ulcers of the lower limb in patients with diabetes mellitus in Ontario*

Daria O'Reilly (Principal Investigator); Ron Goeree, Jim Bowen, Lisa Patterson, **Feng Xie**, Jean-Eric Tarride, Ludwik Fedorko, Ron Linden (Co-Investigators)

Ontario Ministry of Health and Long Term Care (MOHLTC)
October 2006 – February 2010 (\$360,525)

RESEARCH FUNDING

ii) Non-peer reviewed or non-government organizations, private agencies and industry:

Year 2019

124. *Cost Effectiveness Analysis of Mobile Integrated Health Teams in Niagara Emergency Services*
Feng Xie (Principal Investigator), Gina Agarwal, Richard Ferron (Co-Investigators)
Regional Municipality of Niagara
August 2019-July 2020 (\$16,960)

Year 2015

125. *Comparison of robotic-assisted thoracoscopic surgery, with video-assisted thoracoscopic surgery for early stage, non-small cell lung cancer: a cost-analysis*
Wael Hanna (Principal Investigator), **Feng Xie**, Christine Fahim, Manraj Kaur, Andrea Shiwcharan, Teresa Dalimonte (Co-Investigators)
Boris Family Centre for Robotic Surgery (\$5000 in-kind support)
August 2015-August 2016
126. *A pragmatic randomized trial to investigate the effectiveness of Behavioural Activation group therapy in reducing depressive symptoms and improving quality of life in patients with depression: BRAVE Feasibility and Pilot Study*
Zainab Samaann (Principal Investigator), Kathryn Litke, Kathleen McCabe, Jeff Whattam, Laura O'Neill, Terri Ann Tabak, Scott Simons, Sandra Chalmers, Meredith Vanstone, **Feng Xie**, Gordon Guyatt, Lehana Thabane (Co-Investigators)
St. Joseph's Healthcare Hamilton and the Gabe Cicci Foundation
127. *Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer: Analysis of Accuracy and Added Value*
Wael Hanna (Principal Investigator) Sriharsha Athreya, **Feng Xie**, Christine Fahim (Co-Investigators)
Intuitive Surgical Inc. (\$32,659)
November 2015-October 2016
128. *Robotic ICG Guided Surgery: A Novel Technique for Detecting and Targeting Small Lung Tumors*
Wael Hanna (Principal Investigator) Sriharsha Athreya, **Feng Xie**, Christine Fahim (Co-Investigators)
Boris Family Centre for Robotic Surgery (in-kind support)
129. *Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: A Randomized Controlled Trial*
Wael Hanna (Principal Investigator), Cyndie Horner, Andrea Shiwcharan, **Feng Xie**, Lehana Thabane, Gary Foster, Christine Fahim (Co-Investigators).
Boris Family Centre for Robotic Surgery (\$22,000, in-kind support)

Year 2012

130. *Review and application of statistical methods to correct for cross-over bias in oncology drug trials*

RESEARCH FUNDING

ii) Non-peer reviewed or non-government organizations, private agencies and industry:

Lehana Thabane (Principal Investigator); Natasha Burke, Kaitryn Campbell, Lisa Dolovich, Gary Foster, Ron Goeree, Jathishinie Jegathisawaran, Mitch Levine, Daria O'Reilly, Eleanor Pullenayegum, **Feng Xie** (Co-Investigators)

Roche Canada

December 2012 – April 2013 (\$47,600)

131. *Review, synthesis and classification of Performance-Based Risk-Sharing Agreements for HTA reimbursement decision making in Canada*

Ron Goeree (Principal Investigator); Natasha Burke, Kaitryn Campbell, Lisa Dolovich, Gary Foster, Jathishinie Jegathisawaran, Mitch Levine, Daria O'Reilly, Eleanor Pullenayegum, Lehana Thabane, **Feng Xie** (Co-Investigators)

Roche Canada

December 2012 – March 2013 (\$31,000)

132. *Burden of illness of diabetic foot ulcers in Canada*

Feng Xie (Principal Investigator); Rob Hopkins, Natasha Burke, Camilla von Keyserlingk, Ron Goeree (Co-Investigators)

Shire Regenerative Medicine

October 2012 – March 2013 (\$79,100)

133. *Budget impact analysis and cost effectiveness of DERMAGRAFT for patients with diabetic foot ulcers in Canada*

Feng Xie (Principal Investigator); Natasha Burke, Gord Blackhouse, Camilla von Keyserlingk, Jean-Eric Tarride, Ron Goeree (Co-Investigators)

Shire Regenerative Medicine

May 2012 – November 2012 (\$84,700)

Year 2011

134. *Time and healthcare resources utilized for preparation and administration of zoledronic acid and pamidronate in Canadian patients with metastatic bone disease: A Delphi Study*

Feng Xie (Principal Investigator); Rob Hopkins, Natasha Burke, Jean-Eric Tarride, Ron Goeree (Co-Investigators)

Amgen Canada Inc.

January 2011 – May 2011 (\$30,800)

Year 2010

135. *Measuring Health-related Quality-of-life for Alzheimer's Disease Using the General Public*

Feng Xie, Mark Oremus (Co-Principal Investigators); Kathy Gaebel (Co-Investigator)

McLaughlin Foundation

May 2010 – November 2010 (\$8209)

RESEARCH FUNDING

ii) Non-peer reviewed or non-government organizations, private agencies and industry:

136. *Feasibility of developing an economic model for a novel topical treatment for patients with venous leg ulcers*

Feng Xie (Principal Investigator); Ron Goeree (Co-Investigator)

CoDa Therapeutics Inc.

June 2010 – September 2010 (\$10,000)

137. *Pediatric acute diarrhea and gastroenteritis: Development of a health related quality of life instrument*

Bradley C. Johnston, Gordon Guyatt (Co-Principal Investigators); **Feng Xie**, Suneel Upadhye, Rachel Donen (Co-Investigators)

Biocodex

January 2010 – August 2010 (US\$35,000)

Year 2009

138. *Economic burden of illness study of atrial fibrillation in Canada*

Daria O'Reilly (Principal Investigator); **Feng Xie**, Robert Hopkins, Anjori Pasricha, Ron Goeree (Co-Investigators)

Sanofi Aventis Canada

September 2009 – August 2011 (\$306,700)

139. *Study feasibility and proposal development for a financial burden of illness study of atrial fibrillation in selected provinces in Canada*

Daria O'Reilly (Principal Investigator), **Feng Xie**, Robert Hopkins, Ron Goeree (Co-Investigators)

Sanofi-Aventis Canada Inc.

June 2009 (\$6,020)

140. *A cost-effectiveness analysis of Panitumumab in the treatment of metastatic colorectal cancer patients with non-mutated (wild-type) Kirsten Ras Sarcoma Virus (KRAS)*

Jean-Eric Tarride (Principal Investigator); Matthias Bischof, Gord Blackhouse, **Feng Xie**, Rob Hopkins, Ron Goeree (Co-investigators)

Amgen Canada Inc.

May 2009 – August 2009 (\$86,800)

141. *A time in motion study for intravenous bisphosphonates in patients with metastatic bone disease in Canada*

Feng Xie (Principal Investigator); Jean-Eric Tarride, Robert Hopkins, Natasha Burke, Ron Goeree (Co-investigators)

Amgen Canada Inc.

April 2009 – December 2010 (\$123,200)

142. *A review of health utilities across conditions common in pediatric and adult populations*

RESEARCH FUNDING

ii) Non-peer reviewed or non-government organizations, private agencies and industry:

Jean-Eric Tarride (Principal Investigator); Natasha Burke, Matthias Bischof, Robert B. Hopkins, Linda Goeree, Kaitryn Campbell, **Feng Xie**, Daria O'Reilly, Ron (Co-Investigators)

Amgen Canada Inc.

February 2009 – August 2009 (\$11,591)

143. *The cost-effectiveness of strontium ranelate for the management of osteoporosis*

Feng Xie (Principal Investigator); Robert Hopkins, Gord Blackhouse, Ron Goeree (Co-investigators)

Servier Canada

February 2009 – June 2009 (\$78,960)

Year 2008

144. *Evaluation of Etanercept for psoriasis in paediatrics*

Jean-Eric Tarride (Principal Investigator); Matthias Bischof, Natasha Burke, Gordon Blackhouse, Daria O'Reilly, **Feng Xie**, Ron Goeree (Co-investigators)

Amgen Canada Inc.

October 2008 – June 2009 (\$100,800)

145. *The burden of obesity, osteoarthritis and rheumatoid arthritis in Ontario*

Jean-Eric Tarride, **Feng Xie**, Daria O'Reilly, Jim Bowen, Lisa Dolovich, Ron Goeree (Co-Principal Investigators)

Pfizer Canada Inc.

September 2008 – December 2009 (\$98,950)

Year 2007

146. *Evaluation of etanercept for psoriasis in adults*

Jean-Eric Tarride (Principal Investigator); Gord Blackhouse, Rob Hopkins, **Feng Xie**, Ron Goeree (Co-investigators)

Amgen Canada Inc.

November 2007 – June 2008 (\$47,000)

147. *Cost-effectiveness of ENBREL in Canada*

Jean-Eric Tarride (Principal Investigator); **Feng Xie**, Gord Blackhouse, Rob Hopkins, Ron Goeree (Co-investigators)

Amgen Canada Inc.

September 2007 – December, 2007 (\$49,000)

148. *Cost-effectiveness analysis of escitalopram in treatment of severe major depressive disorder in the United Kingdom*

Feng Xie (Principal Investigator); Nicolas Despiegel, Natalya Danchenko, Karina Hansen (Co-Investigators)

Lundbeck SAS Global Outcomes and Health Technology Assessment Department

June 2007-May 2008 (€15,000)

RESEARCH FUNDING

ii) Non-peer reviewed or non-government organizations, private agencies and industry:

149. *Cost-effectiveness analysis of Escitalopram compared with Venlafaxine, Fluvoxamine, and Fluoxetine as a first-line treatment of major depressive disorder in Singapore*

Feng Xie (Principal Investigator); Jacquelyn Mah, Bindoo Chahal, Hoe-Chong Sim (Co-Investigators)

Lundbeck SAS Singapore

March 2007-January 2008 (€15,000)

LIFETIME PUBLICATIONS

a) Books

1. Thoma A, **Xie F**, Santos J, Goldsmith CH, Economic Evaluation in Surgery. In Achilles Thoma, Sheila Prague, Sphocles Voineskos, Charles Goldsmith (eds). Evidence-Based Surgery : A Guide to Understanding and Interpreting the Surgical Literature. Springer Nature Switzerland, 2019 Page 239-253.
2. Srinathan SK, **Xie F**. Clinical Decision Analysis. In Peter Angelos and Raymon Grogan (eds). Difficult Decisions in Endocrine Surgery : An Evidence-Based Approach. Springer International Publishing, 2018.
3. Kuar M, **Xie F**, Devji T. Chapter 2 : The Basics of Economic Evaluation. In Mohit Bhandari and Parag Sancheti (eds). Clinical Research Made Easy: A Guide to Publishing in Medical Literature, 2ed. Jaypee Brothers Medical Publishers. New Delhi, 2017.
4. **Xie F**, Johnson J (eds): 30th Scientific Plenary Meeting of EuroQol Group Proceedings, 2014.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

Year 2021

1. Zhou T, Chen Z, Li H, **Xie F**. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease. *Med Decis Making*. 2021 Apr 3;272989X211004532. doi: 10.1177/0272989X211004532. Online ahead of print.
2. Humphries B, León-García M, Bates S, Guyatt G, Eckman M, D'Souza R, Shehata N, Jack S, Alonso-Coello P, **Xie F**. Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed methods pilot study protocol. *BMJ Open*. 2021 Mar 22;11(3):e046021. doi: 10.1136/bmjopen-2020-046021.
3. Hay JW, Gong CL, Jiao X, Zawadzki NK, Zawadzki RS, Pickard AS, **Xie F**, Crawford SA, Gu NY. A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. *J Gen Intern Med*. 2021 Mar 8:1-10. doi: 10.1007/s11606-021-06674-z.
4. **Xie F**, Yan J, Agarwal G, Ferron R. Economic Analysis of Mobile Integrated Health Care Delivered by Emergency Medical Services Paramedic Teams. *JAMA Netw Open*. 2021 Feb 1;4(2):e210055.
5. Lau VI, **Xie F**, Basmaji J, Cook DJ, Fowler R, Kiflen M, Sirotich E, Iansavichene A, Bagshaw SM, Wilcox ME, Lamontagne F, Ferguson N, Rochweg B. Health-Related Quality-of-Life and Cost Utility Analyses in Critical Care: A Systematic Review. *Crit Care Med*. 2021 Feb 12. doi: 10.1097/CCM.0000000000004851.
6. Kaur MN, Klassen AF, **Xie F**, Bordeleau L, Zhong T, Cano SJ, Tsangaris E, Breitkopf T, Kuspinar A, Pusic AL. An international mixed methods study to develop a new preference-based measure for women with breast cancer: the BREAST-Q Utility module. *BMC Womens Health*. 2021 Jan 6;21(1):8.

Year 2020

7. Thoma A, Avram R, Dal Cin A, Murphy J, Duku E, **Xie F**. Cost-effectiveness Analysis of Abdominal-based Autogenous Tissue and Tissue-expander Implant following Mastectomy. *Plast Reconstr Surg Glob Open*. 2020 Apr 11;8(10):e2986. doi: 10.1097/GOX.0000000000002986.
8. Thoma A, Avram R, Dal Cin A, Murphy J, Duku E, **Xie F**. Comparing the Clinical and Cost-Effectiveness of Abdominal-based Autogenous Tissue and Tissue-Expander Implant: A Feasibility Study. *Plast Reconstr Surg Glob Open*. 2020 Apr 11;8(10):e3179. doi: 10.1097/GOX.0000000000003179.
9. Zhang M, Ma J, **Xie F**, Thabane L. Identifying factors associated with high use of acute care in Canada: protocol of a population-based retrospective cohort study. *BMJ Open*. 2020 Oct 15;10(10):e038008.
10. Michalowsky B, Hoffmann W, Kennedy K, **Xie F**. Is the Whole Larger than the Sum of its Parts? Impact of Missing Data Imputation in Economic Evaluation Conducted alongside Randomized Controlled Trials. *Eur J Health Econ*. 2020 Jul;21(5):717-728.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

11. Michalowsky B, Xie F, Kohlmann T, Wübbeler M, Gräske J, Thyrian J, Hoffmann W. Acceptability and Validity of the EQ-5D in Patients living with Dementia. *Value in Health* 2020. *Value Health*. 2020 Jun;23(6):760-767.
12. Rädke A, Michalowsky B, Thyrian J, Eichler T, Xie F, Hoffmann W. Who benefits most from collaborative dementia care from a patient and payer perspective? A subgroup cost-effectiveness analysis. *J Alzheimers Dis*. 2020;74(2):449-462.
13. Brozek JL, Canelo-Aybar C, Akl EA, Bowen JM, Bucher J, Chiu WA, Cronin M, Djulbegovic B, Falavigna M, Guyatt GH, Gordon AA, Boon MH, Hutubessy RCW, Joore MA, Katikireddi V, LaKind J, Langendam M, Manja V, Magnuson K, Mathioudakis AG, Meerpohl J, Mertz D, Mezencev R, Morgan R, Morgano GP, Mustafa R, O'Flaherty M, Patlewicz G, Riva JJ, Posso M, Rooney A, Schlosser PM, Schwartz L, Shemilt I, Tarride JE, Thayer KA, Tsaioun K, Vale L, Wambaugh J, Wignall J, Williams A, Xie F, Zhang Y, Schünemann HJ; GRADE Working Group. GRADE Guidelines 30: The GRADE Approach to Assessing the Certainty of Modelled Evidence - an Overview in the Context of Health Decision-making. *J Clin Epidemiol*. 2020 Sep 24:S0895-4356(20)31103-3.
14. Tarride JE, Doumouras AG, Hong D, Paterson JM, Tibebu S, Perez R, Ma J, Taylor VH, Xie F, Boudreau V, Pullenayegum E, Urbach DR, Anvari M. Association of Roux-en-Y Gastric Bypass With Postoperative Health Care Use and Expenditures in Canada. *JAMA Surg*. 2020 Sep 1;155(9):e201985.
15. Lau VI, Cook DJ, Fowler R, Rochweg B, Johnstone J, Lauzier F, Marshall JC, Basmaji J, Heels-Ansdell D, Thabane L, Xie F; PROSPECT Collaborators. Economic evaluation alongside the Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (E-PROSPECT): study protocol. *BMJ Open*. 2020 Jun 28;10(6):e036047.
16. Yang S, Ni R, Lu Y, Wang S, Xie F, Zhang C, Lu L. A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for Living Fetuses (ILIFE) trial. *Trials*. 2020 Sep 9;21(1):771.
17. Murphy KJ, Swaminathan S, Howard E, Altschuler A, Rogan J, Beauchet O, Dupuis K, Galea LAM, Hogan D, Lingum N, Rowe G, Tsotsos L, Szczepura A, Wittich W, Xie F, Hasher L. Accessible Virtual Arts Recreation for Wellbeing Promotion in Long-Term Care Residents. *J Appl Gerontol*. 2020 Oct 26:733464820967195.
18. Grenier LN, Atkinson SA, Mottola MF, Wahoush O, Thabane L, Xie F, Vickers-Manzin J, Moore C, Hutton EK, Murray-Davis B. Be Healthy in Pregnancy: Exploring factors that impact pregnant women's nutrition and exercise behaviours. *Matern Child Nutr*. 2020 Jul 23:e13068..
19. Thomas S, Johnson JA, Xie F. 3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set. *Qual Life Res*. 2020 29(11):3109-3118.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

20. Waudby-Smith I, Pickard AS, **Xie F**, Pullenayegum EM. Using Both Time Tradeoff and Discrete Choice Experiments in Valuing the EQ-5D: Impact of Model Misspecification on Value Sets. *Med Decis Making*. 2020 May;40(4):483-497.
21. D'Elia A, Bawor M, Dennis BB, Bhatt M, Litke K, McCabe K, Whattam J, Garrick L, O'Neill L, Simons S, Chalmers S, Key B, Goyert S, Laplante P, Vanstone M, **Xie F**, Guyatt G, Thabane L, Samaan Z. Feasibility of behavioral activation group therapy in reducing depressive symptoms and improving quality of life in patients with depression: the BRAVE pilot trial. *Pilot Feasibility Stud*. 2020 May 7;6:61.
22. Parackal A, Tarride JE, **Xie F**, Blackhouse G, Hoogenes J, Hylton D, Hanna W, Adili A, Matsumoto ED, Shayegan B. Economic evaluation of robot-assisted radical prostatectomy compared to open radical prostatectomy for prostate cancer treatment in Ontario, Canada. *Can Urol Assoc J*. 2020 Aug;14(8):E350-E357.
23. Cox JL, Parkash R, Foster GA, **Xie F**, MacKillop JH, Ciaccia A, Choudhri SH, Hamilton LM, Nemis-White JM, Thabane L; IMPACT-AF Investigators. Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF): A cluster randomized trial of a computerized clinical decision support tool. *Am Heart J*. 2020 Jun;224:35-46.
24. Zoratti MJ, **Xie F**, Thorlund K, Allen N, Levine M. An Exploratory Analysis of Predictors of Concordance between Canadian Common Drug Review Reimbursement Recommendations and the Subsequent Decisions by Ontario, British Columbia and Alberta. *Healthc Policy*. 2020 Feb;15(3):90-101.
25. Hylton DA, Turner S, Kidane B, Spicer J, **Xie F**, Farrokhyar F, Yasufuku K, Agzarian J, Hanna WC; Canadian Association of Thoracic Surgery (CATS) Working Group. The Canada Lymph Node Score for prediction of malignancy in mediastinal lymph nodes during endobronchial ultrasound. *J Thorac Cardiovasc Surg*. 2020 Jun;159(6):2499-2507.e3.
26. Foroutan N, Tarride JE, **Xie F**, Jameel B, Mills F, Levine M. Stakeholders' feedback on the proposed recommendations for updating the patented medicine prices review board (PMPRB) budget impact analysis guidelines. *Journal of Population Therapy and Clinical Pharmacology*. 2020 Jan 3;27(1):e1-e24.
27. Zoratti MJ, Siddiqua A, Morassut RE, Zeraatkar D, Chou R, van Holten J, **Xie F**, Druyts E. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. *EClinicalMedicine* 2020 Jan 5;18:100237. doi: 10.1016/j.eclinm.2019.12.007.
28. Kaur M, Pusic AL, Cano SJ, **Xie F**, Bordeleau L, Zhong T, Klassen A. International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module. *BMJ Open* 2020 Jan 7;10(1):e034451.
29. Zhang T, Lin T, Wang Y, Wang B, Qin X, **Xie F**, Cui Y, Huo Y, Wang X, Zhang Z, Jiang J. Estimated Stroke-Free Survival of Folic Acid Therapy for Hypertensive Adults: Projection Based on the CSPPT. *Hypertension* 2020 Feb;75(2):339-346.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

30. Lau VI, Rochweg B, **Xie F**, Johnstone J, Basmaji J, Balakumaran J, Iansavichene A, Cook DJ. Probiotics in hospitalized adult patients: a systematic review of economic evaluations. *Canadian Journal of Anesthesia*. 2020 Feb;67(2):247-261. doi: 10.1007/s12630-019-01525-2.
31. Murray-Davis B, Grenier L, Atkinson SA, Mottola MF, Wahoush O, Thabane L, **Xie F**, Vickers-Manzin J, Moore C, Hutton EK. Experiences regarding nutrition and exercise among women during early postpartum: a qualitative grounded theory study. *BMC Pregnancy Childbirth* 2019 Oct 21;19(1):368. doi: 10.1186/s12884-019-2508-z.

Year 2019

32. Guan H, Liu G, **Xie F**, Sheng Y, Shi L. Cost-Effectiveness of Osimertinib as a Second-Line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. *Clinical Therapeutics*, 2019. S0149-2918(19)30485-0.
33. Zoratti MJ, Zhou T, Chan K, Levine O, Krahn M, Husereau D, Clifford T, Schunemann H, Guyatt G, **Xie F**. Health Utility Book (HUB)-Cancer: Protocol for a Systematic Literature Review of Health State Utility Values in Cancer. *MDM Policy and Practice*. 2019 Aug 13;4(2):2381468319852594.
34. Zhao Y, **Xie F**, Bai X, Yang A, Wu D. Educational virtual reality videos in improving bowel preparation quality and satisfaction of outpatients undergoing colonoscopy: protocol of a randomised controlled trial. *BMJ Open*. 2019 Aug 20;9(8):e029483.
35. Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, **Xie F**, Oppe M, Boye KS, Chapman RH, Gong CL, Balch A, Busschbach JJV. *Value in Health*. 2019 Aug;22(8):931-941.
36. Michalowsky B, **Xie F**, Eichler T, Hertel J, Kaczynski A, Kilimann I, Teipel S, Wucherer D, Zwingmann I, Thyrian JR, Hoffmann W. Cost-effectiveness of a collaborative dementia care management-Results of a cluster-randomized controlled trial. *Journal of Alzheimers and Dementia*. 2019;15(10):1296-1308.
37. Kennedy K, Podbielski D, Nanji K, Muratov S, Ahmed I, **Xie F**. Disease-specific Preference-based Measure of Glaucoma Health States: HUG-5 Psychometric Validation. *Journal of Glaucoma*. 2019 Jul;28(7):593-600.
38. Foroutan N, Tarride JE, **Xie F**, Mills F, Levine M. A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers. *Pharmacoeconomics Open*. 2019 Apr 30. doi: 10.1007/s41669-019-0139-y.
39. Humphries B, Irwin A, Zoratti M, **Xie F**. How do financial (dis)incentives influence health behaviour and costs? Protocol for a systematic literature review of randomised controlled trials. *BMJ Open*. 2019 Apr 24;9(4):e024694.
40. Pullenayegum EM, Pickard AS, **Xie F**. Latent Class Models Reveal Poor Agreement between Discrete-Choice and Time Tradeoff Preferences. *Medical Decision Making*. 2019 May;39(4):421-436.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

41. Humphries B, Xie F. Canada's amendment to patented drug price regulation: A prescription for global drug cost control? *JAMA*, 2019 Mar 29. doi: 10.1001/jama.2019.2280.
42. Xie F, Zoratti M, Chan K, Husereau D, Krahn M, Levine O, Clifford T, Schunemann H, Guyatt G. Toward a Centralized, Systematic Approach to the Identification, Appraisal, and Use of Health State Utility Values for Reimbursement Decision Making: Introducing the Health Utility Book (HUB). *Medical Decision Making*. 2019 Mar 22:272989X19837969.
43. Van Spall HG, Lee SF, Xie F, Oz UE, Perez R, Mitoff PR, Maingi M, Tjandrawidjaja MC, Heffernan M, Zia MI, Porepa L, Panju M, Thabane L, Graham ID, Haynes RB, Haughton D, Simek KD, Ko DT, Connolly SJ. Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure: The PACT-HF Randomized Clinical Trial. *JAMA* 2019; 321(8):753-761.
44. Zoratti MJ, Devji T, Levine O, Thabane L, Xie F. Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. *Cancer Treatment Review*. 2019;74:43-48.
45. Wu B, Gu X, Zhang Q, Xie F. Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. *Oncologist*. 2019;24(3):349-357.

Year 2018

46. Perreault M, Atkinson SA, Mottola MF, Phillips SM, Bracken K, Hutton EK, Xie F, Meyre D, Morassut RE, Prapavessis H, Thabane L; BHIP Study team. Structured diet and exercise guidance in pregnancy to improve health in women and their offspring: study protocol for the Be Healthy in Pregnancy (BHIP) randomized controlled trial. *Trials* 2018;19(1):691.
47. Foroutan N, Tarride JE, Xie F, Levine M. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions. *ClinicoEconomics and Outcomes Research* 2018;126:525-530
48. Law E, Pickard SA, Xie F, Walton S, Lee T, Schwartz A. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. *Medical Decision Making* 2018;38(8):968-982.
49. Kovic B, Jin X, Kennedy SA, Hylands M, Pedziwiatr M, Kuriyama A, Gomaa H, Lee Y, Katsura M, Tada M, Hong BY, Cho SM, Hong PJ, Yu AM, Sivji Y, Toma A, Xie L, Tsoi L, Waligora M, Prasad M, Bhatnagar N, Thabane L, Brundage M, Guyatt G, Xie F. Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analyses. *JAMA Internal Medicine* 2018;178(12):1586-1596.
50. Jin X, Liu GG, Gerstein HC, Levine MAH, Guan H, Li H, Xie F. Minimally important difference and predictors of change in quality of life as measured using the EQ-5D among Chinese Type 2 Diabetic Patients: A community-based survey in China. *Diabetes Metabolism Research and Review*. 2018;34(8):e3053.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

51. Cox JL, Parkash R, Abidi SS, Thabane L, **Xie F**, MacKillop J, Abidi SR, Ciaccia A, Choudhri SH, Abusharekh A, Nemis-White J; IMPACT-AF Investigators. Optimizing primary care management of atrial fibrillation: The rationale and methods of the Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF) study. *American Heart Journal* 2018;201:149-157.
52. Zhang Y, Alonso Coello P, Guyatt G, Yepes-Nuñez JJ, Akl EA, Hazlewood G, Pardo-Hernandez H, Etxeandia-Ikobaltzeta I, Qaseem A, Williams JW Jr, Tugwell P, Flottorp S, Chang Y, Zhang Y, Mustafa RA, Rojas MX, **Xie F**, Schünemann HJ. GRADE Guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences - Inconsistency, Imprecision, and other Domains. *Journal of Clinical Epidemiology*. 2018 May 22. pii: S0895-4356(17)31061-2.
53. Muratov S, Podbielski DW, Kennedy K, Jack SM, Pemberton J, Ahmed IIK, Baltaziak M, **Xie F**. Preference-based Glaucoma-specific Health-related Quality of Life Instrument: Development of the Health Utility for Glaucoma. *Journal of Glaucoma*. 2018;27(7):585-591.
54. **Xie F**, Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation. *Pharmacoeconomics* 2018;36(8):883-888.
55. Jin X, Liu GG, Gerstein HC, Levine MAH, Steeves K, Guan H, Li H, **Xie F**. Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). *Health and Quality of Life Outcomes*. 2018 Apr 27;16(1):78. doi: 10.1186/s12955-018-0905-z.
56. Van Spall HG, Lee SF, **Xie F**, Ko D, Quazi I, Thabane L, Mitoff P, Heffernan M, Maingi M, Porepa L, Tjandrawidjaja M, Zia M, Panju M, Graham I, Haughton D, Connolly S. Knowledge to Action: Rationale and Design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) Stepped Wedge Cluster Randomized Trial. *American Heart Journal* 2018; 199:75-82.
57. Oremus M, Sharafoddini A, Morgano GP, Jin X, **Xie F**. A Computer-Assisted Personal Interview App in REDCap for Administering Time Trade-off Surveys: Development and Pretest. *JMIR Formative Research* 2018;2(1):e3.
58. Richardson J, Tang A, Guyatt G, Thabane L, **Xie F**, Sahlas D, Hart R, Fleck R, Hladys G, Macrae L. FIT for FUNCTION: study protocol for a randomized controlled trial. *Trials* 2018 Jan 15;19(1):39.
59. Graeme B, **Xie F**, Tarride JE, Economic evaluation of bevacizumab for treatment of platinum resistant recurrent ovarian cancer in Canada. *Pharmacoeconomics-Open* 2018;2(1):19-29.
60. Kaur MN, **Xie F**, Shiwcharan A, Patterson L, Shargall Y, Finley CJ, Schieman C, Dalimonte T, Fahim C, Hanna W. Robotic vs. Video-assisted thoracoscopic lung resection during early program development. *Annals of Thoracic Surgery* 2018;105(4):1050-1057.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

61. Tanvejsilp P, Pullenayegum E, Loeb M, Dushoff J, **Xie F**. Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand. *Pharmacoeconomics Open* 2018;2(3):281-296.
62. Tanvejsilp P, Loeb M, Dushoff J, **Xie F**. Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand. *Pharmacoeconomics Open* 2018;2(3):297-308.
63. Chan KK, **Xie F**, Willan A, Pullenayegum E, Conducting EQ-5D Valuation Studies in Resource-Constrained Countries: The Potential Use of Shrinkage Estimators to Reduce Sample Size. *Medical Decision Making* 2018;38(1):26-33.

Year 2017

64. Levine O, Devji T, **Xie F**. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. *Human Vaccine and Immunotherapy*. 2017 Aug 3;13(8):1765-1767.
65. Yepes-Nuñez JJ, Zhang Y, **Xie F**, Alonso-Coello P, Selva A, Schünemann H, Guyatt G. Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences' studies. *Journal of Clinical Epidemiology*. 2017 May;85:21-31.
66. Levine O, Devji T, **Xie F**. Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape. *Immunotherapy*. 2017 Mar;9(5):375-378.
67. **Xie F**, Pullenayegum E, Pickard AS, Ramos Goñi JM, Jo MW, Igarashi A. Transforming Latent Utilities to Health Utilities: East Does Not Meet West. *Health Economics*. 2017;26(12):1524-1533.
68. Devji T, Levine O, Neupane B, Beyene J, **Xie F**. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. *JAMA Oncology* 2017 3(3):366-373.
69. Beauchamp MK, Brooks D, Ellerton C, Lee A, Alison J, Camp PG, Dechman G, Haines K, Harrison SL, Holland AE, Marques A, Moineddin R, Skinner EH, Spencer L, Stickland MK, **Xie F**, Goldstein RS. Pulmonary rehabilitation with balance training for fall reduction in chronic obstructive pulmonary disease: Protocol for a randomized controlled trial. *JMIR Research Protocol* 2017;6(11):e228
70. Al Sayah F, Qiu W, **Xie F**, Johnson JA. Comparative performance of the EQ-5D-5L and SF-6D in adults with type 2 diabetes. *Quality of Life Research* 2017;26(8):2057-2066.
71. McClure N, Al Sayah F, **Xie F**, Luo N, Johnson JA. Instrument-defined estimates of minimally important difference in the EQ-5D-5L index scores. *Value in Health* 2017;20(4):644-650.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

72. Tanvejsilp P, Pullenayegum E, Loeb M, Dushoff J, Xie F. Role of pharmaceutical care for self-administered pulmonary tuberculosis treatment in Thailand. *Journal of Clinical Pharmacy and Therapeutics*. 2017;42(3):337-344.
73. Al Sayah F, Johnson JA, Ohinmaa A, Xie F, Bansback N. Canadian EQ-5D-5L Valuation Study Group. Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study. *Quality of Life Research* 2017;26(6):1483-1492.
74. O'Reilly D, Bowen JM, Perampaladas K, Qureshi R, Xie F, Hughes E. Feasibility of an altruistic sperm donation program in Canada: results from a population-based model. *Reproductive Health*. 2017;14(1):8.
75. Tarride JE, Breau R, Sharma AM, Hong D, Gmora S, Guertin JR, O'Reilly D, Xie F, Mehran A. The Effect of Bariatric Surgery on Mobility, Health-Related Quality of Life, Healthcare Resource Utilization, and Employment Status. *Obesity Surgery*. 2017;27(2):349-356.
76. Pullenayegum EM, Sunderland KM, Johnson JA, Xie F; Canadian EQ-5D-5L Valuation Study Group. Handling Regional Variation in Health State Preferences within a Country: A Methodological Framework. *Medical Decision Making*. 2017;37(3):252-261.
77. Chan KK, Xie F, Willan A, Pullenayegum E, Underestimation of variance of predicted health utilities derived from multi-attribute utility instruments: The use of multiple imputation as a potential solution. *Medical Decision Making*, 2017 37(3):262-272.
78. Shortt C, Xie F, Whitlock R, Ma J, Clayton N, Sherbino J, Hill SA, Pare G, McQueen M, Mehta SR, Devereaux PJ, Worster A, Kavsak P. Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers. *Clinical Chemistry*. 2017;63(2):593-602.
79. Krabbe PF, Stolk EA, Devlin NJ, Xie F, Quik EH, Pickard AS. Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale. *European Journal of Health Economics*. 2017 18(8):967-977.

Year 2016

80. Sergei Muratov S, Podbielski D, Jack SM, Ahmed IK, Mitchell L, Baltaziak M, Xie F. Preference-based disease-specific health-related quality of life instrument for glaucoma: a mixed methods study protocol. *BMJ Open* 2016;6:e012732.
81. Xie F, Kovic B, Jin X, He X, Wang M, Silvestre C. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. *Pharmacoeconomics* 2016 Nov;34(11):1087-1100.
82. Kovic B, Guyatt G, Brundage M, Thabane L, Bhatnagar N, Xie F. Association between progression-free survival and health-related quality of life in oncology: a systematic review protocol. *BMJ Open* 2016;6:e012909.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

83. Oremus M, **Xie F**, Gaebel K. Development of Clinical Vignettes to Describe Alzheimer's Disease Health States: A Qualitative Study. *PLoS One*. 2016 Sep 2;11(9):e0162422.
84. Tsiplova K, Pullenayegum E, Cooke T, **Xie F**. EQ-5D-derived health utilities and minimally important differences for chronic health conditions: 2011 Commonwealth Fund Survey of Sicker Adults in Canada. *Quality Life Research*. 2016;25(12):3009-3016.
85. Samaan Z, Dennis BB, Kalbfleisch L, Bami H, Zielinski L, Bawor M, Litke K, McCabe K, Whattam J, Garrick L, O'Neill L, Tabak TA, Simons S, Chalmers S, Key B, Vanstone M, **Xie F**, Guyatt G, Thabane L. Behavioral activation group therapy for reducing depressive symptoms and improving quality of life: a feasibility study. *Pilot Feasibility Studies*. 2016 Apr 29;2:22.
86. Pullenayegum EM, Chan KK, **Xie F**. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach. *Medical Decision Making*, 2016; 36(2):223-33.
87. **Xie F**, Pullenayegum EM, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA on behalf of Canadian EQ-5D-5L Valuation Study Group. A TTO-derived value set of the EQ-5D-5L for Canada, *Medical Care*, 2016;54(1):98-105.
88. **Xie F**, Pullenayegum E, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA. How different are composite and traditional TTO valuations of severe EQ-5D-5L states? *Quality of Life Research* 2016;25(8):2101-2108.
89. Oremus M, **Xie F**, Pullenayegum E, Gaebel K. Can the general public use vignettes to discriminate between Alzheimer's disease health states? *BMC Geriatrics* 2016 Feb 3;16(1):36.
90. Al Sayah F, Mladenovic A, Gaebel K, **Xie F**, Johnson JA. How dead is dead? Qualitative findings from participants of combined traditional and lead-time time trade-off valuations. *Quality of Life Research*, 2016;25(1):35-43.
91. Al Sayah F, Bansback N, Bryan S, Ohinmaa A, Poissant L, Pullenayegum E, **Xie F**, Johnson JA. Determinants of Time-Trade Off Valuations for EQ-5D-5L Health States: Data from the Canadian EQ-5D-5L Valuation Study. *Quality of Life Research* 2016;25(7):1679-85.
92. Jin X, Liu GG, Luo N, Li H, Guan H, **Xie F**. Is bad living better than good death? Impact of demographic and cultural factors on health state preference. *Quality of Life Research* 2016; 25(4):979-86.

Year 2015

93. Samaan Z, Litke K, McCabe K, Dennis B, Whattam J, Garrick L, O'Neill L, Tabak TA, Simons S, Chalmers S, Key B, Vanstone M, **Xie F**, Guyatt G, Thabane L. pragmatic pilot randomized trial to investigate the effectiveness of behavioural activation group therapy in reducing depressive symptoms and improving quality of life in patients with depression: the BRAVE pilot trial protocol. *Pilot Feasibility Studies*. 2015 Nov 10;1:39.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

94. Pullenayegum EM, Perampaladas K, Gaebel K, Doble BM, **Xie F**, Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection? *European Journal of Health Economics* 2015;16(8):847-855
95. Wang Y, **Xie F**, Kong MC, Lee LH, Ng HJ, Ko Y. Patient-reported health preferences of anticoagulant-related outcomes. *Journal of Thrombosis and Thrombolysis* 2015;40(3):268-273.
96. Kovic B, **Xie F**, Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. *Journal of Clinical Oncology*, 2015; 33(20):2296-2302.
97. **Xie F**, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D. A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE). *Pharmacoeconomics*, 2015;33(8):867-877.
98. **Xie F**, The Economics of Adalimumab for Ulcerative Colitis. *Expert Review in Pharmacoeconomics and Outcomes Research* 2015;15(3):373-377.

Year 2014

99. Wang Y, **Xie F**, Kong MC, Lee LH, Ng HJ, Ko Y. Cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for stroke prevention in patients with atrial fibrillation. *Cardiovascular Drugs and Therapy*, 2014;28(6):575-585.
100. Tan XY, Aung MM, Ngai MI, **Xie F**, Yu K. Assessment of preference for hormonal treatment-related health states among patients with breast cancer. *Value in Health Regional Issue* 2014 May;3:27-32.
101. Krabbe PF, Devlin NJ, Stolk EA, Shah KK, Oppe M, van Hout B, Quik EH, Pickard AS, **Xie F**. Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values. *Medical Care*. 2014;52(11):935-943.
102. Li H, Li X, **Xie F**, Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration. *Chinese Journal of Ophthalmology* 2014;50(6):426-433.
103. **Xie F**, Gaebel K, Perampaladas K, Doble B, Pullenayegum E. Comparing EQ-5D Valuation Studies: A Systematic Review and Methodological Reporting Checklist. *Medical Decision Making* 2014;34:8-20.
104. **Xie F**, Hopkins RB, Burke N, Habib M, De Angelis C, Pasetka M, Giotis A, Goeree R. Time and labour costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: A time and motion study. *Hospital Practice* 2014;42(2):38-45.
105. **Xie F**, Pullenayegum E, Gaebel K, Oppe M, Krabbe PF. Eliciting preferences to the EQ-5D-5L health states: discrete choice experiment or multiprofile case of best-worst scaling? *European Journal of Health Economics* 2014;15(3):281-288.

Year 2013

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

106. Whelan JP, Bowen JM, Burke N, Woods EA, McIssac GP, Hopkins RB, O'Reilly DJ, **Xie F**, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride JE. A prospective trial of GreenLight PVP (HPS120) versus transurethral resection of the prostate in the treatment of lower urinary tract symptoms in Ontario, Canada. *Canadian Urology Association Journal* 2013 Sep;7(9-10):335-341.
107. Bowen JM, Whelan JP, Hopkins RB, Burke N, Woods EA, McIsaac GP, O'Reilly DJ, **Xie F**, Sehatzadeh S, Levin L, Mathew SP, Patterson LL, Goeree R, Tarride JE. Photoselective vaporization for the treatment of benign prostatic hyperplasia. *Ontario Health Technology Assessment Series*. 2013;13(2):1-34.
108. Blackhouse G, Assasi N, **Xie F**, Gaebel K, Campbell K, Healey JS, O'Reilly D, Goeree R. Cost-effectiveness of catheter ablation for rhythm control of atrial fibrillation. *International Journal Vascular Medicine*. 2013;262809. doi: 10.1155/2013/262809.
109. Smaill F, Jeyanathan M, Smieja M, Medina MF, Thantrige-Don N, Zganiacz A, Yin C, Heriazon A, Damjanovic D, Puri L, Hamid J, **Xie F**, Foley R, Bramson J, Gaudie J, Xing Z. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. *Science Translational Medicine*. 2013;5(205):205ra134.
110. Doble B, Blackhouse G, Goeree R, **Xie F**. Cost-effectiveness of the Edwards SAPIEN transcatheter heart valve compared with standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis: A Canadian perspective. *The Journal of Thoracic and Cardiovascular Surgery*, 2013;146(1):52-60.
111. **Xie F**. Model-based economic evaluation for medical decision making: learn from the past and prepare for the future. *Journal of Thoracic Disease* 2013;5(3):209-210
112. **Xie F**. Cost effectiveness of treatment options for early prostate cancer: can we put the puzzle pieces together? *European Urology* 2013;63(2):411-412.
113. Tarride J-E, Haq M, Nakhai-Pour HR, O'Reilly DJ, **Xie F**, Dolovich L, Blackhouse G, Goeree R. The excess burden of rheumatoid arthritis in Ontario, Canada. *Clinical and Experimental Rheumatology* 2013;31(1):18-24.
114. **Xie F**, Tanvejsilp P, Campbell K, Gaebel K. Cost-effectiveness of pharmaceutical management for osteoarthritis pain: a systematic review of the literature and recommendations for future economic evaluation. *Drugs & Aging* 2013;30(5):277-284.
115. Pullenayegum E, **Xie F**. Scoring the 5-Level EQ-5D: Can Latent Utilities Derived from a Discrete Choice Model Be Transformed to Health Utilities Derived from Time Tradeoff Tasks? *Medical Decision Making* 2013;33(4):567-578.
116. Zhao FL, **Xie F**, Hu H, Li SC. Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis. *Pharmacoeconomics* 2013;31:501-508.

Year 2012

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

117. **Xie F**, Oremus M, Gaebel K, Measuring Health-related Quality-of-life for Alzheimer's Disease Using the General Public. *Quality of Life Research* 2012;21(4):593-601.
118. Sehatzadeh S, Doble B, **Xie F**, Blackhouse G, Campbell K, Kaulback K, Chandra K, Goeree R. *Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based analysis (part B)*. *Ontario Health Technology Assessment Series* 2012;12(14):1-62.
119. Blackhouse G, Assasi N, **Xie F**, Marshall J, Irvine EJ, Gaebel K, Campbell K, Hopkins R, O'Reilly D, Tarride JE, Goeree R. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF drugs for refractory Crohn's Disease. *Journal of Crohn's and Colitis* 2012;6(1):77-85.
120. Tarride J-E, Haq M, Taylor V, Sharma AM, Nakhai-Pour HR, O'Reilly D, **Xie F**, Dolovich L, Goeree R. Health status, hospitalization, day procedures and physician costs associated with body mass index (BMI) levels in Ontario, Canada. *ClinicoEconomics and Outcomes Research* 2012;4:21-30.
121. Zhang XH, Li SC, **Xie F**, Lo NN, Yang KY, Yeo SJ, Fong KY, Thumboo J. An exploratory study of response shift in health-related quality of life and utility assessment among patients with osteoarthritis undergoing total knee replacement surgery in a tertiary hospital in Singapore. *Value Health* 2012;15(1 Suppl):S72-8.
122. Tarride JE, Haq M, O'Reilly DJ, Bowen JM, **Xie F**, Dolovich L, Goeree R. The excess burden of osteoarthritis in the province of Ontario, Canada. *Arthritis & Rheumatism* 2012;64(4):1153-1161.
123. Blackhouse G, **Xie F**, Levine MAH, Campbell K, Assasi N, Gaebel K, O'Reilly D, Tarride J-E, Goeree R. Canadian cost-utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura. *Journal of Population Therapeutics and Clinical Pharmacology* 2012;19(2):e166-78.
124. **Xie F**, Hopkins R, Burke N, Tarride JE, Goeree R. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study. *Hospital Practice* 2012;40(2):131-137.
125. Shih V, Chan A, **Xie F**, Ko Y. Economic evaluation of anastrozole versus tamoxifen for early stage breast cancer in Singapore. *Value in Health Regional Issues* 2012;1:46-53.
126. Shih V, Chan A, **Xie F**, Ko Y. Health state utility assessment for breast cancer. *Value in Health Regional Issues* 2012;1:93-97.
127. He J, Bowen JM, **Xie F**, Goeree R. Cost-effectiveness of antiviral treatments for HBeAg-positive chronic Hepatitis B in Canada. *Value in Health* 2012 Sep;15(6):894-906.
128. Assasi N, Schwartz L, Tarride JE, Goeree R, **Xie F**. Economic evaluations conducted for assessment of genetic testing technologies: a systematic review. *Genetic Testing and Molecular Biomarkers* 2012;16(11):1322-1335.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

129. Johnston BC, Donen R, Pooni A, Pond J, **Xie F**, Giglia L, Kam A, Bamber A, Bami K, Patel Y, Gupta R, Guyatt GH. A conceptual framework of health related quality of life impact in acute gastroenteritis. *Journal of Pediatric Gastroenterology and Nutrition* 2013;56(3):280-289.
130. Tarride J-E, Burke N, von Keyserlingk C, O'Reilly D, **Xie F**, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. *Clinicoeconomics and Outcomes Research* 2012;4:287-298.
131. Assasi N, **Xie F**, Blackhouse G, Gaebel K, Robertson D, Hopkins R, Healey JS, Goeree R. Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis. *Journal of Interventional Cardiac Electrophysiology* 2012;35(3):259-275.
132. Puhan MA, Akl EA, Bryant D, **Xie F**, Apolone G, Riet G. Discussing study limitations in reports of biomedical studies- the need for more transparency. *Health and Quality of Life Outcomes* 2012; 10:23.
133. Sehatzadeh S, Doble B, **Xie F**, Blackhouse G, Campbell K, Kaulback K, Chandra K, Goeree R. Transcatheter aortic valve implantation (TAVI) for treatment of aortic valve stenosis: an evidence-based Analysis (part B). *Ontario Health Technology Assessment Series*. 2012;12(14):1-62.

Year 2011

134. **Xie F**, Ye H, Zhang Y, Liu X, Lei T, Li SC. Extension from inpatients to outpatients: validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis. *International Journal of Rheumatic Diseases* 2011;14(2):206-210.
135. Pullenayegum EM, Tarride J-E, **Xie F**, O'Reilly D. Calculating utility decrements associated with an adverse event: marginal Tobit and CLAD coefficients should be used with caution. *Medical Decision Making* 2011;31(6):790-799.
136. Chow BJW, Freeman MR, Bowen JM, Levin L, Hopkins RB, Provost Y, Tarride J-E, Dennie C, Cohen EA, Marcuzzi D, Iwanochko R, Moody AR, Paul N, Parker JD, O'Reilly DJ, **Xie F**, Goeree R. Ontario Multi-detector Computed Tomographic Coronary Angiography Study (OMCAS): field evaluation of diagnostic accuracy. *Archives of Internal Medicine* 2011;171(11):1021-1029.
137. Chow BJW, Freeman MR, Bowen JM, Levin L, Hopkins RB, Provost Y, Tarride J-E, Dennie C, Cohen EA, Marcuzzi D, Iwanochko R, Moody AR, Paul N, Parker JD, O'Reilly DJ, **Xie F**, Goeree R. Using the appropriate fishing net for computed tomographic coronary angiography in daily clinical practice. *Archives of Internal Medicine* 2011;171(16):1512-1513.
138. O'Reilly DJ, **Xie F**, Pullenayegum E, Gerstein HC, Greb J, Blackhouse GK, Tarride JE, Bowen J, Goeree R. Estimation of the impact of diabetes-related complication on quality of life for patients with type 2 diabetes in Ontario, Canada. *Quality of Life Research* 2011;20(6):939-943.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

139. von Keyserlingk C, Hopkins R, Anastasilakis, Toulis K, Goeree R, Tarride J-E, O'Reilly D, **Xie F**. Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: A meta-analysis. *Seminars in Arthritis and Rheumatism* 2011;41(2):178-186.
140. Tarride J-E, Blackhouse G, DeRose G, Bowen JM, Nakhaipour H, O'Reilly D, **Xie F**, Novick T, Hopkins R, Goeree R. Should endovascular repair be reimbursed for low risk abdominal aortic aneurysm patients? Evidence from Ontario, Canada. *International Journal of Vascular Medicine* 2011;308685.
141. Gaebel K, Mclvor RA, **Xie F**, Blackhouse G, Robertson D, Assasi N, Hernandez P, Goeree R. Triple Therapy for a Management of COPD: A Review. *COPD* 2011 8(3):206-243.
142. Goeree R, He J, O'Reilly D, Tarride J-E, **Xie F**, Lim M, Burke N. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. *ClinicoEconomics and Outcomes Research* 2011;3:89-104.
143. **Xie F**, Bowen JM, Sutherland CS, Burke N, Blackhouse G, Tarride JE, O'Reilly D, Goeree R. Using Health Technology Assessment to Support Evidence-Based Decision Making in Canada: An Academic Perspective. *Expert Review of Pharmacoeconomics & Outcomes Research* 2011;11(5):513-521.
144. O'Reilly D, Gaebel K, **Xie F**, Tarride J-E, Goeree R. Health economic evaluations help inform payers of the best use of scarce healthcare resources. *International Journal of Circumpolar Health* 2011;70(4):419-427.
145. Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, **Xie F**, Thabane L. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. *BMC Musculoskeletal Disorders* 2011;12(1):209.

Year 2010

146. **Xie F**, Lo NN, Tarride JE, O'Reilly D, Goeree R, Lee HP. Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a two-year observational study. *European Journal of Health Economics* 2010;11(1):27-34.
147. Tarride JE, Burke N, Bischof M, Hopkins RB, Goeree L, Campbell K, **Xie F**, O'Reilly D, Goeree R. A review of health utilities across conditions common in pediatric and adult populations. *Health and Quality of Life Outcomes* 2010;8(12).
148. Tarride JE, Hopkins R, Blackhouse G, Bowen JM, Bischof M, Von Keyserlingk C, O'Reilly D, **Xie F**, Goeree R. A review of methods used in long-term cost-effectiveness models of diabetes treatment. *Pharmacoeconomics* 2010;28(4):255-277.
149. Pullenayegum EM, Tarride JE, **Xie F**, Goeree R, Gerstein H, O'Reilly D. Analysis of health utility data when some subjects attain the upper bound of 1: Are tobit and clad models suitable for the analysis of health utility data? *Value in Health* 2010;13(4):487-494.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

150. Gaebel K, Blackhouse G, Campbell K, Robertson D, **Xie F**, Assasi N, Chalk C, Levine M, Goeree R. Intravenous immunoglobulin for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and meta-analysis. *Open Medicine* 2010;4(3)e154-e166.
151. Goeree R, Tarride JE, O'Reilly D, **Xie F**, Bowen J, Blackhouse G, Hopkins R. Conditionally funded field evaluations: PATHs coverage with evidence development program for Ontario. *Value in Health* 2010;13 Suppl 1:S8-11.
152. Assasi N, Blackhouse G, **Xie F**, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Patient outcomes after anti TNF-alpha drugs for Crohn's disease. *Expert Review of Pharmacoeconomics & Outcomes Research* 2010;10(2):163-175.
153. Blackhouse G, Gaebel K, **Xie F**, Campbell, Assasi N, Tarride J-E, O'Reilly D, Chalk C, Levine M, Goeree R. Cost-utility of intravenous immunoglobulin (IVIg) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. *Cost Effectiveness and Resource Allocation* 2010;8:14.
154. **Xie F**, Lo NN, Pullenayegum EM, Tarride JE, O'Reilly DJ, Goeree R, Lee HP. Evaluation of health outcomes in osteoarthritis patients after total knee replacement: a two-year follow-up. *Health and Quality of Life Outcomes* 2010;8(1):87.
155. Goeree R, O'Reilly D, Hopkins R, Blackhouse G, Tarride JE, **Xie F**, Lim M. General population versus disease-specific event rate and cost estimates: potential bias for economic appraisals. *Expert Review of Pharmacoeconomics & Outcomes Research* 2010;10(4):379-384.
156. Johnston BC, Thorlund K, Schunemann HJ, **Xie F**, Murad MH, Montori VM, Guyatt GH. Improving the interpretation of quality of life evidence in meta-analyses: the application of minimal important difference units. *Health and Quality of Life Outcomes* 2010;8:116.
157. **Xie F**, Pullenayegum EM, Li SC, Hopkins R, Thumboo J, Lo NN. Use of a disease-specific Instrument in economic evaluations: mapping Western Ontario and McMaster Universities Osteoarthritis Index onto the EQ-5D utility. *Value in Health* 2010;13(8):873-978.

Year 2009

158. Blackhouse G, Hopkins R, Bowen JM, DeRose G, Novick T, Tarride J-E, O'Reilly D, **Xie F**, Goeree R. A cost-effectiveness model comparing endovascular repair to open surgical repair of abdominal aortic aneurysms in Canada. *Value in Health* 2009;12(2):245-252.
159. **Xie F**, Despiegel N, Danchenko N, Hansen K. Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. *International Journal of Psychiatry in Clinical Practice* 2009;13(1):59-69.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

160. Tarride JE, Lim ME, Bowen JM, McCarron CE, Blackhouse G, Hopkins R, O'Reilly D, **Xie F**, Goeree R. In search of the evidentiary foundation of published Canadian economic evaluations (2001-2006). *International Journal of Technology Assessment in Health Care* 2009;25(2):214-221.
161. Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride J-E, **Xie F**, O'Reilly D. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. *Canadian Journal of Diabetes* 2009;33(1):35-45.
162. Bowen JM, Patterson LL, O'Reilly DJ, Hopkins RB, Blackhouse G, Burke N, **Xie F**, Tarride J-E, Goeree R. Conditionally funded field evaluations and practical trial design within a HTA framework. *Journal of the American College of Radiology* 2009;6(5):324-331.
163. **Xie F**, O'Reilly D, Ferrusi I, Blackhouse G, Bowen JM, Tarride J-E, Goeree R. Illustrating economic evaluation of diagnostic technologies: Comparing helicobacter pylori screening strategies in prevention of gastric cancer in Canada. *Journal of the American College of Radiology* 2009;6(5):317-323.
164. Tarride J-E, Blackhouse G, Bischof M, McCarron EC, Lim M, Ferrusi I, **Xie F**, Goeree R. Approaches to economic evaluations of healthcare technologies. *Journal of the American College of Radiology* 2009;6(5):307-316.
165. Goeree R, Levin L, Chandra K, Bowen JM, Blackhouse G, Tarride JE, Burke N, Bischof M, **Xie F**, O'Reilly D. Health technology assessment and primary data collection for reducing decision making uncertainty. *Journal of the American College of Radiology* 2009;6(5):332-342.
166. **Xie F**, Blackhouse G, Assasi N, Campbell K, Levin M, Bowen J, Tarride JE, Pi D, Goeree R. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura. *Clinical Therapeutics* 2009;31(5):1082-1091.
167. Goeree R, Lim M, Hopkins R, Blackhouse G, Tarride J-E, **Xie F**, O'Reilly D. Excess risk of mortality and complications associated with newly diagnosed cases of diabetes in Ontario, Canada. *Canadian Journal of Diabetes* 2009;33(2):93-104.
168. **Xie F**, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. *Cost Effectiveness and Resource Allocation* 2009;7:20.

Year 2008

169. Luo N, Seng BK, **Xie F**, Li SC, Thumboo J. Validation of the Schizophrenia Quality of Life Scale (SQLS) in Asian Patients with Schizophrenia in Singapore. *Quality of Life Research* 2008;17:115-122.
170. **Xie F**, Luo N, Blackhouse G, Goeree R, Lee HP. Cost Effectiveness Analysis of Helicobacter Pylori Screening in Prevention of Gastric Cancer in Chinese. *International Journal of Technology Assessment in Health Care* 2008;24:87-95.
171. **Xie F**, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, Li SC. A Study on Indirect and Intangible Costs for Patients with Knee Osteoarthritis in Singapore. *Value in Health* 2008;11:S84-S90.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

172. Wee HL, Li SC, Xie F, Zhang XH, Luo N, Feeny D, Cheung YB, Machin D, Fong KY, Thumboo J. Validity, Feasibility and Acceptability of Time Trade-off and Standard Gamble Assessments in Health Valuation Studies: A Study in A Multiethnic Asian Population in Singapore. *Value in Health* 2008;11:S3-S10.
173. Zhang XH, Xie F, Wee HL, Thumboo J, Li SC. Applying the Expectancy-Value Model to Understand Health Values. *Value in Health* 2008;11:S61-S68.
174. Xie F. The Need for Standardization: A Literature Review of Indirect Costs of Rheumatoid Arthritis and Osteoarthritis. *Arthritis & Rheumatism* 2008;59(7):1027-1033.
175. Xie F, Li SC, Goeree R, Tarride JE, O'Reilly D, Lo NN, Yeo SJ, Yang KY, Thumboo J. Validation of Chinese Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) in Patients Scheduled for Total Knee Replacement. *Quality of Life Research* 2008;17:595-601.
176. Xie F, Luo N, Lee HP. Cost Effectiveness Analysis of Population-Based Serology Screening and ¹³C-Urea Breath Test for *Helicobacter pylori* to Prevent Gastric Cancer: A Markov Model. *World Journal of Gastroenterology* 2008;14(19):3021-3027.
177. Xie F, Lo NN, Lee HP, Cieza A, Li SC. Validation of the International Classification of Functioning, Disability, and Health (ICF) Brief Core Set for Osteoarthritis. *Scandinavian Journal of Rheumatology* 2008;37(6):450-461.
178. Wee HL, Li SC, Zhang XH, Xie F, Feeny D, Luo N, Cheung Y-B, Machin D, Fong K-Y, Thumboo J. Are symbols useful and culturally acceptable in health-state valuation studies? An exploratory study in multi-ethnic Asian population. *Patient Preference and Adherence* 2008;2:271-276.
179. Tarride J-E, McCarron CE, Lim M, Bowen JM, Blackhouse G, Hopkins R, O'Reilly D, Xie F, Goeree R. Economic Evaluations Conducted by Canadian Health Technology Assessment Agencies: Where Do We Stand? *International Journal of Technology Assessment in Health Care* 2008;24(4):437-444.

Year 2007

180. Xie F, Thumboo J, Lo NN, Yeo SJ, Yang KY, Yeo W, Chong HC, Fong KY, Li SC. Cross-Cultural Adaptation and Validation of Singapore English and Chinese Versions of the Lequesne Algofunctional Index of Knee in Asians with Knee Osteoarthritis in Singapore. *Osteoarthritis Cartilage* 2007;15:19-26.
181. Xie F, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, Li SC. Direct and Indirect Costs of Osteoarthritis: A Comparative Study among Multiethnic Asian Patients with Osteoarthritis in Singapore. *Journal of Rheumatology* 2007;34:165-171.
182. Xie F, Thumboo J, Li SC. True Difference or Something Else? Problems in Cost of Osteoarthritis Studies. *Seminars in Arthritis and Rheumatism* 2007;37:127-132.
183. Xie F, Li SC, Lo NN, Yeo SJ, Yang KY, Thumboo J. Cross-Cultural Adaptation and Validation of Singapore English and Chinese Versions of the Oxford Knee Score (OKS) in Knee Osteoarthritis Patients Undergoing Total Knee Replacement. *Osteoarthritis and Cartilage* 2007;15:1019-1024.

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

184. **Xie F**, Li SC, Luo N, Lo NN, Yeo SJ, Yang KY, Fong KY, Thumboo J. A Comparison of EQ-5D and SF-6D in Multiethnic Asian Patients with Knee Osteoarthritis in Singapore. *Arthritis & Rheumatism* 2007;57:1043-1049.
185. **Xie F**, Lo NN, Lee HP, Cieza A, Li SC. Validation of the Comprehensive ICF Core Set for Osteoarthritis from the Singaporean Perspective. *Journal of Rheumatology* 2007;34:2301-2307.

Year 2006

186. **Xie F**, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, Li SC. Are They Relevant? A Critical Evaluation of the International Classification of Functioning, Disability and Health Core Sets for Osteoarthritis from the Perspective of Patients with Knee Osteoarthritis in Singapore. *Annals of the Rheumatic Diseases* 2006;65:1067-1073.
187. **Xie F**, Li SC, Fong KY, Lo NN, Yeo SJ, Yang KY, Thumboo J. What Health Domains & Items Are Important to Patients with Knee Osteoarthritis? A Focus Group Study in a Multiethnic Urban Asian Population. *Osteoarthritis Cartilage* 2006;14:224-230.
188. **Xie F**, Li SC, Roos E, Fong KY, Lo NN, Yeo SJ, Yang KY, Yeo W, Chong HC, Thumboo J. Cross-Cultural Adaptation and Validation of Singapore English and Chinese Versions of the Knee Injury and Osteoarthritis Outcome Score (KOOS) in Asians with Knee Osteoarthritis in Singapore. *Osteoarthritis Cartilage* 2006;14:1098-1103.
189. Wee HL, Li SC, **Xie F**, Zhang XH, Luo N, Cheung YB, Machin D, Fong KY, Thumboo J. Are Asians Comfortable with Discussing Death in Health Valuation Studies? A Study in Multi-ethnic Singapore. *Health and Quality of Life Outcomes* 2006;4:93-105.
190. Luo N, **Xie F**, Wang QN, Li SC. Does Education Level Affect the Measurement of Health Utilities? *China Journal of Pharmaceutical Economics* 2006;3:79-86.

Year 2005

191. Luo, N, Fones CSL, Lim SE, **Xie F**, Thumboo J, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation of English version in Singapore. *Quality of Life Research* 2005;14:1181-1186.
192. **Xie F**, Tan CH, Li, SC. Are They Being Used Safely? A Retrospective Cross-sectional Tertiary Health Care Survey of Selective Serotonin Reuptake Inhibitors Prescribing Practice in Singapore. *Human Psychopharmacology: Clinical & Experimental* 2005;20:1-7.
193. **Xie F**, Li SC, Thumboo J. Do the Health-related Quality of Life Domains and Items in Knee and Hip Osteoarthritis Vary in Importance Across Social-cultural Contexts? A Qualitative Systematic Literature Review. *Seminars in Arthritis and Rheumatism* 2005;34(6):793-804.

Year 2004

LIFETIME PUBLICATIONS

b) Published Journal Articles (underline denotes senior author):

194. **Xie F**, Xu HL. New Drug Protection Policies in China and the U.S.A and the Comparison. *China Pharmaceutical Affairs* 2004;18:96-99.

Year 2003

195. **Xie F**, Xu HL, Wang LD. Introduction on New Drug Application Review Process of FDA. *China Pharmaceutical Affairs* 2003;17:49-51.

LIFETIME PUBLICATIONS

c) Technical Reports:

1. **Xie F**, Gaebel K, Johnson JA, Understanding participant's responses to the EQ-VT tasks: A qualitative study. Report Submitted to the EuroQol Research Foundation, November 12, 2015.
2. **Xie F**, Pullenayegum E, Pickard AS. Transforming latent utilities to health utilities: Can one function fit other countries? Report Submitted to the EuroQol Research Foundation, November 9, 2015.
3. **Xie F**, Pickard AS, Krabbe PF, Revicki D, Viney R, Devlin N, Feeny D. A checklist for reporting valuation studies of multi-attribute utility-based instruments (CREATE). Report Submitted to the EuroQol Research Foundation, November 9, 2015.
4. Assasi N, Blackhouse G, Campbell K, **Xie F**, Goeree R. Health System Design and Health Services Reforms for Aboriginal and Other Vulnerable Populations: A Systematic Review of the Evidence. Report No: HTAP-RE0027-2012.REP. Report submitted to Canadian Agency for Drugs and Technologies in Health (CADTH), February 2 2012 (77p)
5. Assasi N, Blackhouse G, Campbell K, **Xie F**, Goeree R. Newborn Screening for Krabbe Leukodystrophy: Clinical and Cost effectiveness and Guidelines: Report No: HTAP-RC0328-2012.REP. Report submitted to Canadian Agency for Drugs and Technologies in Health (CADTH), February 15 2012 (19p)
6. Assasi N, Blackhouse G, Campbell K, **Xie F**, Goeree R. Codeine and Acetaminophen for Pain Relief: A Review of the Clinical Efficacy and Safety. Report No: HTAP-RC0344-2012.REP. Report submitted to Canadian Agency for Drugs and Technologies in Health (CADTH), April 19 2012 (29p)
7. Assasi N, Blackhouse G, Campbell K, **Xie F**, Goeree R. HTAP-OP0511: High sensitivity cardiac troponin for the rapid diagnosis of acute coronary syndrome and acute myocardial infarction in the emergency department: A clinical cost-effectiveness evaluation. Report No: HTAP-OP0511-2012.REP. Report prepared for CADTH, November 21, 2012 (119p).
8. Von Keyserlingk C, Hopkins R, Campbell K, Burke N, **Xie F**. Budget impact analysis of treating patients with diabetic foot ulcer using Dermagraft compared to standard of care: a hospital perspective. Report No. TEMMP-X065a-2012.REP. Prepared for Shire Regenerative Medicine Inc. November 30, 2012 (49p.)
9. **Xie F**, Hopkins R, Burke N, Goeree R. Time and health care resource utilization associated with preparation and administration of intravenous bisphosphonates for cancer patients with metastatic bone disease: A Delphi study. Report No.: TEMMP-X015b-2011.REP. Report prepared for Amgen Canada, April 29, 2011 (17p.).
10. **Xie F**, Hopkins R, Burke N, Goeree R. Time and costs associated with preparation and administration of intravenous bisphosphonates for cancer patients with metastatic bone disease: A time in motion study. Report No: TEMMP-X015a.REP. Prepared for Amgen Canada. August 4, 2011 (34p).

LIFETIME PUBLICATIONS

c) Technical Reports:

11. Gaebel K, Kaulback K, Robertson D, Blackhouse G, **Xie F**, Assasi N, Goeree R. Portable ultrasound in small emergency departments: A review of the guidelines and the clinical effectiveness. Report No: HTAP-M003-2009.REP. Submitted to CADTH, January 7, 2009. (29p).
12. Gaebel K, Blackhouse G, Campbell K, Robertson D, **Xie F**, Assasi N, Chalk C, Levine M, Giacomini M, Goeree R. Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy: Clinical and cost-effectiveness analyses. Report No: HTAP-H-0298c-2008.REP. Version 3.0 Submitted to CADTH January 5, 2009 (117p.).
13. Assasi N, Blackhouse G, **Xie F**, Gaebel K, Marshall J, Irvine EJ, Giacomini M, Robertson D, Campbell K, Hopkins R, Goeree R. Anti-TNF- α drugs for refractory inflammatory bowel disease: Clinical and cost-effectiveness analysis. Report No: HTAP-H-0479-2008.REP, version 4.0. Submitted to CADTH February 11, 2009. (76p.).
14. Tarride JE, Bischof M, Burke N, Blackhouse G, O'Reilly D, **Xie F**, Goeree R. Cost-effectiveness of Etanercept in Canada for the treatment of children and adolescents with plaque psoriasis. Final Report to Amgen Canada (TEMMP-T-007b-2009.REP). July 28, 2009 (34p.).
15. Blackhouse G, **Xie F**, Campbell K, Assasi N, Goeree R. Primary Economic Model for Childhood Idiopathic Thrombocytopenia Purpura. CADTH, March 28, 2008 (15p).
16. O'Reilly D, **Xie F**, Pullenayegum E, Gerstein HC, Blackhouse GK, Tarride J-E, Bowen J, Goeree. Estimation of utility values for diabetes-related complications and impact of antidiabetic medication on quality of life for patients with type 2 diabetes in Ontario: further "Canadianization" and updates for the Ontario Diabetes Economic Model (ODEM). Report No: TEMMP – 2007-02-2008 –REP. Hamilton, ON: Programs for Assessment of Technology in Health, St. Joseph's Healthcare Hamilton, McMaster University, October 2008.
17. Blackhouse G, **Xie F**, Campbell K, Assasi N, Gaebel K, Levine M, Pi D, Giacomini M, Goeree R, Banks R. Intravenous immunoglobulin for treatment of idiopathic thrombocytopenic purpura: Economic and health service impact analyses. Report No: HTAP-H0298b-2008.REP. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008 (76p)
18. Assasi N, Blackhouse G, **Xie F**, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Anti-TNF- α drugs for refractory inflammatory bowel disease: clinical and cost-effectiveness analysis. Version 1.0, Report no: HTAP:H0479-2008.REP. Submitted to CADTH, November 18, 2008. (211p)
19. **Xie F**. Cost-Effectiveness Analysis of Escitalopram Compared to Venlafaxine, Fluvoxamine, and Fluoxetine in Treatment of Major Depressive Disorder in Singapore, August 2007 (43p).
20. Tarride J-E, Blackhouse G, Hopkins R, O'Reilly D, **Xie F**, Goeree R. Cost-effectiveness of Etanercept in Canada in the Treatment of Severe Psoriasis. Amgen Canada Inc. November, 2007 (45p).

LIFETIME PUBLICATIONS

c) Technical Reports:

21. Tarride JE, Blackhouse G, Hopkins R, **Xie F**, Goeree R. Cost-effectiveness of Etanercept in the Treatment of Severe Psoriasis in Ontario. November, 2007 (37p).
22. Tarride JE, Blackhouse G, Hopkins R, **Xie F**, Goeree R. Cost-effectiveness of Etanercept in the Treatment of Severe Psoriasis in Quebec. November 2007 (34p).

INVITED PRESENTATIONS (presenters underlined)

1. Xie F, Cost Effectiveness Threshold for Reimbursement Policy, Beijing Association of Pharmacoeconomics, Beijing, China, December 24, 2020 (Invited Seminar)
2. Xie F. Is the Use of Economic Evaluation to Inform Reimbursement Policy a Mirage in China? China Society for Clinical Pharmacy Annual Meeting (Virtual), Chengdu, China, December 6, 2020 (Invited Seminar).
3. Xie F, Systematic Literature Review and Meta-Analysis: Totem on Evidence Pyramid, Beijing Society for Evidence-Based Medicine Virtual Annual Meeting, Beijing, China, August 22, 2020 (Invited Seminar)
4. Xie F, Value Assessment Framework. Drug Value Assessment and Purchasing National Continuing Education Program, Peking University, Beijing, China, August 1, 2020 (Invited Seminar)
5. Xie F, Introduction to Patient-Reported Outcomes. PRO in HIV Virtual Seminar, Beijing, China, July 16, 2020 (Invited Seminar)
6. Xie F, Cost Effectiveness Threshold. Pharmacoeconomics Virtual Seminar, Beijing, China, June 7, 2020 (Invited Seminar)
7. Xie F, The use of Cost-Effectiveness Analysis in Drug Pricing in Canada. Forbidden City Pharmacist Virtual Forum, Beijing, China, May 14, 2020 (Invited Podium Presentation)
8. Xie F, Health Technology Assessment in Canada. National Chinese Medicine Administration, Beijing, China, October 30, 2019 (Invited Seminar)
9. Xie F, Health Technology Assessment and Drug Coverage Policy. National Healthcare Security Administration, Beijing, China, October 28, 2019 (Invited Seminar)
10. Xie F, Kun Zhao. Strategic importance of developing patient-reported outcome measures in China. Second National HTA Conference. Beijing, China, October 26, 2019 (Plenary).
11. Xie F. Conventional and retrospective change in health-related quality of life of trauma patients: what is the contribution of recall bias and response shift? The EuroQol Group Plenary Meeting 2019: Brussels, Belgium September 18-19, 2019 (Discussant).
12. Xie F. Trial-based Economic Evaluation: When Edward Meets Bella. Peking Union Medical College Hospital, Beijing, China, August 26, 2019 (Invited Seminar).
13. Xie F. Patients: The Centre of Modern Health Care and Research. 26th Annual Meeting of China Society of Clinical Epidemiology and Evidence-Based Medicine. Dalian, China, August 22-25, 2019 (Plenary).
14. Xie F, The Use of Trial-based Economic Evaluations to Inform Drug Coverage Policy Making. 1st China Health Economics and Health Insurance Summit, Hangzhou, China, August 16-17, 2019 (Podium)
15. Xie F. Academic HTA: An Endangered Species in Canada. School of Public Health, University of Alberta, Edmonton, Canada, July 16, 2019 (Invited Seminar)

INVITED PRESENTATIONS (presenters underlined)

16. Xie F, Xue Li, Xiaoning He. Developing Patient-Reported Outcome Measures in China. National Huaxia Pharmacoeconomics Forum, Nanjing, China, June 30, 2019 (Podium).
17. Xie F. Canadian Amendment to Patented Drug Pricing. National Huaxia Pharmacoeconomics Forum, Nanjing, China, June 29, 2019 (Plenary).
18. Xie F. Economic evaluation and HTA in Canada. Xiongan Pharmacoeconomics Forum, Shijiazhuang, China, May 10, 2019 (Plenary).
19. Xie F. The use of economic evaluation to inform reimbursement policy. Xiongan Pharmacoeconomics Forum, Shijiazhuang, China, May 11, 2019 (Podium).
20. Xie F. Is Cost Effectiveness Analysis Useful for Health Insurance Policy? WHEN and HOW? South China Pharmacoeconomics Forum, Fuzhou, China, October 28, 2018.
21. Xie F. Patient Reported Outcome Measures: The role of disease-specific measures. China Health Outcome Research Alliance Meeting, Beijing, China, October 27, 2018.
22. Xie F. HTA for Health Insurance Policy: Survive-Strive-Thrive. First National HTA Conference. Beijing, China, October 26, 2018.
23. Xie F. From CEB to HEI: The Changing Landscape of Global Health Research. 25th Annual Meeting of China Society of Clinical Epidemiology and Evidence-Based Medicine. Beijing, China Oct 20-21, 2018.
24. Xie F. HTA for Health Insurance Policy: Survive-Strive-Thrive. University of Greifswald, September 23, 2018.
25. Xie F. HTA in Academia: Hope or Hype. Department Seminar, University of Illinois at Chicago, Chicago, China, July 9, 2018.
26. Xie F. HTA for Health Insurance Policy: Survive-Strive-Thrive. 2018 Huaxia Pharmacoeconomics Forum. Tianjing, China, June 30-July 1, 2018.
27. Xie F. From explanatory to pragmatic clinical trial design. Shanghai Renji Hospital. Shanghai, China, December 7, 2017.
28. Xie F. Pharmacoeconomics for coverage policy: From innovation to suspicion, and (im)possible solutions? Jiangsu Pharmacoeconomics Academic Committee Annual Meeting, Nanjing, China December 3, 2017
29. Xie F. Drug investment and disinvestment. ISPOR Beijing Chapter Annual Meeting. Beijing China, November 25-26, 2017.
30. Xie F. Pharmacoeconomics for coverage policy: From innovation to suspicion, and (im)possible solutions? Health Care Insurance Forum, Tianjing University, Tianjing, China, November 19, 2017
31. Xie F. The use of economic evaluation in Canada: where have we been and where we are going? Pharmacoeconomics International Forum. ISPOR Northern China Chapter, Shenyang, China, March 19, 2017.
32. Xie F. Health utility for coverage decision making: Imagination, prediction, and deception. Toronto Health Economics and Technology Assessment Collaborative (THETA) Rounds. Toronto, Canada, December 18, 2015

INVITED PRESENTATIONS (presenters underlined)

33. Xie F. IMPACT-AF Economic Evaluation: The Impact on the Health Care System and Society. 2015 IMPACT-AF Annual Advisory Committee Meeting, Halifax, Nova Scotia, Canada, November 5, 2015
34. Xie F, Designing and reporting economic evaluation. China Pharmacoeconomics Summit, Shanghai Pharmaceutical Association, July 2-4, 2015.
35. Xie F, Measuring health utilities for economic evaluation. China Pharmacoeconomics Summit, Shanghai Pharmaceutical Association, July 2-4, 2015.
36. Xie F, Decoding the EQ-5D: A Patient-Reported Outcome Measure for Clinical and Economic Evaluations. Clinical Epidemiology and Biostatistics Rounds, December 1, 2014.
37. Xie F, Cost Effectiveness Analysis: The vampire approach versus the Frankenstein approach. Chinese Pharmaceutical University Seminar, May 23, 2014.
38. Xie F, Pharmacoeconomics: The model-based approach. Forbidden City International Pharmacist Forum 2014, May 16-18, Beijing, China (podium presentation)
39. Xie F, Pharmacoeconomics to inform Reimbursement decision making: Regulator's minefield, academia's utopia, or industry's playground? Pharmacoeconomics and Health Policy Forum, May 19, 2014 Beijing, China (plenary presentation)
40. Xie F, Decoding the EQ-5D: A Patient-Reported Outcome Measure for Clinical and Economic Evaluations. McMaster Asia Forum, April 4, 2014.
41. Kind P, Pickard AS, Xie F, New developments in valuing health: directions for the EQ-5D. International Society of Quality of Life Research Annual Conference, Miami, USA, October 9-12, 2013 (Symposium speaker)
42. Xie F. EQ-5D-5L Overview of methodology and results for EQ-5D-5L valuation studies, The EuroQol Group Plenary Meeting 2013: Montreal, Canada, September 12-13, 2013 (Discussant).
43. Assasi N, Blackhouse G, Campbell K, Hopkins R, Xie F, Goeree R, High sensitivity cardiac troponin for rapid diagnosis of acute coronary syndrome and acute MI in the emergency departments: A clinical and cost effectiveness evaluation. Presentation to the Canadian Agency for Drugs and Technologies in Health, Ottawa, Canada, January 18, 201.
44. Pullenayegum E, Perampaladas K, Gaebel K, Doble BM, Xie F, Between-country heterogeneity in EQ-5D-3L scoring algorithms: how much is due to differences in health state selection? The EuroQol Group Plenary Meeting 2013: Montreal, Canada, September 12-13, 2013 (Paper presentation).
45. Xie F, HTA Insight on Region Specific Review Process, Evidence-based Market Access Strategies for Medical Devices in Canada Annual Conference, Toronto, Canada, April 11-12, 2013 (Plenary speaker).
46. Xie F. EQ-5D-5L valuation project for the Spanish population-a descriptive overview and preliminary results by Ramos-Goni JM, Errea M, Rivero-Arias O, Pinto-Prades JL, Cabases JM, The EuroQol Group Plenary Meeting 2012: Rotterdam, The Netherlands, September 13-14, 2012 (Discussant).

INVITED PRESENTATIONS (presenters underlined)

47. Xie F. Canadian Pharmacoeconomics Guidelines. Pharmacoeconomics and Evidence-based Medical Decision Making International Forum 2011: Beijing, January 19, 2011 (Keynote).
48. Goeree R, Tarride, JE, Bowen J, O'Reilly D, Xie F. PATH program updates, PATH Health Technology Assessment Management Committee Meeting, Presentation to Medical Advisory Secretariat, Toronto, ON. January 31, 2012.
49. Goeree R, Xie F, Blackhouse G. The cost-effectiveness of transcatheter aortic valve implantation compared to standard management and surgical aortic valve replacement in patients with severe symptomatic aortic stenosis. Health Quality Ontario, Toronto, ON, February 7, 2012.
50. Xie F. Improving health care system, can health technology assessment do a better job? Presentation at the Grand Rounds of Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China, July 31st, 2012.
51. Bowen JM, Snead OC, Elliott I, O'Reilly D, Xie F, Tarride, JE, Hopkins RB, Burke N, Goeree R. Diagnostic evaluation of children and adolescents with epilepsy for surgery candidacy and the role of magnetoencephalography (MEG). Presentation to OHTAC, MOHLTC, Toronto, ON. January 28, 2011.
52. Xie F. Using economic evaluation to inform drug formulary decision. Pharmacoeconomics Salon: Guanghua School of Management, Beijing University Beijing, China January 20, 2011 (Plenary).
53. O'Reilly D, Bowen JM, Tarride J-E, Xie F, Campbell K, Goeree R. Introduction to Health Technology Assessment (HTA). Radiation Oncology Departmental Seminar Series, Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, ON. July 20, 2011.
54. Bowen J, O'Reilly D, Tarride J-E, Xie F, Blackhouse G, Hopkins R, Campbell K, Nunes E, Goeree R. Standardization considerations for planning, conducting, analyzing and reporting EXCITE field evaluations. Meeting of EXCITE Methodological Centres, Toronto, ON, November 23, 2011 (oral presentation).
55. Bowen JM, O'Reilly DJ, Tarride J-E, Xie F, Blackhouse G, Hopkins RB, Campbell K, Burke N, Goeree R. Field evaluation and economic assessment program (FEEAP). Presentation to a delegation from the Health Insurance Review and Assessment Services (HIRA) South Korea, Toronto, ON, June 9, 2011.
56. Bowen JM, O'Reilly D, Xie F, Tarride J-E, Nunes E, MacDougald C, Goeree R. PATH's experience in conducting field evaluations of multifaceted intermediate care interventions. Presentation to MAS and THETA, Toronto, ON, July 26, 2011.
57. Goeree R, Tarride JE, O'Reilly D, Xie F. Going beyond effectiveness and cost-effectiveness: How can we identify and incorporate other important factors for healthcare decision-making? CAPT Conference: Decisional Balance Session. Ottawa, ON, April 19, 2011.
58. Xie F. Improving health care system: Can health technology assessment do a better job? Huaxia Pharmacoeconomics Forum, Shanghai, April 24-25, 2011 (plenary presentation)

INVITED PRESENTATIONS (presenters underlined)

59. Bowen JM, O'Reilly DJ, Tarride J-E, **Xie F**, Blackhouse G, Hopkins RB, Campbell K, Burke N, Nunes E, Goeree R. Non-pharmaceutical technologies – Field evaluations in Ontario. 2011 Annual CHASPR Conference, Halifax, NS, May 9, 2011 (podium presentation).
60. **Xie F**, Supporting Evidence-Based Policy Making: Health Technology Assessment in Canada. Forbidden City International Pharmacist Forum 2011, May 21-25, Beijing, China (podium presentation)
61. **Xie F**. A comparison of the scaling properties of the English, Spanish, French, and Chinese EQ-5D descriptive by Luo N, Li MH, Herdman M, Lloyd A, The EuroQol Group Plenary Meeting 2011: Oxford, the United Kingdom, September 15-16, 2011 (Discussant).
62. **Xie F**. Towards evidence-based decision making: The role of Health Technology Assessment. International Health Economics Conference 2010: Application of Economic Models in Drug Listing and Reimbursement Policy, Hong Kong, September 10-11, 2010 (Plenary).
63. **Xie F**. Real life application of economic models in healthcare decision-making. International Health Economics Conference 2010: Application of Economic Models in Drug Listing and Reimbursement Policy, Hong Kong, September 10-11, 2010.
64. **Xie F**. Exercise in modelling – estimation using pre-developed software. International Health Economics Conference 2010: Application of Economic Models in Drug Listing and Reimbursement Policy, Hong Kong, September 10-11, 2010.
65. **Xie F**. Using economic evaluation to inform drug formulary decision. International Health Economics Conference 2010: Application of Economic Models in Drug Listing and Reimbursement Policy, Hong Kong, September 10-11, 2010 (Plenary).
66. O'Reilly D, Blackhouse G, Hopkins R, Bowen JM, **Xie F**, Tarride J-E, Goeree R. The Ontario Diabetes Economic Model (ODEM). Presentation to the Partnerships for Health Initiative in the Southwest Ontario LHIN, London, ON. February 10, 2010.
67. Bowen JM, Campbell K, O'Reilly DJ, Tarride J-E, **Xie F**, Goeree R. Negative pressure wound therapy: systematic review(s) & current research. Building Bridges III: Connecting the Dots... Best Practice, Research, Knowledge Translation and Policy for Wound Care. St. Michael's Hospital Wound Healing and Skin Ulcer Prevention Program Conference. St. Michael's Hospital, Toronto, Ontario, April 16, 2010 (Podium presentation).
68. Bowen JM, Snead OC, Elliott I, Burke N, Hopkins RB, O'Reilly DJ, **Xie F**, Goeree R. A retrospective, single-centre, descriptive chart review to characterize the health system utilization patterns associated with the neurological evaluation for surgery of children and adolescents referred to an epilepsy monitoring unit (EMU) for video electroencephalogram (VEEG) and to characterize the role of magnetoencephalography (MEG) in this process. Presentation to Senior Administration. The Hospital for Sick Children, Toronto, ON. December 7, 2010
69. **Xie F**. Test of refinements of lead time TTO by Stolk E, Oppe M, The EuroQol Group Plenary Meeting 2010: Athens Greece, September 15-18, 2010 (Discussant).

INVITED PRESENTATIONS (presenters underlined)

70. Xie F. Using HTA to Support Evidence-based policy making: An academic perspective. The Annual Meeting of Taiwan Society of Pharmacoeconomics and Outcomes Research, December 11, 2010. Taipei, Taiwan (Keynote)
71. Xie F, Pharmacoeconomics Modeling using Excel, Pre-conference workshop of Annual Meeting of Taiwan Society of Pharmacoeconomics and Outcomes Research, December 10, 2010, Taipei, Taiwan.
72. Goeree R, Tarride JE, O'Reilly D, Xie F, Bowen J, Blackhouse G, Hopkins R, Patterson L. Conditionally funded field evaluations (CFFE) in Ontario. Presentation at CADTH Symposium, Ottawa, ON. April 5, 2009.
73. Goeree R, Tarride JE, O'Reilly D, Xie F, Bowen J, Blackhouse G, Hopkins R. Conditionally funded field evaluations: PATHs coverage with evidence development program for Ontario. ISPOR 15th Annual International Meeting, Orlando, Florida May 15, 2009.
74. Goeree R, O'Reilly D, Blackhouse G, Chandra K, Bowen JM, Hopkins R, Xie F, Tarride JE. Development and application of an economic model: The Ontario diabetes economic model (ODEM). Ontario's Specialized Multidisciplinary Community Care Expert Advisory Panel, Toronto, ON, January 21, 2009.
75. Hughes E, Perampaladas K, Bowen J, O'Reilly D, Xie F. Feasibility of an altruistic sperm donation in Canada: an iterative population-bases analysis. Presentation to Assisted Human Reproduction Canada, Health Canada, December 4, 2009.
76. Goeree R, Blackhouse G, Chandra K, Tarride JE, Xie F, Bowen JM, Hopkins R, O'Reilly D. Using the Ontario Diabetes Economic Model (ODEM) to help inform program decision making in the province of Ontario. Presentation to Ontario's Diabetes Evidentiary Working Group (DEWG), Toronto, ON, February 20, 2009.
77. Xie F, Tarride JE, O'Reilly D, Goeree R. The PATH to informing decisions for new and existing health technologies. Department of Community Health Sciences Seminar, University of Calgary, October 16, 2009.
78. Xie F. Statistics in health economic evaluation: Applications and challenges. Department of Mathematics and Statistics, Statistics Seminar, McMaster University, December 1, 2009. .
79. Goeree R, Blackhouse G, Chandra K, Tarride J-E, Xie F, Bowen JM, Hopkins R, O'Reilly D. Application of the Ontario Diabetes Economic Model (ODEM) to diabetes programs considered by MAS and OHTAC. Presentation to OHTAC, Toronto, ON, February 28, 2009.
80. Tarride JE, Bowen J, De Rose G, Blackhouse G, Hopkins R, Novick T, O'Reilly D, Xie F, Goeree R. How conditional funded field evaluations can be used to make policy? A case study of endovascular repair (EVAR) for the treatment of abdominal aortic aneurysms (AAAs). Ontario Ministry of Health and Long-Term Care's Health Research Showcase, Toronto, ON. October 8th, 2009 (poster).
81. O'Reilly D, Tarride JE, Bowen J, Blackhouse G, Xie F, Goeree R. Using the Ontario Diabetes Economic Model (ODEM) to help inform program decision making in the Province of Ontario. Ontario Ministry of Health and Long-Term Care's Health Research Showcase, Toronto, ON. October 8th, 2009 (poster).

INVITED PRESENTATIONS (presenters underlined)

82. O'Reilly D, Tarride JE, Bowen J, Blackhouse G, **Xie F**, Goeree R. Using the Ontario Diabetes Economic Model (ODEM) to help inform program decision making in the Province of Ontario. Ontario Ministry of Health and Long-Term Care's Health Research Showcase, Toronto, ON. October 8th, 2009 (Podium presentation).
83. Bowen JM, O'Reilly DJ, **Xie F**, Tarride J-E, Blackhouse G, Hopkins RB, Campbell K, Burke N, Assasi N, Goeree R. Health technology assessment: an overview. Presented at the 2008 Annual Scientific Meeting of the Canadian Society of Nuclear Medicine, Toronto, ON, April 14, 2008.
84. Goeree R, Tarride JE, O'Reilly D, **Xie F**, Bowen J, Blackhouse G, Hopkins R, Campbell K, Burke N, Lim M. Using HTA to inform publicly financed health care decision-making: The case study of drug eluting stents in Ontario, Canada. HTAi Conference, Montreal, PQ, July 6, 2008 (podium presentation).
85. Goeree R, Tarride JE, O'Reilly D, **Xie F**, Bowen J, Blackhouse G, Hopkins R, Campbell K, Burke N, Lim M. Using conditionally funded field evaluations (CFFE) for evidence development, uncertainty reduction and reimbursement decision making: Case studies from Ontario. HTAi Conference, Montreal, PQ. July 10, 2008 (podium presentation).
86. O'Reilly D, Blackhouse G, Hopkins R, Bowen JM, **Xie F**, Tarride JE, Goeree R. The long-term costs and consequences of various diabetes management strategies: Results from the Ontario Diabetes Economic Model (ODEM). CDA/CSEM Professional Conference, Montreal, QC. October 16, 2008 (podium presentation).
87. Bowen JM, O'Reilly DJ, Patterson L, Hopkins RB, Nunes E, MacDougald C, Assasi N, Blackhouse G, Burke N, Campbell K, Tarride J-E, **Xie F**, Goeree R. The PATH to decisions for new & existing health technologies. Building Bridges II: Discovering, Navigating & Integrating Knowledge for Safer Wound Care, Niagara-on-the-Lake, November 23, 2008 (podium presentation).
88. Bowen JM, O'Reilly DJ, Patterson L, Hopkins RB, Nunes E, MacDougald C, Assasi N, Blackhouse G, Burke N, Campbell K, Tarride JE, **Xie F**, Goeree R. _Conditionally funded field evaluations (CFFE) in Ontario: Process and infrastructure needs. Alberta Health and Wellness, Edmonton, AB, November 27, 2008 (podium presentation).
89. **Xie F**, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): Validation of English Version in Singapore. 1st National Health Outcomes Conference, Kuala Lumpur, Malaysia, July 27-28, 2004 (podium presentation).

OTHER PRESENTATIONS (presenters underlined):

1. Kaur M, Pusic AL, Cano SJ, **Xie F**, Bordeleau L, Zhong T, Klassen A. Development of health-state classification system for a new breast cancer-specific preference-based measure: the BREAST- Q-U. CanPROS Congress meeting, Calgary, Alberta, Canada, November 13-15, 2019 [Poster Presentation – Best Student Poster Award].
2. **Xie F**, Humphries B, Magrini N, Drummond M. Value or Value Traps: Innovative Value-Based Pricing. The European Congress of International Society for Pharmacoeconomics and Outcome Research, Nov 2-6, 2019, Copenhagen, Denmark [Issue Panel Presentation]
3. Zhou T, Chen Z, Li H, **Xie F**. Discrepancies in using published health utilities between cost utility analysis and referenced original health utility studies for Cardiovascular disease: A Registry-Based Analysis. The European Congress of International Society for Pharmacoeconomics and Outcome Research, Nov 2-6, 2019, Copenhagen, Denmark [Podium Presentation-Best Podium Presentation]
4. Kaur M, Pusic AL, Cano SJ, **Xie F**, Bordeleau L, Zhong T, Klassen A. Development of health-state classification system for a new breast cancer-specific preference-based measure: the BREAST- Q-U. 25th Annual Conference of the International Society for Quality of Life Research, Dublin, Ireland, 24 - 27 October 2018 [Oral Presentation].
5. Humphries B, **Xie F**. Can Decision Analysis Improve Shared Decision Making with Patients? Evaluation of Medicines Research Group Rounds, Hamilton, October 2019
6. Humphries B, Zoratti M, Irwin A, Chen N, Zhou T, **Xie F**. Impact of patient-targeted financial incentives on healthcare costs: A systematic review of randomized controlled trials. Canadian Association for Population Therapeutics (CAPT) 2019 Annual Conference, Toronto, Ontario [Oral Presentation, Best Oral Presentation Award].
7. Humphries B, **Xie F**. Shared decision making for thromboprophylaxis during pregnancy: A mixed methods experimental study. Evaluation of Medicines Research Group Summer Student Research Day, Hamilton, August 2019.
8. Thomas S, **Xie F**. Non-parametric analysis for valuing the EQ-5D-5L: An international comparison. The Canadian Economics Association Annual Meeting, May 2019, Calgary, Canada.
9. Zoratti MJ, Zhou T, Chan K, Levine O, Krahn M, Husereau D, Clifford T, Schünemann H, Guyatt G, **Xie F**. The Health Utility Book (HUB): A registry of health state utility values in oncology. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, New Orleans, Louisiana, May 22-25, 2019 [Poster Presentation].
10. **Xie F**, Zoratti MJ, Chan K, Husereau D, Krahn M, Levine O, Clifford T, Schünemann H, Guyatt G. (May 2019). The Health Utility Book (HUB): Toward a centralized, systematic approach to the identification, appraisal, and use of health state utility values for reimbursement decision making. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, New Orleans, Louisiana, May 22-25, 2019 [Poster Presentation].
11. Humphries B, Irwin A, Zoratti MJ, **Xie F**. Impact of patient-targeted financial incentives on healthcare costs: A systematic review of randomized controlled trials.

OTHER PRESENTATIONS (presenters underlined):

- International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting, New Orleans, Louisiana, May 22-25, 2019 [Poster Presentation, Student Travel Award].
12. Zoratti MJ, Chan K, Levine O, Krahn M, Husereau D, Clifford T, Schünemann H, Guyatt G, **Xie F**. Health Utility Book (HUB): Enhancing the selection and application of health utilities in reimbursement decision-making. Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium, Edmonton, Alberta, April 2019 (Poster).
 13. Michalowsky B, **Xie F**, Eichler T, Kilimann I, Teipel S, Kaczynski A, Thyrian J, Hoffmann W. *Cost-Effectiveness of a Collaborative Dementia Care Management – Results of a Cluster-Randomized Controlled Trial*. Alzheimer's Association International Conference (AAIC); 2019 Jul 18; Los Angeles, USA (Podium).
 14. Michalowsky B, Hoffmann W, Kennedy K, **Xie F**. *Imputation Methods for Missing Data in Cost-Utility Analyses Alongside Randomized Controlled Trials: Aggregate or Non-Aggregate?* 40th Annual North American Meeting of the Society for Medical Decision Making; 2018 October 17; Montreal, Canada [Poster Presentation].
 15. Law EH, Pickard AS, **Xie F**, Walton S, Lee TA, Schwartz A. Time-specific Differences in Stated Preferences for Health in the United States. 40th Annual North American Meeting of the Society for Medical Decision Making; 2018 October 17; Montreal, Canada [Poster Presentation].
 16. Law EH, Pickard AS, **Xie F**, Walton S, Lee TA, Schwartz A. Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. 40th Annual North American Meeting of the Society for Medical Decision Making; 2018 October 17; Montreal, Canada [Poster Presentation].
 17. Michalowsky B, **Xie F**, Kaczynski A, Kilimann I, Teipel S, Wucherer D, Zwingmann I, Thyrian J, Hoffmann W. Cost-Effectiveness of a Dementia Care Management alongside a Cluster-randomized Controlled Interventional Trial. ISPOR Europe 2018; 2018 Nov 12; Barcelona, Spain [Podium presentation].
 18. Kaur M, Klassen A, David P, Pieris D, Sharma M, Bordeleau L, Zhong T, Pusic A, **Xie F**. Improving Breast Cancer Care by Understanding Health Utilities: The Work Before the Work. (2018) 25th Annual conference of the International Society for Quality of Life Research, Dublin, Ireland [Podium presentation]
 19. Kaur M, Pusic A, **Xie F**, Bordeleau L, Matros E, Zhong T, Cano S, Dimitry S, Klassen A. Development of health-state classification system for a new breast cancer-specific preference-based measure: the BREAST-Q-U. ISOQOL 2018 October 25 Dublin, Ireland [Podium presentation].
 20. Michalowsky B, **Xie F**, Kilimann I, Teipel S, Thyrian J, Wucherer D, Zwingmann I, Hoffmann W. Cost-effectiveness of a dementia care management – Results of the cluster-randomized, controlled, interventional trial DelpHi-MV. Deutsches Kongress für Versorgungsforschung; 2018 October 11; Berlin, Germany [Podium presentation].
 21. Michalowsky B, Hoffmann W, Kennedy K, **Xie F**. Imputation Methods for Missing Data in Cost-Utility Analyses alongside Randomized Controlled Trials: Aggregate or

OTHER PRESENTATIONS (presenters underlined):

- Non-Aggregate? ISPOR Europe 2018; 2018 Nov 13; Barcelona, Spain [Poster Presentation].
22. Xie F, Bryan S. Bringing a patient-oriented research lens to the work of the EuroQoL Group: Reflections from across the Atlantic. 2018 EuroQoL Group Plenary Meeting, September 18-25. Lisbon, Portugal [Paper presentation].
 23. Kennedy K, Pullenayegum E, Xie F. Efficient Use of Response Heterogeneity Improves Prediction Precision: A Case Study Using BWS to Value EQ-5D-3L Health States. 2018 EuroQoL Group Plenary Meeting, September 18-25. Lisbon, Portugal [Poster presentation].
 24. Zhao FL, Xie F, Wu JH. Dynamic Adjustment Mechanism for National Drug Formulary: International Experiences and the Development in China. 2018 ISPOR Asia Pacific Meeting, September 8-11. Tokyo, Japan [Workshop].
 25. Zoratti MJ, Thorlund K, Allen N, Xie F, Levine, M. An exploratory analysis of predictors of concordance between Canadian Common Drug Review reimbursement recommendations and the subsequent decisions by Ontario, British Columbia, and Alberta. The Canadian Association for Health Services and Policy Research Conference, Montreal, Quebec. May 2018.
 26. Podbielski DW, Muratov S, Pemberton J, Ahmed KI, Baltaziak M, Xie F. Preference-Based Glaucoma-Specific Health-Related Quality of Life Instrument: Development of Its Descriptive System. 2018 Canadian Ophthalmological Society Annual Meeting, May 31-June 3, 2018 Toronto, Ontario, Canada.
 27. Kennedy K, Podbielski D, Nanji K, Muratov S, Ahmed II, Xie F. *Disease-specific preference-based measure of glaucoma health states: HUG-5 psychometric validation*. HEI Research Day, FHS Research Plenary, MILO Showcase; 2018 March, May, October; Hamilton, Canada [Poster Presentation].
 28. Thomas S, Xie F. EQ-5D-5L Value Set Development Using Nonparametric Regression. 2017 Society for Medical Decision Making. Oct 22-25, Pittsburgh, PA, USA [Poster Presentation].
 29. Muratov S, Podbielski DW, Pemberton J, Ahmed KI, Baltaziak M, Xie F. Preference-Based Glaucoma-Specific Health-Related Quality of Life Instrument: Development of Its Descriptive System. 2017 Society for Medical Decision Making. Oct 22-25, Pittsburgh, PA, USA [Poster Presentation].
 30. Kaur M, Klassen A, David P, Pieris D, Sharma Manraj, Bordeleau L, Pusic A, Xie F. Health State Utilities in Breast Cancer Research: A Systematic Review. 2017 Society for Medical Decision Making. Oct 22-25, Pittsburgh, PA, USA [Poster Presentation].
 31. Jin X, Liu G, Guan H, Xie F. Self-reported health status among type 2 diabetic patients: A community-based survey in China. 2017 Society for Medical Decision Making. Oct 22-25, Pittsburgh, PA, USA [Poster Presentation].
 32. Jin X, Liu G, Guan H, Li H, Xie F. Modeling Composite Time Trade-Off Data for EQ-5D-5L Health States: An Interval Regression Approach. 2017 Society for Medical Decision Making. Oct 22-25, Pittsburgh, PA, USA [Poster Presentation].

OTHER PRESENTATIONS (presenters underlined):

33. Nalder E, Dawson D, Anderson N, Murphy K, Donnelly C, **Xie F**, Hussein H. Maintaining the autonomy of older adults with subjective cognitive decline using tele-rehabilitation: a randomized pilot study in a primary care setting. 2017 AGE-WELL Annual Conference. Oct 17-19. Winnipeg, Canada [Poster Presentation].
34. Thomas S, **Xie F**. EQ-5D-5L Value Set Development Using Nonparametric Regression. 2017 EuroQoL Group Plenary Meeting, September 20-22. Barcelona, Spain [Paper presentation]
35. Kovic B, Jin X, Thabane L, Guyatt G, Brundage MD, **Xie F**, for the PFS-HRQoL Review Team. Association between progression-free survival and health-related quality of life in oncology: A systematic review and regression analysis. 2017 American Society of Clinical Oncology Annual Meeting, June 1-5, Chicago, USA [Poster Presentation].
36. Kaur MN, **Xie F**, Shiwcharan A, Patterson L, Shargall Y, Finley CJ, Schieman C, Dalimonte T, Fahim C, Hanna W. Robotic-assisted thoracoscopic lobectomy versus video-assisted thoracoscopic lobectomy for early-stage non-small cell lung cancer: a health-care resource utilization analysis. 2017 International Society for Pharmacoeconomic and Outcomes 22nd Annual International Meeting. May 20-24, 2017, Boston, Massachusetts, USA (Nominated for Best Student Poster Presentation)
37. Xu M, Fox-Robichaud A, Thabane L, **Xie F**. Rapid Response Systems: Cost and Clinically Effective? A Cost Effective Economic Evaluation of Rapid Response Systems. 2017 International Conference on Rapid Response Systems and Medical Emergency Teams. May 11-12 Chicago, USA [Podium presentation].
38. Muratov S, Podbielski DW, Pemberton J, Ahmed KI, Baltaziak M, **Xie F**. Preference-Based Glaucoma-Specific Health-Related Quality of Life Instrument: Development of Its Descriptive System. 2017 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium. April 23-25. Ottawa, Canada [Poster Presentation].
39. Nowak C, Fang H, Shkredova D, Gordon C, Adachi J, **Xie F**, Phillips S, Richardson J, Tang A. An Ounce of Prevention: The use of an innovative resistance training program to improve physical function in pre-frail older adults: a randomized controlled trial. Optimal Aging Conference. Louisville, KY: June 11-13, 2017 [Poster Presentation].
40. Al Sayah F, Johnson JA, Ohinmaa A, **Xie F**, Bansback N. Health literacy and logical inconsistencies in health state valuations: Results from the Canadian EQ-5D-5L valuation study. 38th Annual North American Society for Medical Decision Meeting, October 23-26, 2016. [Poster Presentation].
41. Oremus M, Jantzi M, **Xie F**, Hirdes J. Development of a Conceptual Crosswalk Between Resident Assessment Instruments and the EQ-5D-5L. 38th Annual North American Society for Medical Decision Meeting, October 23-26, 2016. [Poster Presentation].
42. Jin X, Liu G, Guan H, **Xie F**. Self-reported health status among type 2 diabetic patients: A community-based survey in China. 38th Annual North American Meeting of the Society for Medical Decision Making. Vancouver, BC, Canada. October 23-26, 2016.

OTHER PRESENTATIONS (presenters underlined):

43. Al Sayah F, Johnson JA, Ohinmaa A, **Xie F**, Bansback N. Health literacy and logical inconsistencies in health state valuations: Results from the Canadian EQ-5D-5L valuation study. ISOQOL 23rd Annual Conference, Copenhagen, Denmark, October 19-22, 2016. Quality of Life Research 2016:25(Suppl 1):24(A102.4). [Oral Presentation].
44. Al Sayah F, Qiu W, **Xie F**, Johnson JA. Comparative Performance of the EQ-5D-5L and SF-6D in Adults with Type 2 Diabetes. ISOQOL 23rd Annual Conference, Copenhagen, Denmark, October 19-22, 2016. Quality of Life Research 2016:25(Suppl1):132(A2103) [Poster Presentation].
45. Kaur MN, **Xie F**, Shiwcharan A, Patterson L, Dalimonte T, Shargall Y, Finley C, Schieman C, Fahim C, Hanna W. Robotic-assisted Thoracoscopic Pulmonary Resection versus Video-Assisted Thoracoscopic Pulmonary Resection for Early-Stage Non-Small Cell Lung Cancer: A Healthcare Utilization Analysis. Canadian Surgery Forum, Toronto September 10, 2016 [Podium Presentation]
46. Al Sayah F, Johnson JA, Ohinmaa A, **Xie F**, Bansback N. Health literacy and logical inconsistencies in health state valuations: Results from the Canadian EQ-5D-5L valuation study. 33rd EuroQol Plenary Meeting, Berlin Sept 15-17, 2016 [Poster Presentation]
47. **Xie F**, Pullenayegum E, Pickard S, Ramos Goni J, Woo JM. Transforming latent utilities to health utilities: East doesn't meet West. 33rd EuroQol Plenary Meeting, Berlin Sept 15-17, 2016 [Poster Presentation]
48. Devji T, Levine O, Neupane B, Beyene J, **Xie F**. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. McMaster Department of Clinical Oncology Research Day, June 23, 2016. [Poster Presentation]
49. **Xie F**, Pullenayegum E, Pickard S, Johnson JA. Variation in health preferences across populations: when (where) does it matter, and what are the implications? HTAi Annual Meeting, Tokyo, Japan, May 9-12, 2016 [Issue Panel].
50. **Xie F**, Chan KW, Pullenayegum E. Measuring health utilities for QALYs: Get it right and use it properly. HTAi Annual Meeting, Tokyo, Japan, May 9-12, 2016 [Issue Panel]
51. **Xie F**, Pullenayegum E, Pickard S, Johnson JA. Variation in health state preferences across local and international populations: East doesn't meet West. CADTH Annual Symposium, Ottawa, Canada, April 10-12, 2016. [Issue Panel].
52. **Xie F**, Introduction to Health Economic Evaluation. Firestone Respiratory Grand Rounds, St Joseph's Healthcare Hamilton, Hamilton, Canada, March 3, 2015.
53. **Xie F**, Pickard AS, Krabbe PFM, Revicki D, Viney R, Devlin N, Feeny D, A checklist for reporting valuation studies of multi-attribute utility-based instruments (CREATE). 2015 SMDM Annual Meeting, St Louis, USA, October 18-22, 2015 (Podium presentation).
54. **Xie F**, Pullenayegum EM, Gaebel K, Bansback N, Bryan S, Ohinmaa A, Poissant L, Johnson JA. A Time trade-off-derived value set of the EQ-5D-5L for Canada. 22nd

OTHER PRESENTATIONS (presenters underlined):

- ISOQOL Annual Meeting, Vancouver, Canada, October 21-24, 2015 (Podium presentation).
55. McClure N, Al Sayah F, **Xie F**, Luo N, Johnson JA. Instrument-defined estimates of minimally important difference in the EQ-5D-5L index score for Canadian, Chinese, and Spanish scoring algorithm. 22nd ISOQOL Annual Meeting, Vancouver, Canada, October 21-24, 2015 (Poster presentation).
 56. Al Sayah F, Bansback N, Bryan S, Ohinmaa A, Poissant L, Pullenayegum E, **Xie F**, Johnson JA. Determinants of Time-Trade Off Valuations for EQ-5D-5L Health States. 22nd ISOQOL Annual Meeting, Vancouver, Canada, October 21-24, 2015 (Poster presentation).
 57. **Xie F**, Johnson, JA, Bansback N, Bryan S. A Canadian value set for the EQ-5D-5L: One answer, more questions. 2015 CADTH Symposium, Saskatoon, Canada, April 6-8, 2015 (Issue panel).
 58. Jin X, Liu G, Luo N, Li H, Guan H **Xie F**. Estimating A Value Set from the China EQ-5D-5L Valuation Study: An Interval Regression Approach. The EuroQol Plenary Meeting, Krakow, Poland, September 8-9, 2015 (paper presentation)
 59. **Xie F**, Pickard AS, Krabbe PFM, Revicki D, Viney R, Devlin N, Feeny D, A checklist for reporting valuation studies of multi-attribute utility-based instruments (CREATE). The EuroQol Plenary Meeting, Krakow, Poland, September 8-9, 2015 (paper presentation)
 60. Pullenayegum E, Sunderland K, Johnson J, **Xie F**, Handling regional variation in health state preferences within a country: a methodological framework with application to Canada. The EuroQol Plenary Meeting, Krakow, Poland, September 8-9, 2015 (paper presentation)
 61. Bansback N, Mohammadi T, Ohinmaa A, Pullenayegum E, **Xie F**, Bryan S, Using a discrete choice experiment to estimate values for the EQ-5D-5L: findings from the Canadian Valuation study. The EuroQol Plenary Meeting, Krakow, Poland, September 8-9, 2015 (poster presentation)
 62. **Xie F**, Introduction to health economic evaluation. Nephrology Grand Rounds, St. Joseph's Healthcare Hamilton, Canada, May 29, 2015.
 63. Jin X, Liu G, Luo N, Li H, Guan H, **Xie F**. Demographic and Cultural Impact on Health Preferences in China: An Exploratory Analysis of China EQ-5D-5L Valuation Study. Department of Clinical Epidemiology and Biostatistics Annual Research Day. Hamilton, ON, Canada. March 26, 2015 [Poster Presentation].
 64. Tarride JE, Petrella RJ, O'Reilly D, **Xie F**, Reza Nakhai-Pour H, Blackhouse G, Goeree R. Economic evaluation of treating diabetes patients according to guidelines in South-Western Ontario, Canada. ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, 2012 (poster).
 65. Nakhai-Pour H, Tarride JE, Blackhouse G, **Xie F**, O'Reilly D, Goeree R, Petrella RJ. Characteristics of the aboriginal people with diabetes in the South-Western of Ontario, Canada. ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, 2012 (poster).

OTHER PRESENTATIONS (presenters underlined):

66. Petrella RJ, Tarride JE, O'Reilly D, **Xie F**, Goeree R. Characteristics of patients with diabetes in Southwestern Ontario, Canada. ISPOR 15th Annual European Congress, Berlin, Germany, November 3-7, 2012 (poster).
67. Perampaladas K, Doble B, Pullenayegum E, Bowen J, Goeree R, **Xie F**. Methodological differences in EQ-5D scoring systems: A systematic review and analysis. 2011 CADTH Symposium, Vancouver, BC, April 3-5, 2011 (poster).
68. Sutherland CS, Bischof M, Blackhouse G, Goeree R, Tarride J-E, **Xie F**. Economic evaluation of everolimus-eluting stent versus paclitaxel-eluting stent for patients undergoing percutaneous coronary intervention. 2011 CADTH Symposium, Vancouver, BC, April 3-5, 2011 (poster).
69. Doble B, Perampaladas K, von Keyserlingk C, Campbell K, Blackhouse G, Goeree R, **Xie F**. The cost-utility and value of information of transcatheter aortic valve implantation compared to standard management and surgical aortic valve replacement in patients with severe symptomatic aortic valve stenosis. CAPT 2011 Annual Conference, Ottawa, ON, April 18, 2011 (podium presentation).
70. Doble B, Perampaladas K, Blackhouse G, Goeree R, **Xie F**. The cost-utility of transcatheter aortic valve implantation in patients with severe symptomatic aortic valve stenosis. 2011 Annual CAHSPR Conference, Halifax, NS, May 11, 2011 (podium presentation).
71. Doble B, Perampaladas K, von Keyserlingk C, Campbell K, Blackhouse G, Goeree R, **Xie F**. The cost-utility and value of information of transcatheter aortic valve implantation compared to standard management and surgical aortic valve replacement in patients with severe symptomatic aortic valve stenosis. ISPOR 16th Annual International Meeting, Baltimore, MD, May 24, 2011 (poster).
72. Perampaladas K, Doble B, Bowen J, Pullenayegum E, Goeree R, **Xie F**. Methodological differences in the EQ-5D scoring systems: A systematic review and analysis. ISPOR 16th Annual International Meeting, Baltimore, MD, May 21-25, 2011 (poster).
73. Kathy Gaebel, Eleanor Pullenayegum, Mark Oppe, , Paul Krabbe, **Xie F**. Use of discrete choice experiment in measuring utilities: Binary or triplet? The EuroQol Group Plenary Meeting 2011: Oxford, September 15-16, 2011 (Podium).
74. Hughes E, Perampaladas K, Bowen JM, **Xie F**, O'Reilly D. Planning for an altruistic sperm donor program in Canada. CFAS 2011 Annual Meeting, Toronto, ON, September 21-24, 2011 (poster).
75. Perampaladas K, **Xie F**, O'Reilly D, Bowen J, Hughes E. Development of a Canadian population based model to estimate the supply and demand for altruistically donated sperm. CFAS 57th Annual Meeting, Toronto, Ontario, September 21-24, 2011 (poster).
76. Assasi N, **Xie F**, Blackhouse G, Gaebel K, Robertson D, Hopkins R, Healey JS, Goeree R. Catheter ablation strategies for rhythm control in patients with atrial fibrillation: A systematic literature review and meta-analysis. 33rd Annual Meeting of the SMDM, Chicago, IL, October 22-26, 2011 (poster).

OTHER PRESENTATIONS (presenters underlined):

77. Blackhouse G, Assasi N, **Xie F**, Robertson D, Gaebel K, Healey JS, Goeree R. Cost-effectiveness of pulmonary vein ablation for atrial fibrillation in Canada. 33rd Annual Meeting of the SMDM, Chicago, IL, October 22-26, 2011 (poster).
78. Bowen JM, O'Reilly DJ, Tarride J-E, **Xie F**, Blackhouse G, Hopkins R, Burke N, Nunes E, Goeree R. Coverage with evidence development in Ontario: Experience with designing field evaluations to inform health policy decisions. 33rd Annual Meeting of the Society for Medical Decision Making, Chicago, IL, October 22-26, 2011 (poster).
79. Bowen JM, Snead, OC, Hopkins R, Elliott I, Burke N, Atkin J, Hebbard M, Brown L, **Xie F**, Tarride J-E, O'Reilly DJ, Goeree R. Characterizing the utilization of magnetoencephalography in the determination of surgical candidacy in children and adolescents with medically refractory epilepsy – a field evaluation to inform health policy. 33rd Annual Meeting of the Society for Medical Decision Making, Chicago, IL, October 22-26, 2011 (poster).
80. Sutherland CS, Campbell K, Bowen JM, Blackhouse G, Goeree R, **Xie F**. A cost-effective analysis of four drug eluting stents for patients undergoing percutaneous coronary intervention. 9th International Congress on Coronary Artery Disease (ICCAD), Venice, Italy, October 23-26, 2011 (poster).
81. Assasi N, Schwartz L, Tarride JE, Goeree R, **Xie F**. A systematic review of economic evaluations conducted for assessment of genetic testing technologies. ISPOR 14th Annual European Congress, Madrid, Spain, November 5-8, 2011 (poster).
82. O'Reilly D, Pasricha A, Sauriol L, Metge C, LeLorier J, Healey J, Humphries K, Dorian P, Jacobs P, Tarride JE, Hopkins R, **Xie F**, Goeree R. Economic burden of illness study of atrial fibrillation in Canada. CAPT 2010 Annual Conference, Toronto, Ontario, March 28-30, 2010 (poster).
83. Tarride JE, Haq M, Bowen J, Blackhouse G, O'Reilly D, **Xie F**, Goeree R. The burden of osteoarthritis in Ontario. CAPT 2010 Annual Conference, Toronto, Ontario, March 28-30, 2010 (poster).
84. Tarride JE, Haq M, Bowen J, Blackhouse G, O'Reilly D, **Xie F**, Goeree R. The burden of rheumatoid arthritis in Ontario. CAPT 2010 Annual Conference, Toronto, Ontario, March 28-30, 2010 (poster).
85. Blackhouse G, **Xie F**, Gaebel K, Campbell K, Chalk C, Levine M, Assasi N, Goeree R. Cost-utility of intravenous immunoglobulin compared with corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy in Canada. CADTH Symposium "Evidence, Advice, Recommendations: Delivering Value for Money in Healthcare for Canadians". Halifax Nova Scotia, April 19-20, 2010 (poster).
86. Gaebel K, Kaulback K, Robertson D, Blackhouse G, **Xie F**, Assasi N, Goeree R. Clinical effectiveness of portable ultrasound in small emergency departments: A systematic review. CADTH Symposium "Evidence, Advice, Recommendations: Delivering Value for Money in Healthcare for Canadians". Halifax Nova Scotia, April 18-20, 2010 (poster).
87. **Xie F**, Pullenayegum. Incorporating quality of life into economic evaluations: health utilities measurement. The 32nd Annual Meeting of the Society for Medical Decision

OTHER PRESENTATIONS (presenters underlined):

Making, "Evidence, Economics & Ethics: The Future of Health Technology Assessment", Toronto, October 27-27, 2010.

88. Feng Xie, Nick Bansback. Using Discrete Choice Experiment to Estimate Health Utilities. CEB Rounds, McMaster University, Hamilton, ON. May 26, 2010.
89. Tarride JE, Burke N, Bischof M, Hopkins RB, Goeree L, Campbell K, **Xie F**, O'Reilly D, Goeree R. A review of health utilities across conditions common in paediatric and adult populations. CADTH Symposium "Evidence, Advice, Recommendations: Delivering Value for Money in Healthcare for Canadians". Halifax Nova Scotia, April 18-20, 2010 (poster).
90. Johnston BC, Thorlund K, Schünemann H, **Xie F**, Murad H, Montori VM, Guyatt GH. Improving the interpretation of health-related quality of life (HRQL) evidence in meta-analyses. CE&B 7th Annual Research Day. McMaster University, Hamilton, Ontario, April 23, 2010 (podium presentation).
91. Pullenayegum E, Tarride J-E, **Xie F**, O'Reilly D. Calculating decreases in health utilities associated with an adverse event: why traditionally used methods are biased, and simpler methods should be preferred. CE&B 7th Annual Research Day. McMaster University, Hamilton, Ontario, April 23, 2010 (podium presentation).
92. O'Reilly D, **Xie F**, Pullenayegum E, Gerstein H, Blackhouse G, Tarride J-E, Bowen J, Goeree R. Health status impact associated with experiencing a diabetes-related complication for patients with Type 2 Diabetes. CE&B 7th Annual Research Day. McMaster University, Hamilton, Ontario, April 23, 2010 (podium presentation).
93. Gaebel K, Blackhouse G, Robertson D, **Xie F**, Assasi N, Mclvor A, Hernandez P, Goeree R. Clinical effectiveness of triple therapy in the management of COPD: A systematic review. CE&B 7th Annual Research Day. McMaster University, Hamilton, Ontario, April 23, 2010 (poster).
94. Patterson LL, Nunes EL, McGuire A, MacDougald CB, Bowen JM, O'Reilly DJ, Hopkins RB, Blackhouse G, Burke N, Tarride J-E, **Xie F**, Goeree R. Managing health technology trials designed for policy decision making. CE&B 7th Annual Research Day. McMaster University, Hamilton, Ontario, April 23, 2010 (poster).
95. Pasricha A, Sauriol L, Metge C, LeLorier J, Healey J, Humphries K, Dorian P, Jacobs P, Tarride JE, Hopkins R, **Xie F**, Goeree R, O'Reilly D. Economic burden of illness study of atrial fibrillation in Canada. FHS Research Plenary, McMaster University, Hamilton, ON. May 14, 2010 (poster).
96. Blackhouse G, **Xie F**, Assasi N, Gaebel K, Campbell K, Roberston D, Marshall J, Irvine E, O'Reilly D, Tarride J-E, Goeree R. Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF- α drugs for refractory Crohn's Disease. ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA (poster).
97. **Xie F**. HTA and Conditionally-Funded Field Evaluations in Canada. Moving Forward with HTA on Medical Devices and Diagnostic Products, ISPOR 15th Annual International Meeting, May 17, 2010, Atlanta, GA, USA (podium presentation).

OTHER PRESENTATIONS (presenters underlined):

98. Gaebel K, Blackhouse G, Robertson D, Xie F, Assasi N, Mclvor A, Hernandez P, Goeree R. Triple therapy for chronic obstructive pulmonary disease. ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA (poster).
99. Tarride J-E, Haq M, Bowen J, Blackhouse G, O'Reilly D, Xie F, Goeree R. Utilizing health survey and administrative data to estimate the burden of osteoarthritis (OA) in Ontario. ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA (poster).
100. Tarride J-E, Haq M, Bowen J, Blackhouse G, O'Reilly D, Xie F, Goeree R. Health status, physician, day procedures and hospitalization costs associated with rheumatoid-arthritis (RA) in Ontario. ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA (poster).
101. Xie F, Pullenayegum E, Li S-C, Hopkins R, O'Reilly D, Tarride J-E, Goeree R, Thumboo J. Use of a disease-specific instrument in economic evaluations: Mapping the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to the EQ-5D. ISPOR 15th Annual International Meeting, May 15-19, 2010, Atlanta, GA, USA (poster).
102. Gaebel K, Blackhouse G, Hernandez P, Xie F, Robertson D, Mclvor A, Assasi N, Goeree R. Clinical effectiveness of triple therapy in the management of COPD. SMDM Europe 2010, May 30 – June 2, 2010, Hall in Tyrol, Austria (podium presentation).
103. Bowen JM, O'Reilly D, Tarride J-E, Xie F, Blackhouse G, Patterson LL, Hopkins RB, Burke N, Goeree R. Collecting primary data to support policy decision making in Ontario: Why do we need different processes for diffused and non-diffused technologies? HTAi 2010 - 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010 (podium presentation).
104. O'Reilly D, Xie F, Pullenayegum E, Gerstein H, Greb J, Blackhouse G, Tarride J-E, Bowen J, Goeree R. Estimation of decreases in health-related quality of life associated with diabetes-related complications for patients with type 2 diabetes in Ontario, Canada. HTAi 2010 - 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010 (podium presentation).
105. Assasi N, Blackhouse G, Xie F, Marshall JK, Irvine EJ, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Anti-TNF- α drugs for treatment of ulcerative colitis: A systematic review and meta-analysis. HTAi 2010 - 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010 (poster).
106. Blackhouse G, Xie F, Assasi N, Gaebel K, Campbell K, Robertson D, Marshall J, Irvine E, O'Reilly D, Tarride J-E, Goeree R. Canadian cost-utility analysis of initiation and maintenance treatment with Anti-TNF- α drugs for refractory Crohn's disease. HTAi 2010 - 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010 (poster).
107. Gaebel K, Blackhouse G, Robertson D, Xie F, Assasi N, Mclvor A, Hernandez P, Goeree R. Effectiveness of triple therapy for the management of chronic obstructive pulmonary disease. HTAi 2010 - 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010 (poster).

OTHER PRESENTATIONS (presenters underlined):

108. Tarride J-E, Haq M, Bowen J, Blackhouse G, O'Reilly D, **Xie F**, Goeree R. The humanistic and economic burden of osteoarthritis in Ontario. HTAi 2010 - 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010 (poster).
109. Tarride J-E, Haq M, Bowen J, Blackhouse G, O'Reilly D, **Xie F**, Goeree R. Using medical records to estimate the burden of rheumatoid-arthritis in Ontario. HTAi 2010 - 7th Annual Meeting, Dublin, Ireland, June 6-9, 2010 (poster).
110. **Xie F**, Pullenayegum E, Li SC, Hopkins R, Thumboo J. Mapping the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to the EQ-5D 27th Plenary Meeting of the EuroQol Group, Athens, September 16-19, 2010 (poster).
111. Johnston BC, Thorlund K, Schünemann H, **Xie F**, Murad HM, Montori VM, Guyatt GH. Improving the interpretation of Health-Related Quality of Life evidence in meta-analyses. 18th Cochrane Colloquia, Colorado, October 18-22, 2010 (podium presentation).
112. **Xie F**, Pullenayegum E, Li SC, Hopkins R, Goeree R, Tarride J-E, O'Reilly D, Thumboo J. Use of a disease-specific instrument in economic evaluations: mapping the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to the EQ-5D. SMDM 32nd Annual Meeting, Toronto, Ontario. October 24-27, 2010 (podium presentation).
113. Tarride JE, Haq M, O'Reilly D, **Xie F**, Bowen JM, Goeree R. Using utilization records to estimate the burden of obesity in adults living in Ontario. 2009 CAPT Annual Meeting, Montreal, PQ. April 19-21, 2009 (poster).
114. Patterson LL, Nunes EL, McGuire MA, MacDougald CB, Bowen JM, O'Reilly DJ, Hopkins RB, Blackhouse G, Burke N, Tarride J-E, **Xie F**, Goeree R. The conduct of conditionally funded field evaluations to inform health policy decision making in Ontario. 30th Annual Meeting of the Society for Clinical Trials, Atlanta, GA. May 3-6, 2009 (poster).
115. Hopkins R, Bowen JM, Tarride JE, **Xie F**, Patterson L, O'Reilly D, Goeree R. Best Practices for Developing Statistical Analysis Plans for Clinical Trials. FSORC Biostatistics Unit Rounds, St. Joseph's Healthcare Hamilton, Hamilton, ON. January 20, 2009.
116. Hopkins RB, Bowen J, Blackhouse G, Tarride J-E, O'Reilly D, **Xie F**. Reviewing others' biostatistics. A review of peer review. CEM Rounds, St. Joseph's Healthcare Hamilton, Hamilton, ON. May 5, 2009.
117. O'Reilly D, **Xie F**, Pullenayegum E, Gerstein H, Blackhouse G, Tarride JE, Bowen J, Goeree R. Estimating utility values associated with diabetes-related complications for patients with type 2 diabetes in Ontario using the EQ-5D. CEM Rounds, St. Joseph's Healthcare Hamilton, ON. October 20, 2009.
118. **Xie F**, Ye H, Zhang Y, Liu X, Lei T, Li SC. Extension from inpatients to outpatients: Performance of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis. ISPOR 14th Annual International Meeting, Orlando, FL, USA. May 16-20, 2009 (poster).
119. **Xie F**, Blackhouse G, Assasi N, Hopkins R, Gaebel K, O'Reilly D, Tarride JE, Goeree RA. Cost effectiveness analysis of anti-TNF-alpha Drugs for Refractory

OTHER PRESENTATIONS (presenters underlined):

- ulcerative colitis. ISPOR 14th Annual International Meeting, Orlando, FL, USA. May 16-20, 2009 (poster).
120. Tarride JE, Haq M, O'Reilly D, **Xie F**, Bowen JM, Goeree R. Using utilization records to estimate the burden of obesity in adults living in Ontario. ISPOR 14th Annual International Meeting, Orlando, FL, USA, May 16-20, 2009 (poster).
121. O'Reilly D, **Xie F**, Pullenayegum E, Gerstein H, Blackhouse G, Tarride J-E, Bowen J, Goeree R. Estimation of utility values for diabetes-related complications on quality of life for patients with type 2 diabetes in Ontario, Canada. ISPOR 14th Annual International Meeting, Orlando, FL, USA. May 16-20, 2009 (podium presentation).
122. Pasricha A, Burke N, Bowen J, Assasi N, **Xie F**, Goeree R, O'Reilly D. Systematic review of hyperbaric oxygen therapy (HBOT) for non-healing diabetic ulcers of the lower limb. Health Technology Assessment International Conference, Singapore. June 23, 2009 (poster).
123. **Xie F**, Pullenayegum E, Gerstein H, Johnson JA, O'Reilly D. Estimation of utility values for diabetes-related complications in Ontario, Canada. 26th Plenary Meeting of the EuroQol Group, Paris, September 3-5, 2009 (poster).
124. Tarride JE, Bowen J, DeRose G, Blackhouse G, Hopkins R, Novick T, O'Reilly D, **Xie F**, Goeree R. How conditionally funded field evaluations can be used to make policy? A case study of endovascular repair (EVAR) for the treatment of abdominal aortic aneurysms (AAAs). 2009 Health Research Showcase: Linking Health Research and Quality Health Care for Ontarians, Toronto, ON. October 8, 2009 (poster).
125. Goeree R, Bowen J, Blackhouse G, Hopkins R, Tarride JE, O'Reilly D, **Xie F**. Building bridges between academic research and government policy: The case of Drug Eluting Stents (DES) in Ontario. 2009 Health Research Showcase: Linking Health Research and Quality Health Care for Ontarians, Toronto, ON. October 8, 2009 (poster).
126. Assasi N, Blackhouse G, **Xie F**, Gaebel K, Marshall J, Irvine J, Robertson D, Campbell K, Hopkins R, Goeree R. Anti-TNF-alpha drugs for treatment of Crohn's disease: A systematic review and meta-analysis. 31st Annual Meeting of the Society for Medical Decision Making (SMDM), Hollywood (Los Angeles), California, USA, October 18-21, 2009 (poster).
127. Tarride JE, Haq M, Bowen J, Blackhouse G, O'Reilly D, **Xie F**, Goeree R. The burden of obesity in Ontario. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 (poster).
128. Gaebel K, Kaulback K, Robertson D, Blackhouse G, **Xie F**, Goeree R. Clinical effectiveness of portable ultrasound in small emergency departments: A systematic review. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 (poster).
129. Gaebel K, Blackhouse G, Campbell K, Robertson D, **Xie F**, Assasi N, Chalk C, Levine M, Goeree R. A systematic review and meta-analysis of Intravenous Immunoglobulin for the treatment of CIDP. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 (poster).

OTHER PRESENTATIONS (presenters underlined):

130. Goeree RA, Lim ME, Hopkins R, Blackhouse G, Tarride JE, **Xie F**, O'Reilly D. Who are they fooling?: Cost of disease or complications can significantly bias estimates unless control (non-diseased) costs are not also accounted for in the analysis. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 (poster).
131. Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride JE, **Xie F**, O'Reilly D. Using population-based estimates for disease modelling: Potential bias compared to using disease-specific death complication risk estimates. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 (podium presentation).
132. Assasi N, Blackhouse G, **Xie F**, Marshall JK, Irvine J, Gaebel K, Robertson D, Campbell K, Hopkins R, Goeree R. Systematic review: the clinical effectiveness of anti-TNF-alpha drugs in adults with refractory Crohn's disease. ISPOR 12th Annual European Congress, Paris, France, October 24-27, 2009 (poster).
133. Blackhouse G, **Xie F**, Gaebel K, Robertson D, Levine M, Chalk C, Assasi N, Goeree RA. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. ISPOR 12th Annual European Congress, Paris France, October 24-27, 2009 (poster).
134. **Xie F**, Luo N, Lo NN, Goeree R, Tarride JE, O'Reilly D, Lee HP. A two-year evaluation of health outcomes in osteoarthritis patients after knee replacement. ISPOR 13th Annual International Meeting, Toronto, ON, May 3-7, 2008 (poster).
135. **Xie F**, Luo N, Blackhouse G, Goeree R, Lee HP. Cost effectiveness analysis of Helicobacter Pylori screening in prevention of gastric cancer in Chinese. ISPOR 13th Annual International Meeting, Toronto, ON, May 3-7, 2008 (poster).
136. Goeree R, Tarride JE O'Reilly D, **Xie F**, Bowen J, Blackhouse G, Hopkins R, Campbell K, Burke N, Lim M. Using HTA to inform publicly financed health care decision-making: The case study of drug eluting stents in Ontario, Canada. HTAi Conference, Montreal, PQ, July 6, 2008 (podium presentation).
137. Goeree R, Tarride JE, O'Reilly D, **Xie F**, Bowen J, Blackhouse G, Hopkins R, Campbell K, Burke N, Lim M. Using conditionally funded field evaluations (CFFE) for evidence development, uncertainty reduction and reimbursement decision making: case studies from Ontario. HTAi Conference, Montreal, PQ, July 10, 2008 (podium presentation).
138. **Xie F**. Good Practice in Economic Modelling: An Academic Perspective. CEM Rounds, St. Joseph's Healthcare, Hamilton, ON. February 26, 2008.
139. Goeree R, Ferrusi I, Tarride, JE, O'Reilly D, **Xie F**, Bowen J, Blackhouse G, Hopkins R, Burke N, Campbell. Traditional Health Technology Assessment (HTA) Reports: What Are We Missing and How Do We Get the Message Out? CEM Rounds, St. Joseph's Healthcare, Hamilton, ON. May 13, 2008.
140. **Xie F**. Tarride JE, O'Reilly D, Goeree R. Utility measures in economic evaluations. CEM Rounds, St. Joseph's Healthcare, Hamilton, ON. Dec 9, 2008.

OTHER PRESENTATIONS (presenters underlined):

141. Tarride J-E, Blackhouse G, Hopkins R, O'Reilly D, **Xie F**, Goeree R. Cost-effectiveness of Etanercept in Canada. IXth World Conference on Clinical Pharmacology and Therapeutics, Quebec, Canada, July 27-August 1, 2008 (poster).
142. Xie F, Luo N, Lo NN, Tarride JE, O'Reilly D, Goeree R, Lee HP. A two-year evaluation of health outcomes in osteoarthritis patients after total knee replacement. ISPOR 3rd Asia-Pacific Conference, September 7-9, 2008, Seoul, South Korea (poster).
143. **Xie F**, Despiegel N, Danchenko N, Hansen K. Cost-effectiveness of escitalopram compared to venlafaxine and fluvoxamine in the treatment of major depressive disorder in Singapore. ISPOR 3rd Asia-Pacific Conference, September 7-9, 2008, Seoul, South Korea (poster).
144. **Xie F**, Luo N, Lo NN, Lee HP. Total or partial knee replacement? A cost-effectiveness analysis in patients with knee osteoarthritis based on two-year data. Proceedings of the COFM 60th Anniversary Symposium, Clinical Research Centre, National University of Singapore. October 16, 2008 (poster).
145. Luo N, **Xie F**, Lo NN, Lee HP. A two-year evaluation of health outcomes in osteoarthritis patients after total knee replacement. Proceedings of the COFM 60th Anniversary Symposium, Clinical Research Centre, National University of Singapore. October 16, 2008 (poster).
146. O'Reilly D, Blackhouse G, Hopkins R, Bowen JM, **Xie F**, Tarride JE, Goeree R. The long-term costs and consequences of various diabetes management strategies: Results from the Ontario diabetes economic model (ODEM). Presentation at the Canadian Diabetes Association / Canadian Society of Endocrinology and Metabolism Professional Conference, Montreal, PQ. October 16, 2008 (poster).
147. Blackhouse G, **Xie F**, Campbell K, Assasi N, Bowen JM, Tarride J-E, Goeree R. Economic analysis of treatments for childhood idiopathic thrombocytopenia. SMDM 30th Annual International Meeting, Philadelphia, PA. October 18-22, 2008 (poster).
148. Goeree R, O'Reilly D, Tarride J-E, **Xie F**, Bowen J, Blackhouse G, Hopkins R. Do technology evaluations based on evidence from conditional funding lead to increased policy formation?: Findings from Ontario's evidence-based HTA process. SMDM 30th Annual International Meeting, Philadelphia, PA. October 18-22, 2008 (podium presentation).
149. Goeree R, Lim M, O'Reilly D, Tarride JE, **Xie F**, Bowen J, Blackhouse G, Hopkins R. Can VOI analyses be used for setting government research agendas and priorities?: Experience from a province-wide initiative using an iterative VOI analysis framework. 30th Annual Meeting of the Society for Medical Decision Making, Philadelphia, PA, USA. October 19-22, 2008 (poster).
150. **Xie F**, Blackhouse G, Assasi N, Campbell K, Levine M, Pi D, Tarride JE, Bowen J, Goeree R. Economic evaluation of intravenous immunoglobulin in adults with chronic immune thrombocytopenia purpura. 30th Annual Meeting of the Society for Medical Decision Making, Philadelphia, PA, USA. October 19-22, 2008 (poster).
151. Luo N, **Xie F**, Au WL, Lau PN, Tan LC. Detection of Differential Item Functioning between English and Chinese versions of the PDQ-8. ISPOR 12th Annual International Meeting, 19-23 May 2007, Arlington, VA, USA (poster).

OTHER PRESENTATIONS (presenters underlined):

152. **Xie F**, Luo N, Yeoh KG, Lee HP. Cost effectiveness analysis of population-based serology screening and 13C-Urea breath test for Helicobacter Pylori to prevent gastric cancer in Chinese males. Academy Health Annual Research Meeting 2007, 3-5 June, 2007, Orlando, FL, USA (poster).
153. **Xie F**, Li SC, Luo N, Lo NN, Yeo SJ, Yang KY, Fong KY, Thumboo J. A comparison of EQ-5D and SF-6D in multiethnic Asian patients with knee osteoarthritis in Singapore, ISOQOL 14th Annual International Conference, 13-16 October 2007, Toronto, ON, Canada (poster).
154. Zhang XH, Li SC, **Xie F**, Lo NN, Yang KY, Yeo SJ, Thumboo J. Investigation of response shift in health-related quality of life among patients undergoing total knee. ISPOR 10th Annual European Congress, 20-23 October 2007, Dublin, Ireland (poster).
155. Zhang XH, **Xie F**, Wee HL, Thumboo J, Li SC. Applying the Expectancy-value Model to Understand Health Preference. ISPOR 11th Annual International Meeting 20-24 May 2006, Philadelphia, PA, USA (poster).
156. Wee HL, Li SC, Zhang XH, **Xie F**, Luo N, Cheung YB, Machin D, Fong KY, Thumboo J. How Do Survey Respondents Interpret and Utilize Symbols Used in Health Valuation Studies? ISPOR 2nd Asia-Pacific Conference, 5-7 March 2006, Shanghai, China (poster).
157. Wee HL, Li SC, **Xie F**, Zhang XH, Luo N, Feeny D, Cheung YB, Machin D, Fong KY, Thumboo J. Feasibility, Acceptability and Factors Influencing Acceptability of Time Trade-Off and Standard Gamble: An Exploratory Study among Multiethnic Singaporeans. ISPOR 2nd Asia-Pacific Conference, 5-7 March 2006, Shanghai, China (poster).
158. Wee HL, Li SC, **Xie F**, Zhang XH, Luo N, Cheung YB, Machin D, Fong KY, Thumboo J. The Impact of Talking about Death on the Health State Valuation: A Study among Chinese and Indian Singaporeans. ISPOR 2nd Asia-Pacific Conference, 5-7 March 2006, Shanghai, China (poster).
159. **Xie F**, Li SC, Wee HL, Zhang XH, Luo N, Cheung YB, Machin D, Fong KY, Thumboo J. What Factors Influence the Ranking of Health Domains? An Exploratory Study among Chinese and Indian Singaporeans. ISPOR 2nd Asia-Pacific Conference, 5-7 March 2006, Shanghai, China (poster).
160. **Xie F**, Li SC, Wee HL, Zhang XH, Luo N, Cheung YB, Machin D, Fong KY, Thumboo J. Does Ranking of Health Domains Influence Health Utilities? An Exploratory Study among Chinese and Indian Singaporeans. ISPOR 2nd Asia-Pacific Conference, 5-7 March 2006, Shanghai, China (poster).
161. **Xie F**, Li SC, Fong KY, Lo NN, Yeo SJ, Yang KY, Thumboo J. What Health Domains & Items Are Important to Patients with Knee Osteoarthritis? A Focus Group Study in a Multiethnic Urban Asian Population. ISPOR 2nd Asia-Pacific Conference, 5-7 March 2006, Shanghai, China (podium presentation).
162. Zhang XH, **Xie F**, Wee HL, Thumboo J, Li SC. Applying the expectancy-value model to understand health preference. ISPOR 2nd Asia-Pacific Conference, 5-7 March 2006, Shanghai, China (podium presentation).

OTHER PRESENTATIONS (presenters underlined):

163. **Xie F**, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, Li SC. Are They Measurable? A Study on Eliciting Indirect and Intangible Costs of Knee Osteoarthritis Using Human Capital Approach and Willingness-to-Pay in Multiethnic Asia Population in Singapore. ISPOR 9th Annual European Congress, 28-31 October 2006, Copenhagen, Denmark (poster).
164. **Xie F**, Li SC, Fong KY, Lo NN, Yeo SJ, Yang KY, Thumboo J. What Health Domains & Items Are Important to Patients with Knee Osteoarthritis? A Focus Group Study in a Multiethnic Urban Asian Population. ISOQOL 12th Annual International Conference, 19-22 October 2005, San Francisco, CA, USA (poster).
165. **Xie F**, Thumboo J, Fong KY, Lo NN, Yeo SJ, Yang KY, Li SC. Are They Relevant? A Critical Evaluation of the International Classification of Functioning, Disability and Health Core Sets for Osteoarthritis from the Perspective of Patients with Knee Osteoarthritis in Singapore. ISPOR 8th Annual European Congress 6-8 November 2005, Florence, Italy (poster).
166. **Xie F**, Luo N, Li SC. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30): Validation of English Version in Singapore. ISPOR 9th Annual International Meeting, 16-19 May 2004, Arlington, VA, USA (poster).
167. **Xie F**, Li SC, Thumboo J. Which Domains of Health-related Quality of Life are Important in Hip and Knee Osteoarthritis? A Qualitative Systematic Literature Review. ISOQOL 11th Annual International Conference, 16-19 October 2004, Hong Kong, China (poster).

ADMINISTRATIVE RESPONSIBILITIES

i) Department of HEI

- 2021- Member, HEI Finance Committee
- 2019- Chair, Board of Comprehensive Examination, HEI
- 2017-2020 Chair, HEI Graduate Education Council
- 2017-2020 Member, HEI APT Committee
- 2017-2020 Member, HEI Steering Committee
- 2015-2016 Member, CEB Steering Committee (as Acting Assistant Dean HRM)
- 2015-2016 Member, MPH Management Committee
- 2014- Member, David Sackett Scholarship Review Committee, McMaster University
- 2013-2019 Member, HRM PhD Admission Committee
- 2012-2013 Associate Professor Representative, Clinical Epidemiology and Biostatistics Steering Committee, McMaster University
- 2012-2013 Associate Professor Representative, Clinical Epidemiology and Biostatistics Appointment Committee, McMaster University
- 2010-2018 Member, HRM MSc Admission Committee
- 2009-2012 Assistant Professor Representative, Clinical Epidemiology and Biostatistics Steering Committee, McMaster University
- 2009-2012 Assistant Professor Representative, Clinical Epidemiology and Biostatistics Appointment Committee, McMaster University
- 2009-2013 Events Coordinator, Clinical Epidemiology and Biostatistics, McMaster University
- 2009-2013 Member, Graduate Education Committee, Clinical Epidemiology and Biostatistics, McMaster University
- 2009-2013 Chair, CE&B Research Day Organizing Committee
- 2009 Co-Chair, 2010 David Sackett Symposium Organizing Committee
- 2009-2012 Chair, PATH Annual Report Committee
- 2008- Member, Labelle Lectureship Committee, Clinical Epidemiology and Biostatistics, McMaster University

ii) Faculty of Health Sciences

- 2011-2012 Member, AFP Grant Review Committee
- 2009 Member, Faculty of Health Sciences Assistant Dean (HRM) Selection Committee, McMaster University
- 2008-2011 Member, Faculty of Health Sciences Scholarships Selection Committee, McMaster University

iii) St. Joseph's Healthcare, Hamilton, Ontario

- 2021 Member, VP Research Selection Committee
- 2014-2018 Member, Research HELP (Health Enquiry Learning Panel)
- 2008-2013 Member, Clinical Research Operation Committee (CROC), St. Joseph's Healthcare Hamilton
- 2007- Member, Centre for Evaluation of Medicines, St. Joseph's Healthcare

2007- Hamilton
Member, Father Sean O'Sullivan Research Centre, St. Joseph's
Healthcare Hamilton

iv) Others

2018- Member, CIHR Health Policy and Management Project Grant Panel
2012 Member, CIHR Doctoral Award Review Committee
2012 Member, CIHR Aboriginal People Health Peer Review Committee
2007-2013 Member, Management Committee, Medical Advisory Secretariat, Ministry
of Health and Long-term Care (MOHLTC) /PATH